











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 







Targeting a custom-engineered 
flavonoid to the mitochondria protects 




















Thesis submitted for the degree of Doctor of Philosophy 
The University of Edinburgh 
2014 
	   ii	  
Declaration 
I declare that the work in this thesis is my own, unless otherwise stated. This thesis 
has been composed by myself and has not been previously submitted for any other 



































	   iii	  
Acknowledgements 
Here I would like to thank those people who without which this thesis would not have been 
written. Firstly, I would like to thank my supervisor Dr. Tilo Kunath for giving me the 
opportunity to do a PhD in his lab, for his support, enthusiasm and motivation throughout 
my PhD and especially in the last few months. Additionally, Dr. Donald McPhail and 
Graeme Cook from Antoxis Limited who provided me with AO-1-530 and helped me 
especially in the early stages. I am grateful to Dr. Keisuke Kaji for providing me with the 
cloning plasmids. In addition, I thank my committee members, Dr. Sally Lowell and Dr. 
Anna Williams for their guidance during the project. This studentship was funded by 
BBSRC and SULSA with financial contribution from Antoxis Limited. 
 I am also grateful to Kunath lab members and other members of the ISCR/SCRM 
past and present for their scientific discussions, help with lab work, friendship and support 
with writing up. A special thanks to, Ratsuda for getting me through some of the toughest 
times; Fatima for her help with cloning and her continued support; Maurice and Amy for 
their advice and motivation with thesis writing; Karamjit for scientific discussions and Fella 
for allowing me to use some of her and Xing’s results in this thesis and for her guidance 
through thesis writing. I also want to thank Rachel for training me in slice cultures and Amy 
Pegg for her help and motivation throughout writing this thesis. Hopefully I can do the same 
for you! 
 The core facility staff at the ISCR/SCRM have been fundamental for this work. 
Thank you to Helen and Marilyn for keeping the cell culture facility running smoothly. In 
addition, I would like to thank Dr. Valeria Berno for her microscopy training and patience. 
 The EPR experiments, most of which do not feature in this thesis, would not have 
been possible without the help and patience of Dr. Janet Lovett and Dr. Mark Miller.  
 Finally, my deepest appreciation goes to my parents, family, friends and Paco. 
Thank you to my parents, my brother and sister for their love, support and encouragement 
throughout. Thank you to my friends who have motivated me to complete my PhD. Lastly, 
thank you to Paco for putting up with me, for letting me use his computer and for being there 
when I needed him. I promise Spanish next! 
 






	   iv	  
Lay Summary 
The main symptoms experienced by Parkinson’s disease patients are motor symptoms, 
which are caused by the loss of nerve cells in the brain. A possible cause of this nerve cell 
death is oxidative stress. Oxidative stress is an imbalance between reactive molecules 
containing oxygen, which cause damage to components of the cell, and antioxidants, which 
prevent this damage. This damage can build up over time eventually resulting in cell death. 
Post-mortem analysis of Parkinson’s disease patients' brains show evidence of damage 
caused by oxidative stress. In addition, these brains have clumps of the protein α-synuclein, 
which have also been implicated in nerve cell death. It is possible that reactive molecules 
containing oxygen may damage the α-synuclein protein enhancing it’s clumping, however, 
this has not been proven. Therefore the aim of this thesis was to produce a cell model of 
Parkinson’s disease that would allow investigation of the link between oxidative stress, 
α-synuclein clumping and cell death. As part of such a model, better tools are needed to 
assess the involvement of oxidative stress; therefore the potential of a novel synthetic 
antioxidant was investigated. 
 A doubling in the levels of the α-synuclein protein in humans causes Parkinson’s 
disease. Therefore the levels of the α-synuclein protein were increased in cells to try to 
model Parkinson’s disease. However, this increase in the protein level failed to show toxicity 
in the cells used. This may be due to the length of time the protein was in the cells, the levels 
of the protein or the type of cells used. Further experiments are needed to produce a cell 
model of Parkinson’s disease.  
 One possible tool to examine the involvement of oxidative stress in disease models 
is the compound AO-1-530, which was synthesised by Antoxis Limited. The chemical 
composition of AO-1-530 is based on a group of natural antioxidants found in plants known 
as flavonoids. AO-1-530 was shown to maintain the antioxidant ability of flavonoids and 
was found to enter cells quickly, where it unexpectedly becomes enriched in a part of the cell 
known as the mitochondria. A toxin induced oxidative stress cell model showed AO-1-530 
was protective and it out-performed the other antioxidants tested. This protective potential 
was due to its ability to enter cells and remove damaging reactive molecules. Therefore, 
AO-1-530 is a synthetic antioxidant that may be a powerful novel tool to study the 
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Abstract 
Oxidative stress is caused when there are more reactive oxygen species (ROS), than 
antioxidants to scavenge them, resulting in damage to cellular components. It has been 
implicated as a major player at multiple points in the disease process of Parkinson’s disease 
(PD) and many other conditions. For example, evidence suggests oxidative damage to the 
α-synuclein protein may affect its aggregation propensity. In addition, α-synuclein may 
increase ROS production. However, how this oxidative stress relates to neurodegeneration is 
not known. Therefore, there is a need for models of α-synucleinopathies and tools to assess 
the involvement of oxidative stress in the disease process. 
In order to model α-synucleinopathies, overexpression of the α-synuclein protein 
was used. A BacMam viral expression system containing human α-synuclein was generated 
and used to assess toxicity. α-Synuclein overexpression in undifferentiated or differentiated 
SH-SY5Y cells failed to show toxicity. However, the stability of α-synuclein protein 
expression and the cell line used may have influenced in the lack of toxicity. The current 
work provides important guidance for future experimental design.  
Flavonoids are found in plants and have antioxidant capability. AO-1-530 is a 
synthetic compound with a flavonoid head group and a long hydrocarbon tail. It is highly 
cell permeable and localises to the mitochondria. In order to investigate its protective 
properties, toxin-induced oxidative stress cell assays were established. AO-1-530, in the low 
micromolar range, was protective against high doses of tert-butyl hydroperoxide (tBHP), 
whereas natural antioxidants, such as myricetin and quercetin, showed limited protection or 
required at least 10-fold higher concentrations to achieve similar protection.  
The ability of AO-1-530 to directly scavenge radicals was assessed cell-free in 
solution and in a cell-based assay. In solution the mechanism of action was investigated by 
electron paramagnetic resonance (EPR) spectroscopy. AO-1-530 had similar scavenging 
ability to myricetin, but was a slightly stronger scavenger than quercetin. The intracellular 
scavenging ability was quantified by CellROX® Deep Red live imaging. Although the 
compounds had similar cell-free scavenging abilities, AO-1-530 significantly out-performed 
both myricetin and quercetin in the intracellular assay, suggesting the mitochondrial 
localisation is critical to its highly protective properties. AO-1-530 is a powerful, novel tool 
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Chapter 1 – Introduction  
1.1. General Introduction 
Oxygen is present in the air and is required by aerobic cells to produce sufficient amounts of 
energy. However, exposure of cells to oxygen can result in the production of reactive 
derivatives of oxygen known as reactive oxygen species (ROS) (Gerschman et al, 1954). To 
protect themselves, aerobic cells have developed antioxidant defences that remove these 
reactive species (McCord et al, 1971). Within healthy cells there is usually a balance 
between the production of reactive species and their removal by antioxidants. However, if 
there is a reduction in antioxidants or an increase in reactive species, then oxidative stress 
occurs and the reactive species are free to react with cellular components, causing oxidative 
damage. The oxidative stress theory of aging, which remains controversial, stipulates that the 
build up of oxidative damage over time causes aging (Finkel & Holbrook, 2000). Therefore, 
in diseases, such as Parkinson’s, where age is a significant risk factor, oxidative stress has 
been implicated as a potential cause (Surmeier et al, 2011; Jenner et al, 1992). In addition, 
mitochondrial dysfunction has been implicated in Parkinson’s and may be closely related to 
the oxidative stress observed (Schapira et al, 1990; Surmeier et al, 2011). It is important to 
be able to model the disease accurately in order to determine the relationship between 
oxidative stress and neurodegeneration. This understanding of the disease process will allow 
the rationale design of targeted treatments for people with Parkinson’s disease (PD).  
1.2 α-Synuclein and Neurodegeneration 
PD is part of a larger family of neurodegenerative diseases that are now known collectively 
as α-synucleinopathies. 
1.2.1 α-Synucleinopathies 
α-Synucleinopathies are neurodegenerative diseases that have symptoms of Parkinsonism 
and have some form of α-synuclein protein inclusions. These protein inclusions, known as 
Lewy bodies (LBs), Lewy neurites or glial cytoplasmic inclusions (GCIs), are mainly 
composed of the protein α-synuclein, but also contain a large number of other protein 
constituents (Spillantini et al, 1997; Wakabayashi et al, 1998). The Parkinsonism symptoms 
experienced, including tremor, rigidity, akinesia and postural instability, are caused by the 
loss of dopaminergic neurons in substantia nigra pars compacta (SNpc) (Langston et al, 
1999; Parent & Parent, 2010). The most common α-synucleinopathies are PD, dementia with 
Lewy bodies (DLB) and multiple system atrophy (MSA). These diseases differ in the cell 
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types that contain the α-synuclein protein inclusions and the subsequent brain areas that are 
affected. 
  Some evidence suggests these are not separate diseases but rather a spectrum of 
diseases with differing symptom severity. PD would be the mildest form with degeneration 
of neurons in the substantia nigra, locus coeruleus and raphe nucleus. Surviving neurons in 
these areas contain α-synuclein-rich LBs and Lewy neurites (Braak et al, 2003). A more 
severe form of α-synucleinopathies is DLB, where patients experience Parkinsonism as well 
as psychiatric symptoms, including visual hallucinations. In addition, neurodegeneration and 
LBs are more widespread throughout the brain (McKeith et al, 1996). Another 
α-synucleinopathy more severe than PD is MSA. MSA symptoms include Parkinsonism, 
autonomic failure and cerebellar ataxia, including urinary incontinence and slurred speech 
(Gilman et al, 2008). In MSA the α-synuclein protein inclusions are found in 
oligodendrocytes throughout the white matter of the cerebellum and cerebrum, known as 
GCIs. Post-mortem analysis shows neurodegeneration in the cerebellum and pons (Gilman et 
al, 2008). The presence of α-synuclein protein inclusions in surviving cells of the brain 
implicates α-synuclein in the disease process.  
Further evidence that implicates α-synuclein as a cause of neurodegeneration was 
the discovery of mutations and multiplications of the α-synuclein gene, which encode protein 
modifications, in familial cases of Parkinsonism (Table 1.1). The first α-synuclein mutation 
discovered was an autosomal dominant single amino acid change, A53T (Polymeropoulos et 
al, 1997). Compared to sporadic PD patients, patients with this mutation experience an 
earlier onset of symptoms, faster progression and some develop late onset dementia (Golbe 
et al, 1990). Subsequently, the A30P mutation was reported, which caused milder symptoms 
than A53T, with later onset and slower progression more representative of sporadic PD 
(Krüger et al, 1998; Seidel et al, 2010). Next to be found was the E56K mutation, which 
showed symptoms more representative of DLB including hallucinations and dementia 
(Zarranz et al, 2004). More recently two further mutations have been discovered G51D and 
H50Q. The G51D mutation showed a much earlier age of onset than sporadic PD, as young 
as 19 years, and patients had symptoms of PD, DLB and MSA. Post-mortem analysis 
showed LBs and GCIs throughout the brain with substantial cell loss in the SNpc, 
hippocampus and cerebellum (Kiely et al, 2013; Lesage et al, 2013). The H50Q mutation 
resulted in milder symptoms with later disease onset of 60 years with dementia 
(Appel-Cresswell et al, 2013). These mutations suggest that an alteration in the α-synuclein 
protein can cause the major types of α-synucleinopathies.  
	   3	  
There is also evidence that indicates the level of α-synuclein protein is influential in 
neurodegeneration. α-Synuclein gene triplication patients have twice as much α-synuclein 
protein than control patients (Singleton, AB et al, 2003; Farrer et al, 2004), therefore from 
the gene dosage, duplication patients are expected to have 1.5 times more protein than 
controls (Chartier-Harlin et al, 2004). The affected family members in these kindreds show 
the higher the α-synuclein protein level the earlier the average age of disease onset and the 
more severe the symptoms experienced (Table 1.1) (Nishioka et al, 2006; Chartier-Harlin et 
al, 2004). One report documented an average age of onset of 33 years for triplication patients 
compared to 50 years for duplication patients (Shin et al, 2010). Triplication patients often 
experience hallucinations and dementia, but this is rarely found in duplication patients (Shin 
et al, 2010; Gwinn et al, 2011; Ibáñez et al, 2004; Nishioka et al, 2006). In addition, a 
number of so far asymptomatic duplication carriers have been found through affected family 
members (Ahn et al, 2008). This suggests that simply increasing the α-synuclein protein 
level may result in more aggressive neurodegeneration and earlier onset of disease 
symptoms.  However, α-synuclein multiplications and mutations are rare (Lesage & Brice, 
2009). A number of genome-wide association studies comparing sporadic PD patients and 
unaffected controls have shown single-nucleotide polymorphisms (SNPs) in the SNCA gene 
were associated with sporadic PD (Edwards, 2010). These variations in the SNCA gene may 
be capable of influencing α-synuclein protein expression levels.  
How α-synuclein causes toxicity is unknown but recent progress in the field suggests 
α-synuclein acts in a prion-like manner, with toxic oligomeric α-synuclein species spreading 
between interconnected neurons within the nervous system. The causes of the initial 
oligomer formation is unknown but there is evidence to indicate once formed they can 
spread between neurons. The first piece of evidence came from studies performed by Braak 
and colleagues. They examined the α-synuclein pathology in 168 brains of sporadic PD 
patients, LB and Lewy neurite containing brains and non-LB or Lewy neurite containing 
brains. This analysis suggested α-synuclein pathology starts in specific regions of the brain 
and spreads through connected neurons in a predictable way (Braak et al, 2004; 2003). 
Further evidence to support the spread of α-synuclein came from post-mortem analysis of 
PD patients who had received fetal transplants 11-14 years earlier to reduce PD motor 
symptoms. The grafted neurons contained α-synuclein positive LBs, indicating that 
α-synuclein could spread from affected neurons. However, another possible explanation was 
the environment the grafts were injected into could induce α-synuclein pathology (Chu & 
Kordower, 2010; Kordower et al, 2008; Li et al, 2008). Evidence for the spreading of 
α-synuclein came from in vitro studies where α-synuclein was aggregated in solution to form 
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pre-formed fibrils. These fibrils were then sonicated to produce oligomeric fragments 
(Volpicelli-Daley et al, 2011). When these oligomeric fragments were incubated with mouse 
primary neurons, they were taken up and seeded endogenous cellular α-synuclein. These 
seeded aggregates, like LBs contained phosphorylated α-synuclein and were positive for 
ubiquitin. In addition, the oligomeric fragments induced toxicity in neurons two weeks after 
addition; suggesting α-synuclein oligomers are the toxic form of α-synuclein 
(Volpicelli-Daley et al, 2011). This aggregation and toxicity was only seen in neurons that 
contained endogenous α-synuclein and the more α-synuclein present the quicker aggregates 
developed (Volpicelli-Daley et al, 2011). Sonicated pre-formed fibrils have also been 
injected into α-synuclein containing mice brains (Luk et al, 2012). They were taken up into 
neurons, spread to interconnected neurons and caused neuronal toxicity. The neuronal 
toxicity resulted in impaired balance and motor coordination (Luk et al, 2012). Therefore 
oligomeric α-synuclein may be the toxic species that can spread from one neuron to another 
interconnected neuron causing α-synuclein toxicity. The rate of this toxicity is dependant on 
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Table 1.1- Mutations and multiplications of the α-synuclein gene. 
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1.2.2 α-Synuclein and Oxidative Stress 
There is evidence to suggest oxidative stress may be involved in the toxicity of α-synuclein. 
Oxidative damage to the α-synuclein protein itself may increase its aggregation propensity, 
producing toxic oligomers. Alternatively, α-synuclein aggregates may induce a state of 
oxidative stress within cells. 
 Exposure of α-synuclein to oxidative insults, including rotenone and dopamine, can 
result in modification of the methionine and tyrosine residues (Figure 1.1) (Mirzaei et al, 
2006; Leong et al, 2009). Oxidation of the methionine sulphur atom produces methionine 
sulphoxide and further sulphur oxidation produces methionine sulphone (Figure 1.1b) 
(Mirzaei et al, 2006). It is suggested the oxidation of the methionine residue to methionine 
sulphoxide is an antioxidant function because there is a family of methionine sulphoxide 
reductase (MSR) enzymes in the cell that are capable of reducing the sulphoxide to produce 
methionine (Figure 1.1b) (Maltsev et al, 2013; Liu et al, 2008). Methionine oxidation in the 
α-synuclein protein results in reduced membrane binding affinity and produces soluble 
seemingly non-toxic stable globular oligomers that are unable to produce fibrils (Maltsev et 
al, 2013; Zhou et al, 2010). 
 Oxidative damage to the tyrosine residues in the α-synuclein protein results in 
nitration and phosphorylation (Figure 1.1) (Mirzaei et al, 2006; Souza et al, 2000; Hodara et 
al, 2004). LBs examined on post-mortem analysis of α-synucleinopathy patients contain 
nitrated α-synuclein (Giasson et al, 2000). This nitration is capable of producing α-synuclein 
oligomers, which are heat stable due to the covalent dityrosine bonds that form between 
monomers (Souza et al, 2000; Schildknecht et al, 2011). These nitrated products are 
degraded more slowly, show reduced lipid binding and are capable of fibril formation in the 
presence of non-nitrated α-synuclein (Martinez-Vicente et al, 2008; Hodara et al, 2004; 
Sevcsik et al, 2011). 
 The α-synuclein protein can also be modified by the addition of a product of lipid 
peroxidation, 4-hydroxynonenal (4-HNE), to the lysine or histidine residues. This can result 
in β-sheet α-synuclein aggregates that may seed aggregation and result in increased cellular 
α-synuclein release (Bae et al, 2013). Most of these studies were not performed in cells; 
therefore how the protein modifications relate to cellular toxicity needs to be investigated.   
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Figure 1.1 - Oxidative modification of the α-synuclein protein. (a) The α-synuclein amino acid 
sequence with residues susceptible to oxidative modification highlighted, methionine (blue) and 
tyrosine (red). (b) Methionine undergoes oxidation to methionine sulphoxide and then methionine 
sulphone. The methionine sulphoxide can be reduced back to methionine by the family of enzymes 
known as methionine sulphoxide reductases (MSRs). (c) Tyrosine undergoes nitration to produce 
nitrotyrosine (Figure adapted from Mirzaei et al, 2006). 
  
 There are some studies that indicate α-synuclein protein aggregates are capable of 
increasing the levels of oxidative stress in cells. α-Synuclein fibrils that have been sonicated 
to produce smaller fibril fragments are capable of inducing toxicity in mouse hippocampal 
neurons after 14 days (Volpicelli-Daley et al, 2011). If these fibril fragments are incubated 
with mesencephalic mouse neurons for 14 days there is an increase in cytosolic and 
mitochondrial oxidation. This increase in oxidation was prevented by the antioxidant 
N-acetyl cysteine and by apocynin, a nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (NOX) inhibitor, which both act to reduce the levels of ROS (Dryanovski 
et al, 2013). In another study, α-synuclein oligomers, fibrils and monomers were all taken up 
into rat primary neurons. However, analysis of the rate of ROS production using 
dihydroethidium (DHE) showed that only the oligomeric forms of α-synuclein increased 
cellular production of ROS (Cremades et al, 2012). 
 These studies suggest oxidative damage to the α-synuclein protein can produce 
oligomers that could be toxic. In addition, α-synuclein oligomers may result in an increase in 
the production of ROS. Therefore, this implicates oxidative stress at multiple points within 
the disease process of α-synucleinopathies.	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1.3 Oxidative Stress and Neurodegeneration in Parkinson’s Disease 
PD patients also implicate oxidative stress in the degeneration of neurons through 
post-mortem analysis of PD patients and genes involved in recessive PD. In addition, the 
midbrain SNpc neurons severely affected in Parkinsonism appear to be particularly 
susceptible to oxidative stress.  
1.3.1 Post-Mortem Analyses of Parkinson’s Disease Brains 
Post-mortem analyses of PD brains show evidence of mitochondrial dysfunction and 
oxidative stress. The substantia nigra has an increase in lipid oxidative damage and some 
forms of DNA oxidative modifications (Dexter et al, 1989; Alam et al, 1997). In addition, 
protein oxidative damage to mitochondrial complex I may result in its reduced activity 
(Schapira et al, 1990; Keeney et al, 2006). The levels of the antioxidant glutathione (GSH) 
are also reduced and iron ions that can enhance production of damaging ROS, are increased 
(Sofic et al, 1988; 1992). This indicates oxidative stress is involved at some stage of the 
disease. However, post-mortem analyses are performed at the end-stage in the disease 
process so it is unclear whether oxidative stress acts as a cause or just a by-product of 
neurodegeneration.  
1.3.2 Recessive Parkinson’s Disease 
DJ-1, PTEN-induced putative kinase 1 (PINK1) and parkin are involved in damaged 
mitochondrial removal and mitochondrial ROS scavenging. Mutations in the genes encoding 
these proteins cause recessively inherited PD, implicating mitochondrial dysfunction and 
oxidative stress as a cause for PD. Patients with recessively inherited PD show symptoms of 
Parkinsonism and psychiatric disturbances often before the age of 40, with a good response 
to L-3,4-dihydroxyphenylalanine (L-DOPA) treatment (Bonifati et al, 2003; Valente et al, 
2004a; 2004b; Kitada et al, 1998). In addition, recent studies suggest some recessive PD 
patients have LBs in surviving neurons (Kitada et al, 1998; Farrer et al, 2001a; Pramstaller 
et al, 2005; Samaranch et al, 2010).  
 The first autosomal recessive inherited mutation to be discovered was in the PARK2 
gene, which encodes parkin (Kitada et al, 1998). Parkin is an E3 ubiquitin ligase that 
degrades other proteins and itself through the ubiquitin degradation pathway (Zhang et al, 
2000). It is found in the brain and many other tissues including skeletal muscle and blood 
(Serdaroglu et al, 2005; Kasap et al, 2009). In cells it is located in the cytoplasm and on the 
outer mitochondrial membrane (Darios et al, 2003; Kitada et al, 1998). PARK2 knockout 
mice have nigrostriatal dysfunction but no degeneration (Goldberg et al, 2003). They have 
normal mitochondrial morphology but a reduction in the mitochondrial electron transport 
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chain function, reduced antioxidant capacity and more oxidative damage (Palacino et al, 
2004). In contrast, its absence in Drosophila does cause dopaminergic neurodegeneration 
over time, which can be reduced by increased antioxidant gene expression (Whitworth et al, 
2005).  
 Mutations in PINK1 also cause autosomal recessive inherited Parkinsonism (Valente 
et al, 2004a). PINK1 is a mitochondrial targeted serine/threonine protein kinase (Unoki & 
Nakamura, 2001; Valente et al, 2004a). In Drosophila knockdown of PINK1 caused a 
reduction in lifespan and abnormal flight muscles. The number of mitochondria was reduced 
and those that were present were swollen with disintegrated cristae, and adenosine 
triphosphate (ATP) production was significantly reduced (Yang et al, 2006). The flies also 
showed dopaminergic neurodegeneration similar to parkin null Drosophila. This loss was 
rescued by human PINK1 or PARK2 overexpression (Yang et al, 2006). This indicated 
PINK1 and parkin likely act together or in the same pathway. Further experiments showed 
cellular mitochondrial depolarisation could stabilise PINK1 in the mitochondria. This 
increase in PINK1 caused phosphorylation of mitofusin-2 (Mfn2), which attracts parkin to 
the mitochondria and binds it (Chen & Dorn, 2013). Parkin then ubiquitinates a protein on 
the mitochondria and promotes mitochondrial degradation. Mutations in the PARK2 gene, 
associated with Parkinsonism in patients, interfere with this mitochondrial degradation by 
preventing parkin binding to the mitochondria or by preventing mitochondrial protein 
ubiquitination (Geisler et al, 2010).    
 Mutations in the DJ-1 gene were also found to be responsible for cases of autosomal 
recessive inherited early onset Parkinsonism (Bonifati et al, 2003). DJ-1 is expressed in most 
tissues in a number of subcellular compartments including the mitochondria (Zhang et al, 
2005). It is an atypical peroxiredoxin-like peroxidase that directly scavenges hydrogen 
peroxide (H2O2) and other peroxides (Andres-Mateos et al, 2007). Its absence in mice does 
not lead to substantia nigra neurodegeneration, but there is an increase in mitochondrial 
H2O2 levels and an increase in neuronal susceptibility to oxidative insults (Andres-Mateos et 
al, 2007; Kim et al, 2005).  
 These autosomal recessive mutations are involved in the removal of damaged 
mitochondria or the protection of mitochondria from oxidative insults. Therefore, they 
implicate oxidative stress and mitochondrial dysfunction as central to the etiology of 
Parkinsonism.  
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1.3.3 Midbrain Substantia Nigra Dopaminergic Neuron Susceptibility to 
Oxidative Stress 
The loss of the midbrain SNpc dopaminergic neurons causes the motor symptoms of 
Parkinsonism. There are several pieces of evidence to suggest they are more susceptible to 
oxidative stress than other neurons of the brain, further suggesting increased oxidative stress 
could be critical to their degeneration.   
 One piece of evidence comes from their susceptibility to oxidative stress related 
toxins. Drug addicts that took heroin containing the impurity 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) showed a relatively selective loss of SNpc neurons, indicating 
these neurons were more susceptible to the MPTP toxin (Langston et al, 1999). Its toxicity 
was found to be due to 1-methyl-4-phenylpyridinium (MPP+), which was produced after 
MPTP metabolism by monoamine oxidase B (Langston et al, 1984; Markey et al, 1984). 
MPP+ is specifically taken up into catecholaminergic neurons and inhibits complex I of the 
mitochondrial electron transport chain, resulting in cell death (Javitch et al, 1985; 
Richardson et al, 2007). Therefore of all the catecholaminergic neurons in the brain, those of 
the SNpc were preferentially susceptible to MPP+ toxicity. Further evidence comes from 
intravenous rotenone injection of rats. Rotenone is also a mitochondrial electron transport 
chain inhibitor but is not specifically taken up into catecholaminergic neurons (Earley & 
Ragan, 1984; Lindahl & Oberg, 1960). These rats showed loss of SNpc neurons, as well as 
the catecholaminergic neurons of the locus coeruleus (Betarbet et al, 2000). This suggests 
that of all the neurons in the brain the SNpc neurons are more susceptible to death due to 
inhibition of complex I of the mitochondrial electron transport chain.  
 The reason for this increased susceptibility may be partly due to an observation 
made by Heiko Braak. He observed the neurons lost in PD have long thin axons and are 
either unmyelinated or poorly myelinated with extensive arborisation (Braak et al, 2004; 
Matsuda et al, 2009). These properties result in greater energy demands and would make 
them more susceptible to oxidative damage or inhibition of the mitochondrial electron 
transport chain.  
 Another related reason for their increased susceptibility might be due to their redox 
state. Mice expressing mitochondrial-targeted redox-sensitive green fluorescent protein 
(GFP) had a higher mitochondrial oxidation state in the SNpc neurons than in the 
neighbouring ventral tegmental area dopaminergic neurons. This higher oxidation state was 
shown to be due to the influx of calcium through L-type calcium channels during the 
pace-making activity of the SNpc neurons (Guzman et al, 2010). The SNpc neurons have 
lower levels of calcium buffering proteins and may therefore require more energy to remove 
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the calcium, putting a greater load on the mitochondria. L-type calcium channel blockers 
prevented the calcium influx, and significantly reduced the oxidation state of the SNpc 
neurons. This higher mitochondrial oxidation state was also present in the locus coeruleus 
and the dorsal motor nucleus of the vagus neurons, which are also lost early in PD (Goldberg 
et al, 2012; Sanchez-Padilla et al, 2014). Therefore this higher mitochondrial oxidation state 
may make it easier to shift the balance towards oxidative stress induced death than other 
neuronal cell types.  
 One more SNpc property that may make it more susceptible to oxidative stress is the 
presence of dopamine in these neurons. Dopamine and catecholamines can undergo 
auto-oxidation in the presence of metal ions or at neutral and basic pH to produce H2O2 
(Klegeris et al, 1995; Rosenberg, 1988). This increase in ROS could shift the redox balance 
causing oxidative stress.  
 The SNpc neurons have properties that may make them more susceptible to 
oxidative insult, including thin, poorly myelinated neurons, an oxidised mitochondrial redox 
potential and the presence of dopamine. Therefore the SNpc and other select neurons that 
degenerate in early PD are more susceptible to oxidative insults than other neurons of the 
brain. 
1.4 Oxidative Stress 
Oxidative stress is an imbalance between reactive species and antioxidants. This imbalance 
results in reactive species that are free to react with cellular components, causing oxidative 
damage.  
1.4.1 Reactive Species 
ROS are formed by the reduction of the oxygen atom (Figure 1.2). These species are reactive 
or unstable, hence the name ROS (Kellogg & Fridovich, 1975). The reactivity of each 
species differs, with the hydroxyl radical being the most reactive (Sies, 1993). In addition to 
ROS, other atoms have reactive derivatives, including reactive nitrogen species. Some of the 
reactive species are free radicals with one or more unpaired electron, including diatomic 
oxygen, the superoxide radical and the hydroxyl radical. 
 Diatomic oxygen has two unpaired electrons that have parallel spins (Pauling, 1931). 
In order to react with another atom or molecule it too must have two unpaired electrons with 
parallel spins. However, this is rare so oxygen usually receives one electron at a time 
(Pauling, 1931; Halliwell & Gutteridge, 1984). Alternatively, energy can be provided to 
oxygen, which results in pairing up of the unpaired electrons. This produces singlet oxygen, 
which has no unpaired electrons and is therefore more reactive than diatomic oxygen 
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(Herzberg & Herzberg, 1947; Halliwell & Gutteridge, 1984). The addition of one electron to 
oxygen produces the superoxide radical, which has one unpaired electron (Figure 1.2) 
(Pauling, 1979; Neuman, 1934). Reduction of the superoxide radical by the addition of 
another electron produces the peroxide ion that becomes protonated to give H2O2 (Figure 
1.2) (Halliwell & Gutteridge, 1984). H2O2 has no unpaired electrons but it has a weak bond 
between the oxygen atoms making it highly reactive (Halliwell & Gutteridge, 1984). The 
breakage of the bond between the oxygen atoms in H2O2 produces the hydroxyl radical, 
which has one unpaired electron. This reaction occurs in the presence of heat or radiation 
(Halliwell & Gutteridge, 1984; Gajewski et al, 1990). In addition, in the presence of metal 
ions the rate of this reaction is increased, and is known as the Fenton reaction (Figure 1.2) 
(Fenton, 1894). The addition of an electron and proton to the hydroxyl radical produces the 
more stable water molecule (Figure 1.2).  
	  
Figure 1.2 - Reduction of the oxygen atom to produce reactive oxygen species (ROS) and 
cellular antioxidant defence enzymes. The superoxide radical is produced by the one electron 
reduction of diatomic oxygen. In cells the superoxide dismutase (SOD) enzyme catalyses the removal 
of the superoxide radical to produce H2O2. A one-electron reduction of the superoxide radical 
produces H2O2, which is removed by glutathione peroxidase (GPx) and catalase to produce water and 
oxygen. The hydroxyl radical is produced by the one-electron reduction of H2O2, which iron or copper 
ions can catalyse, this is a Fenton reaction. There is no known cellular defence enzyme for the 
hydroxyl radical.  
 Other ROS exist that are produced from the reaction of ROS with lipids including 
the alkoxyl radical (RO) and peroxyl radical (ROO) (Bateman, 1954; Bolland, 1949; 
Girotti, 1985).  In addition, ROS can react with other species to produce other reactive 
molecules. For example, the superoxide radical can react with nitric oxide to produce 
peroxynitrite, which is a reactive nitrogen species (Goldstein & Czapski, 1995). 
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1.4.2 Cellular Sources of Reactive Species 
Reactive species are produced at a number of sites within the cell, including the endoplasmic 
reticulum, peroxisome, mitochondria and cytosol (Figure 1.3). The types of ROS produced at 
these sites vary and the mechanism of their production is different.
 
Figure 1.3 – Cellular sources of ROS. Within cells there are a number of sites known to produce 
ROS. Superoxide is produced in mitochondrion due to leakage of electrons from the mitochondiral 
electron transport chain. H2O2 is produced in peroxisomes by the break down of lipids and in the 
endoplasmic reticulum (ER) as a by-product of disulphide bond formation. The enzymes 
lipoxygenase, xanthine oxidase, cytochrome P450 and NADPH oxidase produce ROS either as by-
products or to kill invading organisms (Adapted from Holmström & Finkel, 2014). 
 
 A major source of ROS production in cells is enzymatic activity. NOX enzymes are 
one of the most studied. NOX2, originally isolated from the membrane of phagocytes, 
produces superoxide radicals to kill invading organisms (Babior et al, 1973; 1975). The 
NOX2 enzyme is made up of a complex of subunits that upon activation form a functional 
enzyme, which catalyses the production of the superoxide radical from NADPH and oxygen 
(Clark et al, 1990). A defect in the NOX2 enzyme causes patients to develop chronic 
infections with a disease known as chronic granulomatous disease (Curnutte et al, 1974; 
1975). Further studies have found isoforms of the NOX enzyme in other subcellular 
compartments, including the mitochondria and the endoplasmic reticulum; these isoforms 
may be involved in cell signalling (Chen et al, 2008).  
 Enzymes may also produce ROS as by-products of other cellular functions. For 
example, lipoxygenase produces the superoxide radical as a by-product of lipid breakdown 
(O'Donnell & Azzi, 1996). In addition, the enzyme xanthine oxidase involved in the 
breakdown of purines produces superoxide and H2O2 (Sanders et al, 1997; Harrison, 2002). 
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The cytochrome P450 family of enzymes in the endoplasmic reticulum also produce H2O2, 
as a by-product of xenobiotic breakdown (Gorsky et al, 1984; Zhukov & Ingelman-
Sundberg, 1999; Szczesna-Skorupa & Kemper, 1993). 
 Another source of ROS production in cells is the mitochondria. In isolated 
mitochondria the major site of superoxide production is complex I of the mitochondrial 
electron transport chain (Loschen et al, 1974; Kussmaul & Hirst, 2006). Studies have shown 
the flavin mononucleotide of complex I, which can be found on the matrix side of the inner 
membrane, is the site of superoxide production (Kussmaul & Hirst, 2006; Kudin et al, 2004). 
The levels of superoxide production from complex I in vivo are unknown. Within the 
mitochondria there may be other sites of ROS production, such as the coenzyme Q pool and 
the mitochondrial electron transport chain complex III, but the major source is considered to 
be complex I (Murphy, 2009). 
 The endoplasmic reticulum and peroxisomes also produce H2O2 (Gorsky et al, 1984; 
Zhukov & Ingelman-Sundberg, 1999; Mueller et al, 2002; Boveris et al, 1972). In the 
endoplasmic reticulum a source of this H2O2 is the Ero1p enzyme, which is involved in 
disulphide bond formation, as well as the cytochrome P450 enzymes (Gross et al, 2006; 
Szczesna-Skorupa & Kemper, 1993). In the peroxisomes, H2O2 is produced by the 
metabolism of lipids and oxygen (Mueller et al, 2002; Boveris et al, 1972). 
 The mitochondria, endoplasmic reticulum, peroxisomes and cytosol are all potential 
sources of ROS production in cells (Boveris et al, 1972). Some of this production is 
intentional to kill invading organisms, some is produced to allow cell signalling and some is 
produced as a by-product of other cellular reactions. In addition, ROS can be found in cells 
as a consequence of environmental interactions, for example exposure to sun (Heck et al, 
2003), exposure to toxins (Valavanidis et al, 2009) or as a result of trauma (Tyurin et al, 
2000).  
1.4.3 Oxidative Damage to Cellular Components 
Low levels of reactive species are required for cell signalling (Reviewed Finkel, 2011). 
However, when higher levels are produced the reactive species can attack DNA, lipids and 
proteins in the cell to produce oxidative damage, which eventually results in cell death. 
H2O2, for example, is reported to become toxic above 0.7 µM (Antunes & Cadenas, 2001). 
DNA oxidative damage is the result of reactive species attack on any of the 4 bases; 
guanine, adenine, cytosine or thymidine; or the DNA backbone (Balasubramanian et al, 
1998; Jaruga & Dizdaroglu, 1996; Dizdaroglu et al, 1991). The most susceptible base to 
oxidation is guanine (Steenken & Jovanovic, 1997). In the presence of singlet oxygen or 
peroxyl radicals (ROO) the guanine base was preferentially modified, whereas in the 
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presence of the hydroxyl radical all DNA bases were modified (Valentine et al, 1998; Prat et 
al, 1997). There are many DNA oxidative modifications that have been found after 
irradiation or hydroxyl radical exposure but 8-hydroxy-2-deoxyguanosine (8-OHdG) (Figure 
1.4a) and thymine glycol are among the most commonly observed (Figure 1.4a) (Douki et al, 
2006; Frelon et al, 2000; Pouget et al, 2002). DNA base modifications were also found in 
DNA not exposed to the hydroxyl radical, but the levels were much lower, indicating DNA 
bases may be oxidised under normal conditions (Gajewski et al, 1990). Therefore, cells have 
repair mechanisms that can removed oxidised DNA bases or prevent incorporation of 
oxidised bases into DNA (Jaruga & Dizdaroglu, 1996; Kasai et al, 1986; Hazra et al, 1998; 
Mo et al, 1992). Failure of these repair mechanisms to remove all oxidised bases can 
produce changes in DNA base pairing, resulting in DNA mutations that can alter gene 
expression and cause disease (Cheng et al, 1992; Tan et al, 1999; Harwood et al, 1991). 
Cellular membranes are composed of phospholipids, which are another target for 
ROS attack (Gorter & Grendel, 1925). This oxidative damage to lipids produces lipid 
peroxidation (Figure 1.4b). Initiation of lipid peroxidation occurs due to the removal of 
hydrogen from a lipid (LH). This could be due to attack by a hydroxyl radical, alkoxyl 
radical (RO), peroxyl radical (ROO) or iron ion but not H2O2 or the superoxide radical 
(Fong et al, 1973; Catalá, 2010; Fridovich & Porter, 1981). A lipid alkyl radical (L) is 
produced. This can then react with oxygen to produce a lipid peroxyl radical (LOO), which 
removes hydrogen from another lipid to produce a lipid hydroperoxide (LOOH) and another 
alkyl radical (L) (Bateman, 1954; Bolland, 1949; Girotti, 1985). Therefore creating a lipid 
peroxidation chain reaction. Further degradation of these lipid hydroperoxides produces 
toxic aldehydes, including 4-HNE and malondialdehyde (Mlakar & Spiteller, 1996). Lipid 
peroxidation can cause an increase in membrane fluidity, loss of cell membrane integrity and 
eventually cell death. Therefore, cells have mechanisms to remove these toxic lipid products: 
antioxidants can remove the alkyl radicals (L); GPx can remove the lipid hydroperoxides 
and enzymes like glutathione S-transferase (GST) can remove the aldehydes produced. 
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Figure 1.4- DNA and lipid oxidative damage. (a) Two commonly found Υ–irradiation induced DNA 
base oxidative modifications - 8-hydroxy-2-deoxyguanosine (8-OHdG) and thymine glycol (Figure 
adapted from Aller et al, 2007 and Wu et al, 2004). (b) Lipid peroxidation is initiated by the removal 
of a hydrogen atom from a lipid to produce a lipid radical (L). Propagation occurs when the lipid 
radical reacts with oxygen to produce a lipid peroxyl radical (LOO). This lipid peroxyl radical 
propagates the reaction by removing a hydrogen atom from another lipid, producing a lipid 
hydroperoxide (LOOH) and another lipid radical (L). This lipid radical can then react with oxygen to 
produce the lipid peroxyl radical and so on, creating a chain reaction (Figure adapted from Ishiyama et 
al, 1999). 
  
 Proteins can also be damaged through ROS attack of the amino acids or the peptide 
backbone (Garrison et al, 1962). Some amino acids are more susceptible to oxidative 
damage including histidine, tyrosine, tryptophan, cysteine and methionine (Alvarez et al, 
1999; Davies et al, 1987; Proctor & Bhatia, 1953; Drake et al, 1957; Barron et al, 1955). 
Histidine is converted to 8-oxohistidine by the hydroxyl radical (Uchida & Kawakishi, 
1993). Tyrosine exposure to nitric oxide produces 3-nitrotyrosine and subsequently 
dityrosine (Kikugawa et al, 1994), and H2O2 exposure produces the tyrosyl radical and then 
dityrosine (Heinecke et al, 1993). Tryptophan produces 5-nitroindole after nitric oxide 
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damage (Kikugawa et al, 1994). Cysteine produces sulphenic acid and then a disulphide 
bond on exposure to H2O2 (Carballal et al, 2003). Methionine is oxidised by peroxynitrite to 
methionine sulphoxide and then methinone sulphone (Figure 1.1) (Pryor et al, 1994). One 
repair mechanism that has been found is the family of MSR enzymes that reduce methionine 
sulphoxide to methionine (Ciorba et al, 1997; Moskovitz et al, 2001). In addition, the 
aldehydes produced during lipid peroxidation if not removed are capable of reacting with 
proteins at the histidine, lysine or cysteine residues, producing for example 4-HNE modified 
proteins (Uchida & Stadtman, 1993). Oxidative damage to proteins can prevent them from 
functioning, prevent their degradation or may be involved in cell signalling (Barron et al, 
1955; Friguet et al, 1994).  
 The over production of ROS can result in damage to DNA, lipids and proteins, 
providing a measurable output of cellular oxidative stress. However, if this damage is left 
unrepaired it will eventually cause cell death and potentially initiate disease. 	  
1.4.4 Tools to Measure Reactive Oxygen Species Production 
One method to detect the presence of free radical ROS, with at least one unpaired electron, is 
electron paramagnetic resonance (EPR) spectroscopy. In addition, there are dyes available 
that are non-fluorescent but produce fluorescent products after reaction wth ROS, for 
example DHE and the CellROX® family of dyes. This provides a method to directly 
measure the levels of ROS production.  
1.4.4.1 Electron Paramagnetic Resonance Spectroscopy 
Free radicals possess at least one unpaired electron, which can be detected by a technique 
known as EPR spectroscopy. The unpaired electron acts as a magnet in the presence of a 
magnetic field, aligning either parallel or antiparallel to it, creating two energy levels. 
Application of electromagnetic radiation of the correct energy results in it being absorbed 
allowing the electron to move from the lower energy level to the higher energy level. This 
absorption of energy is measured and is presented as the first derivative, which is the rate of 
change in absorbance. The atoms surrounding the unpaired electron, for example hydrogen 
or nitrogen, can also act as magnets, creating additional energy levels and therefore 
additional energy absorptions. Therefore the spectrum produced from the absorbance of 
energy allows identification of the radicals produced. Most free radicals are highly reactive 
so chemical spin traps, like 5,5-dimethyl-1-pyrroline N-oxide (DMPO), are often employed 
to create radicals with longer half-lives that can be measured by EPR (Figure 1.5). For 
example the DMPO/OH radical adduct has a half-life of hours rather than the nanosecond 
half-life of the hydroxyl radical (Figure 1.5) (Review: Hawkins & Davies, 2014).  
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Figure 1.5 – The chemical spin trap DMPO and the EPR spectra produced after trapping the 
hydroxyl radical. The chemical structure of the spin trap DMPO is shown. DMPO can trap the 
hydroxyl radical to produce the DMPO/OH radical adduct. The unpaired electron in this radical 
adduct can be detected by EPR. A 1:2:2:1 quartet spectrum is produced due to the surrounding 
nitrogen and hydrogen atoms. G stands for Gauss and is the strength of the magnetic field used 
(Figure adapted from Lawrence et al, 2003).	  
1.4.4.2 Dihydroethidium 
DHE, also known as hydroethidine, is used to detect the production of superoxide and the 
presence of other oxidants in cells. It is easily taken up into cells and has a blue fluorescence 
in the reduced state (Bindokas et al, 1996). Once inside cells it can be oxidised to produce 
the red fluorescent products, ethidium and 2-hydroxyethidium, which bind to DNA 
(Bindokas et al, 1996). This oxidation is known to occur in the presence of the superoxide 
radical or cytochrome c, but not H2O2, singlet oxygen, hydroxyl radical, nitric oxide or 
peroxynitrite (Bindokas et al, 1996; Benov et al, 1998). However, other ROS may be 
involved in the oxidation of DHE to ethidium (Zielonka et al, 2006). Therefore ethidium and 
2-hydroxyethidium productions, that is the red fluorescence at excitation 510 nm, does not 
solely report superoxide production. Further investigation into the reaction between the 
superoxide radical and DHE showed 2-hydroxyethidium was produced (Zhao et al, 2003). 
This product is unique to DHE oxidation by the superoxide radical and can be detected by 
high-performance liquid chromatography (HPLC). This method provides a way to solely 
detect superoxide radical production in cells (Zhao et al, 2003; Zielonka et al, 2009; 2006). 
Additional studies using a mitochondrial-targeted form of DHE, MitoSOX, showed it might 
be possible to distinguish between the 2-hydroxyethidium and ethidium fluorescence using 
excitation at 360 nm. This wavelength caused excitation of 2-hydroxyethidium, but not 
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ethidium, to give a semi-quantitative indication of superoxide levels (Robinson et al, 2006). 
In practice, DHE can be used to assess the presence of several oxidants in the cell by 
measuring amount of red fluorescence or rate of increase of red fluorescence over a short 
time-frame. Since ethidium binds DNA, nuclear fluorescence measurements are taken 
although the oxidation of DHE could have occurred elsewhere in the cell. Alternatively, 
when combined with HPLC or 360 nm excitation, DHE can be used to detect the production 
of superoxide radicals in cells.  
1.4.4.3 CellROX® Family  
The CellROX® family of dyes consists of three members; CellROX® Green, CellROX® 
Orange and CellROX® Deep Red, that are sold by Life Technologies. Each member is cell 
permeable with little or no fluorescence in the reduced state but on oxidation they become 
highly fluorescent. The reactivity of these dyes to different ROS differs according to Life 
Technologies. CellROX® Green and CellROX® Deep Red both react with hydroxyl and 
superoxide radicals, but not H2O2, nitric oxide or peroxynitrite. In contrast, CellROX® 
Orange reacts with all of these ROS. In addition, the dyes differ in their cellular localisation 
CellROX® Orange and CellROX® Deep Red are both cytoplasmic whereas CellROX® 
Green binds to DNA after oxidation and is therefore nuclear. A further difference is that 
CellROX® Green and Deep Red can undergo fixation, whereas CellROX® Orange cannot 
(Life Technologies, 2014).  
 These CellROX® dyes have been used in a number of papers to detect ROS 
production. Evidence from these papers that suggest they are suitable for ROS production 
detection come from their increase in fluorescence in the presence of toxins tert-butyl 
hydroperoxide (tBHP) and menadione, which result in an increase in ROS production (Yoon 
et al, 2014; Gemelli et al, 2014). In addition, if antioxidants are added to reduce these ROS 
the fluorescence increase is prevented (Yoon et al, 2014). This suggests CellROX® dyes are 
suitable for use in detecting an increase in ROS production, but cannot be used to distinguish 
the type of ROS produced.  
1.4.5 Cellular Antioxidant Defences   
The cellular antioxidant defence mechanisms include small molecules and enzymes with the 
ability to directly scavenge radicals as well as cellular responses that act to reduce oxidative 
stress. Cells have many endogenous antioxidant defence mechanisms only some of which 
are mentioned here. Here, the enzymatic antioxidant defences, the small antioxidant peptide 
GSH and the transcription factor Nuclear factor-erythroid 2 (NF-E2)-related factor 2 
(NFE2L2 or Nrf2) that activates antioxidant gene transcription, will be covered. Further 
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antioxidant defences include other small molecules synthesised in the cell, small molecules 
that are absorbed from the diet, other transcription factors that activate gene expression of 
antioxidant genes and metal iron chelators. 
1.4.5.1 Enzymatic Defences 
Cellular enzymatic antioxidant defences act to remove ROS produced in cells, thereby 
preventing the formation of oxidative damage. This includes SOD, catalase, GPx (Figure 
1.2) and peroxiredoxins. 
 SOD catalyses the removal of superoxide to produce H2O2 and oxygen (Figure 1.2) 
(McCord & Fridovich, 1969). It is present in a number of aerobes, but absent from many 
anaerobes, since anaerobes die in the presence of oxygen it was suggested that SOD was 
required for survival in the presence of oxygen (McCord et al, 1971). The original report 
isolated SOD with copper and zinc at the active site. Since then further SODs have been 
discovered with different metal ion cofactors, including, manganese, nickel and iron, at their 
active sites. In humans there are 3 forms of SOD. SOD1 or Cu/ZnSOD that is found in the 
cytosol, the mitochondrial intermembrane space and the nucleus (Weisiger & Fridovich, 
1973; Crapo et al, 1992). SOD2 or MnSOD has manganese at its active site and is found in 
the mitochondrial matrix (Keele et al, 1970; Weisiger & Fridovich, 1973). SOD3 also known 
as extracellular SOD has copper and zinc at its active site but its amino acid composition and 
weight are different to SOD1 (Marklund, 1982). The most important of these appears to be 
MnSOD as SOD2 knockout mice die 4-10 days after birth with impaired mitochondrial 
function (Li et al, 1995). SOD1 is also important, as SOD1 mutations have been found in 
patients with amyotrophic lateral sclerosis (ALS) (Rosen et al, 1993). When SOD1 is 
knocked out in mice they show a slightly earlier age of death than normal, an increase in 
oxidative damage, an increased susceptibility to toxins and impaired fertility (Ho et al, 1998; 
Elchuri et al, 2005; Reaume et al, 1996). This suggests SODs are important cellular 
antioxidant enzymes.  
 Another antioxidant enzyme is catalase, which catalyses the reduction of H2O2 to 
water in a two-step process using iron ions at its active site (Figure 1.2) (Loew, 1900; 
Putnam et al, 2000). Catalase has four subunits, with four iron ions at its active site and four 
NADPH molecules (Kirkman & Gaetani, 1984; Sumner & Dounce, 1937). In cells it is 
mainly located in peroxisomes and some other membranous particles, but is not abundant in 
the cytosol (Aikawa et al, 1991). The absence or low levels of catalase in humans produces 
acatalasemia, with mild symptoms of oral gangrene in childhood (Takahara et al, 1960). In 
catalase-null mice there is a delayed removal of H2O2 but no abnormalities were detected 
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(Ho et al, 2004). The reason for these mild phenotypes may be because cells have alternative 
mechanisms for the removal of H2O2, including GPx and peroxiredoxins.  
 Another enzyme capable of the removal of H2O2 and alkyl peroxides is the 
antioxidant protein peroxiredoxin (Chae et al, 1993). Some peroxiredoxin isoforms are also 
capable of peroxynitrite removal (Dubuisson et al, 2004). A cysteine residue in the 
peroxiredoxin proteins is evolutionarily conserved and is essential for their ability to reduce 
peroxides (Chae et al, 1994b). This cysteine residue is oxidised by peroxides, to remove 
them and then reduced by thioredoxin, to produce an active enzyme (Chae et al, 1994a). In 
mammals there are 6 isoforms that are split into 3 subclasses: 2-cysteine peroxiredoxins, 
1-cysteine peroxiredoxin and the atypical 2-cysteine peroxiredoxin. These isoforms are 
located in different regions of the cell: cytosol, mitochondria, extracellular space and 
peroxisomes (Seo et al, 2000; Okado-Matsumoto et al, 2000; Kang et al, 1998; Reviewed by 
Rhee et al, 2005) 
 In summary, the cell has a number of important antioxidant defence enzymes that 
remove ROS and prevent them from producing oxidative damage to the cell. GPx is also 
involved in the removal of peroxides and will be discussed in the next section.  
1.4.5.2 Glutathione Antioxidant  
GSH is a tripeptide synthesised in cells containing cysteine, glycine and glutamic acid 
(Hopkins, 1929; Kosower & Kosower, 1978). A deficiency in GSH results in metabolic 
acidosis and neurological symptoms, possibly as a result of oxidative stress (Wellner et al, 
1974).  The presence of the thiol group in the cysteine residue allows GSH to act as an 
electron donor, or antioxidant. In cells GSH has been reported to have a number of diverse 
functions, but here the focus will be on its antioxidant function.  
 Direct radical scavenging of superoxide and hydroxyl radicals by GSH is possible 
but this would produce a thiyl radical (Eriksen & Fransson, 1988; Sjoberg et al, 1982; 
Wefers & Sies, 1983; Galano & Alvarez-Idaboy, 2011). This may then react with another 
thiyl radical to produce oxidised glutathione known as glutathione disulphide (GSSG). 
However, whether this scavenging occurs in vivo is unknown as other antioxidant 
mechanisms may be more competitive than GSH for the radicals (Jones et al, 2003). A 
known mechanism by which GSH acts as an antioxidant in vivo is by acting in conjunction 
with GST and GPx to remove toxic substrates.  
 GST acts as a xenobiotic or electrophilic substance detoxification enzyme by 
catalysing their conjugation to GSH (Booth et al, 1961; Combes & Stakelum, 1961; Baez et 
al, 1997; Cheng et al, 2001). These conjugates may be broken down further into mercapturic 
acids and excreted in the urine (Barnes et al, 1959; Stekol, 1941). There are 7 different GST 
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gene families with different amino acid sequences, giving them different xenobiotic substrate 
specificities (Mannervik & Jensson, 1982; Stockman et al, 1985). Soluble cytosolic GST 
forms were first discovered, and subsequently membrane-associated forms of GST were 
identified (Pemble et al, 1996). The cytosolic forms are dimers composed of the same 
monomer or monomers from the same family. Each monomer has a hydrophilic binding site 
for GSH and a hydrophobic binding site for the xenobiotic substance (Jakobson et al, 1979).  
 GPx is an enzyme involved in the removal of H2O2 and other peroxides, including 
tBHP and lipid hydroperoxides. The first GPx to be analysed was GPx1, which was isolated 
from the cytosol of cells. It contains four subunits with one selenium atom per subunit at the 
active site (Flohe et al, 1973; Lötscher et al, 1979). These selenium ions catalyse the 
reduction of peroxides to alcohol, using GSH as the hydrogen donor. GSH then becomes 
oxidised to GSSG (Little & O'Brien, 1968; Christophersen, 1969). GPx is not specific for the 
peroxides that it reduces, unlike catalase that has higher specificity for H2O2 (Little & 
O'Brien, 1968). The GSSG produced is then either released from cells or reduced to GSH by 
glutathione reductase, which uses NADPH as the hydrogen donor (Sies et al, 1972). The 
limiting step in this reduction is the NADPH levels (Sies et al, 1972).  
 A number of other GPxs have been discovered which catalyse the same reaction but 
are found in different tissues and have varied specificities for different peroxides. GPx2 and 
3 are both tetramers containing selenium. However, GPx2 is mainly found in the liver and 
colon, therefore it is known as gastrointestinal GPx whereas GPx3 is found at higher levels 
in the plasma (Maddipati & Marnett, 1987; Chu et al, 1993; Akasaka et al, 1990). GPx4 is a 
monomeric enzyme with selenium at its active site and is mainly found in phospholipid 
bilayers, acting as a protector against lipid peroxidation (Ursini et al, 1985; Thomas et al, 
1990). Mutations of GPx4 cause neonatal lethality in mice and humans with cardiac defects 
and nervous system abnormalities, illustrating its importance (Smith et al, 2014; Yant et al, 
2003).  
 Four further GPx enzymes 5, 6, 7 and 8 have been identified but they are less well 
studied. Although, GPx 5, 7 and 8 do not have selenium at their active site, they are capable 
of catalysing the same reaction, possibly at a slower rate (Toppo et al, 2008). GPx6 does 
contain selenium and is expressed in the embryo and olfactory epitheium (Kryukov, 2003). 
 Both the GPx and GST enzymes require GSH to donate electrons, allowing removal 
of toxic compounds from cells. Therefore GSH is an important antioxidant in cells.  
1.4.5.3 Nrf2 
NFE2L2 or Nrf2 is a transcription factor transcribed by the gene NFE2L2. It is involved in 
the activation of antioxidant-associated gene expression in the presence of oxidative stress. 
	   23	  
In Nrf2 knockout mice there is an inability to activate these genes therefore mice are more 
susceptible to toxins (Enomoto et al, 2001; Yoh et al, 2001).   
Figure 1.6 - Nrf2-Keap1 antioxidant response pathway. In the absence of stress Nrf2 is bound to a 
Keap1 dimer and targeted by ubiquitination for proteasomal degradation. In the presence of oxidative 
or electrophilic stress the cysteine sulphur atoms are altered changing the Keap1 secondary structure. 
This prevents Keap1 from associating with the E3 ubiquitin ligase Cul3 and reduces its association 
with Nrf2, preventing Nrf2 degradation. Therefore Nrf2 is stabilised and can accumulate in the 
nucleus. In the nucleus Nrf2 dimerises with small Maf proteins, which then bind to antioxidant 
response element (ARE) DNA sequences activating transcription of target genes, including those 
involved in GSH synthesis and removal of ROS (Figure adapted from Taguchi et al, 2011). 
 
 In the absence of oxidative stress Nrf2 binds to a dimer of Kelch-like 
ECH-associated protein 1 (Keap1) (Kobayashi et al, 2004; Tong et al, 2006; 2007). This 
Keap1 protein acts as an adaptor protein linking Nrf2 with Cullin 3 (Cul3), an E3 ubiquitin 
ligase (Wakabayashi et al, 2003). This results in Nrf2 lysine residues becoming 
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ubiquitinated, targeting it for proteasomal degradation (Figure 1.6) (Kobayashi et al, 2004; 
Furukawa & Xiong, 2005; Cullinan et al, 2004; Zhang et al, 2004).  
 In the presence of stress the Nrf2 protein levels are increased without a change in 
messenger ribonucleic acid (mRNA) expression levels (McMahon et al, 2003). This is due to 
oxidative stress attacking the cysteine residues of the Keap1 protein, altering its secondary 
structure, which prevents it binding to Cul3 and weakens its association with Nrf2 
(Rachakonda et al, 2008; Eggler et al, 2005; Zhang et al, 2004; Kobayashi et al, 2006; 
Yamamoto et al, 2008). This prevents the ubiquitination of Nrf2, allowing it to accumulate 
and move to the nucleus where it forms a dimer with small Maf proteins (Figure 1.6) 
(Kobayashi et al, 2006; McMahon et al, 2003). This dimer can bind to a specific DNA 
sequence known as the antioxidant response element (ARE), activating gene transcription 
(Itoh et al, 1997). AREs are found in genes that counteract oxidative or electrophilic stress, 
including genes involved in GSH synthesis, removal of ROS and breakdown of xenobiotics 
(Figure 1.6) (Yates et al, 2009). Therefore stabilisation of the Nrf2 transcription factor 
mediates an antioxidant transcriptional response in cells.  
1.4.6 Flavonoid Antioxidants 
Flavonoids are a group of polyphenolic compounds found in plants with a similar backbone 
structure (Figure 1.7a). Their name, flavonoid, comes from the Latin word for yellow, which 
is their colour (Baier, 1955). In plants, the flavonoids are pigments that may be involved in 
attracting insects to allow pollination of plants (Brouillard et al, 1990; Iwashina, 2003). In 
addition, they are considered as protectants against harmful ultraviolet rays from light, as 
well as other functions (Skaltsa et al, 1994). There are now over 5000 natural flavonoids 
reported. These flavonoids can be split into six subclasses; flavones, flavonols, flavanones, 
flavanols (or catechins), anthocyanidins and isoflavones (Figure 1.7b). They are reported to 
have a wide range of functions including an antioxidant radical scavenging ability. This 
antioxidant ability comes from the donation of hydrogen atoms from the hydroxyl groups. 
These hydrogen atoms can be donated to a number of radicals, including the hydroxyl, 
peroxyl (ROO) and superoxide radicals (Bors et al, 1990; van Acker et al, 1996; Rafat 
Husain et al, 1987; Arora et al, 1998; Torel et al, 1986). In addition, flavonoids are capable 
of chelating metal ions, thereby preventing their production of radicals (Fernandez et al, 
2002). In studies examining the antioxidant ability of a number of flavonoids, it was found 
the flavonols, quercetin and myricetin were some of the best (Firuzi et al, 2005; Arora et al, 
1998; van Acker et al, 1996; Bors et al, 1990; Yang et al, 2001).  
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Figure 1.7 – Flavonoid backbone structure and the flavonoid subclasses. All flavonoids have a 
similar backbone structure composed of two phenyl rings A and B and a heterocyclic C ring 
containing oxygen (a). The six subclasses show variation on the hydroxyl and carbonyl groups 
attached to these rings and the position of the double bonds (b). In addition isoflavones show a 
different location of the B ring (Figures adapted from Hollman & Arts, 2000 and van Acker et al, 
1996). 
 
 Flavonoids are found in fruits and vegetables with quercetin more abundant than 
myricetin (Bhagwat et al, 2014). In food, flavonoids usually have a sugar group attached, 
known as glycosides (Miean & Mohamed, 2001; Herrmann, 1988). Quercetin in the 
glycoside form was found to be absorbed through the diet more efficiently than without the 
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sugar attached (Hollman et al, 1995). However, it was estimated that around half of the 
quercetin glycoside eaten was not absorbed (Hollman et al, 1995). Further studies have 
shown the food source of quercetin is also influential in its absorption (de Vries et al, 1998). 
Therefore flavonoid antioxidants are potent radical scavengers that can be absorbed through 
the diet. 
1.4.7 Synthetic Mitochondrial-Targeted Antioxidants  
There are other antioxidants synthesised in vivo or absorbed from the diet but none of these 
natural antioxidants are known to locate to the mitochondria or other subcellular 
compartments involved in ROS production. Therefore research is being performed focussed 
on synthesising mitochondrial-targeted antioxidants. Since mitochondrial dysfunction and 
oxidative stress have been implicated in PD, mitochondrial targeted antioxidants may be 
suitable protective compounds (Schapira et al, 1990; Keeney et al, 2006). There are 
currently two published groups of mitochondrial-targeted antioxidants. One is the group of 
Mito compounds and the other is a group of small peptides, originally named the SS Peptides 
(Figure 1.8). Neither of these groups of compounds is available commercially for scientific 
use and both were due to undergo phase II clinical trials.  
Figure 1.8 - Structure of mitochondrial-targeted antioxidants - MitoQ and SS-31. (a) MitoQ is 
based on coenzyme Q10 also known as ubiquinone (b) but a carbon chain has replaced the isoprenoid 
chain and the TPP ion is attached at the end of the carbon chain to attract MitoQ to the mitochondria. 
MitoQ is a mixture of oxidised, ubiquinone, and reduced, ubiquinol, forms of the coenzyme Q10 head 
group (b) and (c). (d) SS-31 is another mitochondrial-targeted antioxidant, which is a peptide, made 
up of D-arginine, dimethyltyrosine (Dmt), lysine and phenylalanine (Figure adapted from Sheu et al, 
2006 and James et al, 2004) 
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1.4.7.1 Mito Compounds 
Mito compounds are synthetic compounds that contain the triphosphonium ion (TPP). TPP 
has a positive charge, which is attracted to the negatively charged mitochondria. Therefore to 
create mitochondrial-targeted antioxidants this TPP has been attached to a number of known 
antioxidants. One of the first published was MitoVitE, which contained the antioxidant head 
group of Vitamin E with a two carbon chain and the TPP attached (Smith et al, 1999). It was 
taken up into cells and accumulated in the mitochondria, if the mitochondrial membrane 
potential was present. However, MitoVitE was less efficient than Vitamin E at protecting 
against lipid peroxidation, possibly due to its higher water solubility. In addition, as with 
other antioxidants it was toxic at high concentrations. 
 The second Mito antioxidant compound synthesised was MitoQ, which was based 
on coenzyme Q10, also known as ubiquinone, but the isoprenoid chain was changed to a 
carbon side chain and the TPP lipophilic cation was attached (Figure 1.8a). MitoQ contained 
both oxidised and reduced forms of the ubiquinone head group, known as ubiquinone and 
ubiquinol, respectively (Figure 1.8b and c). As with MitoVitE, MitoQ was taken up into the 
mitochondria, if the mitochondrial membrane potential was present and was capable of 
protecting against lipid peroxidation (Kelso et al, 2001). Further studies showed ubiquinol 
was the more active antioxidant form and that within the mitochondria the electron transport 
chain complex II continually reduced ubiquinone back to its ubiquinol form, recycling its 
antioxidant capability (Kelso et al, 2001; James et al, 2005). In addition, the length of the 
alkyl chain between the head group and the TPP ion was important. An increase in chain 
length increased the hydrophobicity of the compound, which in turn resulted in increased 
membrane binding and penetration. This increased antioxidant capacity against lipid 
peroxidation (Asin-Cayuela et al, 2004). MitoQ has been tested in Phase II clinical trials for 
its ability to delay the progression of PD. Newly diagnosed PD patients that had movement 
symptoms were given MitoQ or placebo for 12 months. However, no significant differences 
were found between MitoQ and the placebo in rate of disease progression (Snow et al, 
2010). In addition, Antipodean Pharmaceuticals hoped to undertake Phase IIb clinical trial 
with MitoQ for its protection against non-alcoholic fatty acid disease. However, the trial was 
terminated due to low participant enrolment (ClinicalTrials.gov Identifier NCT01167088). 
1.4.7.2 SS Peptides 
Another group of mitochondrial-targeted antioxidants are the SS peptides, the most 
successful of which is SS-31 also known as Bendavia (Figure 1.8d). The SS peptides, which 
were named after their authors Hazel Szeto and Peter Schiller, are short peptide sequences of 
approximately 4 amino acids with a positive charge (Schiller et al, 2000; Zhao et al, 2004). 
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They were originally synthesised as opioid agonists but subsequent research showed they 
also had ROS scavenging capacity (Schiller et al, 2000; Zhao et al, 2004; Cho et al, 2007; 
Szeto, 2006). By altering the sequence of amino acids the opioid agonist action could be 
reduced while still maintaining the antioxidant ability (Petri et al, 2006). This antioxidant 
scavenging ability is due to the presence of the tyrosine derivative; 2,6-dimethyltyrosine 
(Dmt) (Zhao et al, 2004; Cho et al, 2007). However, whether the SS peptide’s cellular 
protection is solely through its antioxidant scavenging is still controversial. In solution ROS 
scavenging appears to require much higher concentrations than in cells so they may be 
protecting cells through an alternative mechanism (Cho et al, 2007; Zhao et al, 2004).  
 The mitochondrial location of the SS peptides was suggested using radioactively 
labelled SS-02 and using a fluorescent derivative SS-19 (Zhao et al, 2004). However, a later 
study with radioactively labelled SS-31 suggested the mitochondrial uptake of SS-31 may be 
less than for other SS peptides (Zhao et al, 2005). These SS peptides, unlike MitoVitE, are 
not fully reliant on the mitochondrial membrane potential for their mitochondrial uptake 
(Zhao et al, 2004). Instead the mitochondrial uptake may be due to a combination of peptide 
lipophilicity and charge (Horton et al, 2008). 
 SOD1 mutations have been found in ALS patients therefore an ALS SOD1 mutation 
mouse model has been created that shows greater motor neuron susceptibility to toxins 
(Reaume et al, 1996). In this ALS mouse model SS-31 was found to slightly increase motor 
neuron survival and improve motor performance (Petri et al, 2006). In addition, SS-31 was 
able to reduce infarct size in rats after myocardial infarction (Cho et al, 2007). Therefore, 
SS-31, now named Bendavia is undergoing Phase II clinical trials with Stealth Peptides to 
assess its potential to reduce infarct size in myocardial infarction patients (Chakrabarti et al, 
2013) (ClinicalTrials.gov Identifier: NCT01572909). 
1.5 Hypothesis and Aims of this Thesis 
As mentioned above, there is evidence to suggest oxidative stress, potentially from 
mitochondria, is involved in α-synucleinopathy neurodegeneration. For example 
post-mortem analysis of PD patients’ brains suggest oxidative stress is involved at some 
stage in the disease process. Further evidence comes from recessive PD patients, which are 
known to have mutations in genes involved in antioxidant or mitochondrial function. In 
addition, the SNpc neurons lost in PD are sensitive to oxidative insults. It is possible that 
oxidative damage to the α-synuclein protein could increase its oligomerisation and thereby 
increase its toxicity. Alternatively, α-synuclein oligomers may increase the levels of 
oxidative stress resulting in toxicity. Therefore the hypothesis proposed is that oxidative 
stress is the cause of α-synuclein induced neurodegeneration. The lack of suitable models 
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has prevented investigation of how early in the disease process oxidative stress is involved 
and how influential it is in neuronal cell death. Therefore, there is a need for models that 
accurately represent the disease process. In addition, there is a need for commercially 
available potent synthetic antioxidants that can be used as tools to examine the involvement 
of oxidative stress in these models.  
 Therefore the aims of this project were to develop a model of α-synuclein-induced 
neuronal cell death and to determine the antioxidant scavenging potential of a synthetic 
flavonoid compound synthesised by Antoxis Limited. The specific aims were: 
 
• to develop an α-synuclein induced toxicity cell model 
• to develop a toxin-induced oxidative stress cell model  
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Chapter 2- Materials and Methods 
2.1  Cell Culture Materials 
2.1.1 Cell Lines  
The human neuroblastoma cell line, SH-SY5Y, was obtained from three different sources. A 
transgenic clone of SH-SY5Y with doxycycline inducible expression of α-synuclein was a 
kind gift from Dr. Kostas Vekrellis (Biomedical Research Foundation of the Academy of 
Athens, Greece) (Vekrellis et al, 2009). The second SH-SY5Y cell line was a kind gift from 
Dr. Mike Devine (Institute of Neurology, University College London). The third SH-SY5Y 
cell line was a kind gift from Professor David Porteous (Centre for Genomic and 
Experimental Medicine, University of Edinburgh). 
The rat cell line Neuroscreen™-1 (NS-1) (Thermo Scientific, R04-0001-AP) is a subclonal 
derivative of the rat adrenal pheochromocytoma cell line PC-12, which was derived for use 
in high-throughput screening (Radio et al, 2008). 
2.1.2 Cell Culture Media 
2.1.2.1 Greece SH-SY5Y Cell Culture Medium 
Since the SH-SY5Y clone from Greece carried a number of transgenes that expressed two 
drug-selectable markers, G418 and Hygromycin B, they were included in the medium. The 
α-synuclein transgene was repressed by doxycycline (Vekrellis et al, 2009). Therefore, the 
culture medium was composed of basal RPMI 1640 medium (Life Technologies, 11875) 
supplemented with 10% fetal bovine serum (FBS) (Life Technologies, 10270), 2 mM 
L-glutamine (Life Technologies, 25030), 200 µg/ml G418 (PAA Laboratories, P27-011), 50 
µg/ml Hygromycin B (Roche, 843 555) and 2 µg/ml doxycycline (Sigma, D9891). 
2.1.2.2 London and Edinburgh SH-SY5Y Cell Culture Medium 
The SH-SY5Y cell lines from London and Edinburgh were cultured in DMEM basal 
medium (Life Technologies, 41965-039) supplemented with 10% FBS, 2 mM glutamine and 
1 mM sodium pyruvate (Life Technologies, 11360-039). 
2.1.2.3 Neuroscreen™-1 Cell Culture Medium 
NS-1 cells were cultured in RPMI 1640 basal medium (Hyclone, SH30027) supplemented 
with 10% horse serum (Life Technologies, 26050-088), 5% FBS and 2 mM L-glutamine. 
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2.1.2.4 N2 Medium 
In order to differentiate SH-SY5Y cells N2 medium was used. The basal medium for N2 
consisted of 50% DMEM:F12 medium (Life Technologies, 21331-020) and 50% Neurobasal 
medium (Life Technologies, 21103). This was supplemented with an N2 supplement (200x) 
and L-glutamine to give a final medium concentration of 12.5 µg/ml insulin (Sigma, I-1882), 
50 µg/ml apo-transferrin (Sigma, T-1147), 37.5 µg/ml bovine serum albumin (BSA) (Life 
Technologies, 15260-037), 9.9 ng/ml progesterone (Sigma, P8783), 8 µg/ml putrescine 
(Sigma, P5780), 15 nM sodium selenite (Sigma, S5261) and 2 mM L-glutamine. 
2.1.2.5 Cell Freezing Medium 
SH-SY5Y and NS-1 cells were frozen in cell freezing medium consisting of 50% cell culture 
media, 40% FBS and 10% dimethyl sulphoxide (DMSO) (VWR International, 23500.260), 
which was ice cold.   
2.1.3 Antioxidants and Toxins 
In the antioxidant protection against tBHP assays (Section 2.2.6.1-2.2.6.4) a number of 
antioxidants and toxins, which are listed, below were used. They were provided as powder or 
solution and stock solutions were made in DMSO, ethanol or media as stated below. 
AO-1-530 (Antoxis Limited)     Stock 10 mM in DMSO 
Myricetin (Sigma, 72576)     Stock 30 mM in DMSO 
Quercetin (Sigma, Q4951)     Stock 30 mM in DMSO 
Vitamin E ((+)-α-tocopherol, Sigma, T1539)  Stock 1.6 mM in ethanol (Fisher) 
Idebenone (Antoxis Limited)     Stock 10 mM in DMSO 
Coenzyme Q10 (Sigma, C9538)    Stock 1 mM in ethanol 
tBHP (Sigma, 19990)    Stock 10 mM in media 
2.2  Cell Culture Methods 
2.2.1 Routine Cell Culture 
2.2.1.1 SH-SY5Y Cell Culture  
SH-SY5Y cells were thawed and cultured in the appropriate medium. Medium was changed 
every 2-3 days. When cells were 70-80% confluent they were passaged using trypsin (Life 
Technologies, 15090) 1 in 5 or counted and seeded for experiments at 1.25x105 cells/cm2, 
unless otherwise stated. Cells were cultured at 37°C in a humidified atmosphere of 5% CO2. 
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2.2.1.2 Neuroscreen™-1 Cell Culture  
NS-1 cells were thawed and routinely passaged on cell culture dishes coated in collagen type 
I or pre-coated collagen type I T75 flasks (Beckton Dickinson, 356485) with NS-1 medium. 
In order to coat dishes or coverslips collagen type I (6 µg/cm2, Sigma, C3867) was added 
and incubated overnight at 4°C or at 37°C for several hours. NS-1 cells were cultured until 
70-80% confluent when they were lifted using trypsin/EDTA (Life Technologies, 25200) 
and passaged 1 in 5 or seeded for differentiation (Section 2.2.4.3). Cells were cultured at 
37°C in a humidified atmosphere of 5% CO2. 
2.2.2  Cell Freezing 
SH-SY5Y and NS-1 cells were frozen at 70-80% confluency. They were lifted and counted 
using a haemocytometer. SH-SY5Y cells were re-suspended to 8x106 cells/ml in freezing 
medium and NS-1 cells were frozen at 4x106 cells/ml in freezing medium. 0.5 ml aliquots of 
cells in freezing medium were added to cryovials and stored at -80°C for a couple of days 
before being transferred to liquid nitrogen for long term storage. 
2.2.3  Coverslip Preparation 
To prepare coverslips for collagen coating or for cell seeding 13 mm (VWR International, 
631-0149) or 25 mm (VWR International, 631-0171) coverslips were washed in ethanol and 
baked at 180°C for at least 2 hours.  
2.2.4  Cellular Differentiation 
2.2.4.1  SH-SY5Y Differentiation (10% FBS with retinoic acid) 
All three SH-SY5Y cell lines were seeded at 11.5x103 cells/cm2 on cell culture treated 
plastic. The next day SH-SY5Y Greece cell culture medium (Section 2.1.2.1, without 
Hygromycin B, G418 and doxycycline) with 10 µM retinoic acid (Sigma, R2625) was added 
to begin differentiation. The medium was changed every 2 days until day 6, when cells were 
fixed in 4% paraformaldehyde (PFA) (Sigma, 158127) for immunocytochemistry (Section 
2.4.6.1). 
2.2.4.2  SH-SY5Y Differentiation (N2 medium with retinoic acid) 
The Edinburgh SH-SY5Y cells were seeded at 11.8x103 cells/cm2 on cell culture plastic or 
30 µg/cm2 poly-L-ornithine (Sigma, P4957) coated sterile glass coverslips (Section 2.2.3). 
Cells were left to attach and proliferate for 48 hours. The medium was then changed to N2 
medium supplemented with 10 µM retinoic acid to begin differentiation. Medium was 
replaced every 2-3 days and cells were cultured until the desired end point when cells were 
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fixed in 4% PFA for immunocytochemistry (Section 2.4.6.1), lifted for RNA extraction and 
subsequent quantitative reverse transcription PCR (qRT-PCR) (Section 2.4.2- 2.4.4) or used 
for an MTS assay (Section 2.2.6.1.1 and Section 2.2.5.2). 
2.2.4.3  Neuroscreen™-1 Differentiation 
NS-1 cells were seeded at 3.125x104 cells/cm2, unless otherwise stated, on 6 µg/cm2 collagen 
I coated dishes or coverslips. The following day medium was replaced with a 1 in 10 dilution 
of NS-1 medium in RPMI 1640 basal medium with 50 ng/ml nerve growth factor β (NGFβ) 
(Sigma, N2513). Medium was replaced on day 2. On day 3 cells were fixed in 4% PFA for 
immunocytochemistry (Section 2.4.6.1), lifted for RNA extraction and subsequent qRT-PCR 
(Section 2.4.2- 2.4.4) or cells were used for an MTS assay (Section 2.2.6.1.1). 
2.2.5  Transfection and Transduction of SH-SY5Y Cells 
2.2.5.1  Transfection by Liposomes  
SH-SY5Y cells at 70-80% confluency were transfected using Lipofectamine® 2000 Reagent 
(Life Technologies, 11668027). 3.5% Lipofectamine® 2000 in Optimem® medium (Life 
Technologies, 31985) was mixed with 500 ng PB-CAG-mtGFP-SNCA plasmid DNA 
(Figure 4.2c) in Optimem® medium at a ratio of 1 to 1 and incubated at room temperature 
for 5 minutes. This Lipofectamine mix was then added to cells and incubated for 24 hours 
when cells were fixed in 4% PFA for immunocytochemistry using the α-synuclein primary 
antibody (Section 2.4.6.1). 
2.2.5.2  BacMam Transduction 
The two BacMam reagents, mitochondrial targeted GFP (mtGFP) (Life Technologies, 
C10600) and the generated mtGFP with α-synuclein (mtGFP-SNCA) (Figure 4.1), were used 
in the same way. The appropriate volume of BacMam viral solution was added to cells in 
culture. The volume added per 100,000 undifferentiated SH-SY5Y cells is stated in the 
figures and figure legends. In differentiated SH-SY5Y cells the volume added to 100 µl of 
media in a 96-well plate is shown, as the number of cells is unknown. Cells were incubated 
for the lengths of time shown below; with a 50% media change every 2 days. 
- 24 hours after BacMam addition to cells they were lifted for fluorescence activated 
cell-sorting (FACS) analysis (Section 2.4.7). Post-acquisition analysis was performed with 
FlowJo X to exclude dead cells and to graph the GFP fluorescence. 
- 24 and 48 hours after BacMam addition to cells they were fixed in 4% PFA for 
immunocytochemistry using the α-synuclein primary antibody (Section 2.4.6.1).  
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- 24 hours after BacMam addition protein was extracted from cells to perform a western blot 
(Section 2.4.5).  
- 4 days after BacMam addition the MTS assay was performed (Section 2.2.6.1.2). 
- 24 hours after BacMam addition, 25-250 nM rotenone (1 mM stock in DMSO, Sigma, 
R8875) was added for 4 days when the MTS assay was performed (Section 2.2.6.1.2). 
- BacMam was added to 12 day differentiated SH-SY5Y cells and was topped up every 7 
days until the desired end point of 2 weeks or 4 weeks when the MTS assay (Section 
2.2.6.1.2) or α-synuclein immunocytochemistry (Section 2.4.6.1) was performed. 
- 24, 48 and 72 hours after BacMam addition mitochondrial fragmentation was assessed 
(Section 2.2.7.8). 
- 3 and 7 days after BacMam addition the DHE assay was performed (Section 2.2.7.9).   
2.2.6 Cell Viability Assays 
2.2.6.1  MTS Assay Experiments 
2.2.6.1.1 Cell Treatments for MTS Assay 
A number of cell treatments were performed where the MTS assay was used as a measure of 
cell viability; including SH-SY5Y and differentiated NS-1 cell number optimisation, 
tBHP-induced toxicity, antioxidant toxicity, antioxidant protection against tBHP-induced 
toxicity, intracellular AO-1-530 protection, and pre and post toxin antioxidant protection.  
 Initially, the cell number of SH-SY5Y and differentiated NS-1 cells was optimised 
for use with the MTS assay. SH-SY5Y cells (1-7 x104 cells per well) were seeded and 
incubated for 24 hours when the MTS assay was performed. In addition, NS-1 cells were 
seeded at different densities (1- 20 x103 cells per well) and differentiated for 3 days when the 
MTS assay was performed.  
 Secondly, the concentration of tBHP to use for toxicity in each cell line was 
assessed. SH-SY5Y cells were seeded at 1.25x105 cells/cm2 and incubated for 24 hours when 
tBHP was added. 5 hours later the MTS assay was performed. The NS-1 cells were 
differentiated for 3 days when tBHP was added for 16 hours. After this time the MTS assay 
was performed. 
 Thirdly, the antioxidant toxicity was examined. SH-SY5Y cells were seeded as 
above and incubated for 24 hours or NS-1 cell were differentiated for 3 days, when 
antioxidants were added for 16 hours or 48 hours, as stated in the figures. After this time the 
MTS assay was performed.  
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Fourthly, the antioxidant protection against tBHP-induced toxicity was assessed. 
SH-SY5Y cells were seeded as above and incubated for 24 hours. The cells were then 
pre-incubated with antioxidants (Section 2.1.3) for 30 minutes when 400 µM tBHP was 
added to the antioxidants for the length of time stated in the figure legends, usually 5 or 16 
hours. Then the MTS assay was performed. 14-day differentiated SH-SY5Y cells (Section 
2.2.4.2) were pre-incubated with antioxidant for 30 minutes when 400 µM tBHP was added 
for 8 hours when the MTS assay was performed. NS-1 cells were differentiated for 3 days, 
when antioxidants were added for 30 minutes. 200 µM tBHP was added to the antioxidants 
for 15 hours prior to performing the MTS assay.  
 Fifthly, the intracellular AO-1-530 protection was determined. SH-SY5Y cells were 
seeded and incubated for 24 hours, when AO-1-530 was added for 30 minutes. AO-1-530 
was then removed and 400 µM tBHP was added for 5 hours when the MTS assay was 
performed. 
 Finally, the ability of AO-1-530 and quercetin to protect after tBHP addition was 
assessed. SH-SY5Y cells were seeded and incubated for 24 hours. Then groups of cells were 
treated in 3 ways: pre-incubated with antioxidant for 30 minutes before addition of tBHP; 
co-incubated with antioxidant and tBHP or treated with tBHP and subsequently antioxidants 
were added. 5 hours after 400 µM tBHP addition the MTS assay was performed. 
 In addition, the MTS assay was performed after BacMam treatment (as stated in 
section 2.2.5.2). 
2.2.6.1.2 MTS Assay  
The MTS assay was performed using the Promega CellTiter 96® Aqueous MTS Reagent 
Powder (Promega, G1112) with phenazine methosulphate (PMS) (Sigma, P9625) as the 
electron coupler. MTS was prepared at 2 mg/ml in dPBS, filter sterilised using a 0.22 µm 
filter, aliquotted and stored at -20°C. PMS was prepared at 0.92 mg/ml in dPBS, filter 
sterilised, aliquotted and stored at -20°C. Immediately before the MTS assay, 100 µl of PMS 
was added to 2 ml of MTS. 20 µl of the MTS/PMS mixture was added to each well of a 
96-well plate containing 100 µl of media. The plate was incubated at 37°C/5% CO2 for 1 
hour. Then the absorbance at 490 nm and reference wavelength of 650 nm was measured 
using the FLUOstar OMEGA (BMG LabTech) plate reader. Subtraction of the 650 nm 
reference absorbance from the 490 nm absorbance gave the well absorbance. The 
background absorbance from the media incubated with MTS/PMS was subtracted from the 
well absorbance to give the sample absorbance. The percentage of the sample absorbance 
relative to control treated cells absorbance gave the % metabolic activity.   
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2.2.6.2  Lactate dehydrogenase (LDH) Assay 
The Source Bioscience LDH-Cytotoxicity Assay Kit II (ABE2423) was used to perform the 
LDH Assay. The LDH assay was used to assess the antioxidant protection against 
tBHP-induced toxicity. SH-SY5Y cells were seeded at 1.25x105 cells/cm2 and incubated for 
24 hours. The cells were then pre-incubated with antioxidants for 30 minutes when 400 µM 
tBHP was added to the antioxidants for 5 or 16 hours, as stated in the figure legends. Thirty 
minutes before the end of tBHP treatment cell lysis buffer was added to the high control 
wells. At the end of tBHP treatment the 96-well plate was gently mixed to distribute the 
LDH in the media. The plate was then centrifuged at 600g for 10 minutes to precipitate cells 
and debris. 10 µl of media from each well was moved to a new 96-well plate and 100 µl of 
LDH reaction mix was added to each well. The plate was then incubated at room 
temperature for 30-60 minutes when absorbance was read using the FLUOstar OMEGA 
(BMG LabTech) plate reader. The 650 nm reference absorbance was subtracted from the 450 
nm absorbance reading to give the well absorbance. The background absorbance was 
subtracted from the well absorbance to give the sample absorbance. The sample absorbance 
was subtracted from control-cultured cells (low control) and divided by the cells that had 
been lysed (high control) minus the control cells (low control) to give the % cytotoxicity. 	  
2.2.6.3  Propidium Iodide (PI) Assay  
The PI assay was performed to assess AO-1-530 protection against tBHP-induced toxicity. 
SH-SY5Y cells were seeded at 1.25x105 cells/cm2 and incubated for 24 hours. The cells 
were then pre-incubated with AO-1-530 (1 or 10 µM) for 30 minutes when 400 µM tBHP 
was added for 6 or 16 hours. Then the media was collected and cells were lifted using 
trypsin, washed in PBS with 2% FBS and resuspended in 100 µl PBS with 2% FBS. This 
cell solution was filtered and incubated with PI (1 µg/ml) at room temperature for 10 
minutes. Then 300 µl PBS with 2% FBS was added to dilute the cells. Cells were kept on ice 
until FACS analysis data was collected using the FACS Calibur and post-acquisition analysis 
was performed using FlowJo X. The unstained sample was used to create gates to determine 
PI positive cells and the percentage of PI positive and negative cells was calculated.  
2.2.6.4  Images and Videos of Antioxidant Protection 
Images and videos were created to show the cellular morphology after antioxidant protection 
against tBHP-induced toxicity. SH-SY5Y cells were seeded at 1.25x105 cells/cm2 and 
incubated for 24 hours. The cells were then pre-incubated with antioxidants for 30 minutes 
when 400 µM tBHP was added to the antioxidants. 5 hours after the addition of tBHP the 
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morphology of the cells was imaged in 96-well plates, using an Olympus IX51 inverted 
microscope. 
 Videos were created with cells in 12-well plates using the Zeiss Axio Observer. 
Immediately after tBHP addition the microscope was prepared to image every 30 minutes for 
12 hours. Videos begin one hour after tBHP addition and end 13 hours after tBHP addition. 
2.2.7  Other Cell Assays 
2.2.7.1  Antioxidant Subcellular Localisation 
SH-SY5Y cells were seeded 1.25x105 cells/cm2 on coverslips. 24 hours later the following 
antioxidants were added for 2 hours; 10 µM AO-1-530, 100 µM quercetin, 100 µM myricetin 
or DMSO as a control. Then cells were fixed in 4% PFA and counterstained with 
4',6-Diamidino-2-phenylindole (DAPI) for 10 minutes. Coverslips were washed in MilliQ 
water and mounted onto slides using Vectashield (Vector Laboratories, H1000). Images 
were taken using the 63x objective of the Leica TCS SPE confocal microscope. The 488 nm 
laser was used to excite the antioxidants and emission was measured between 496-595 nm. 
DAPI was imaged using the 405 nm excitation laser.  
2.2.7.2  AO-1-530 Mitochondrial Localisation 
SH-SY5Y cells on coverslips (as above) were loaded with 100 nM Mitotracker Deep Red 
(Life Technologies, M22426) for 20 minutes before the addition of 10 µM AO-1-530 for 2 
hours. The cells were then fixed in 4% PFA and processed as described above. The 635 nm 
laser was used to excite Mitotracker Deep Red.  
2.2.7.3  Intracellular Antioxidant Fluorescence (FACS)    
SH-SY5Y cells were seeded at 1.25x105 cells/cm2 and treated as above for antioxidant 
localisation but 2 hours after antioxidant addition cells were lifted using trypsin, washed in 
PBS with 2% FBS and resuspended in 100 µl PBS with 2% FBS. The cell solution was then 
filtered and cells were incubated with PI (1 µg/ml) on ice. 300 µl PBS with 2% FBS was 
added. Cells were kept on ice until fluorescence was analysed using the FACS Calibur. 
Post-acquisition analysis using FlowJo X was used to exclude PI positive cells and to graph 
the cells positive for green, FL-1, fluorescence. 
2.2.7.4  CellROX® Deep Red Assay 
SH-SY5Y cells were seeded at 6.25x104 cells/cm2 on 13 mm coverslips. 24 hours later cells 
were incubated with 10 µM CellROX® Deep Red (Life Technologies, C10422) and 2.8 
µg/ml Hoechst 33342 (Fluka, 14533) for 30 minutes. CellROX® and Hoechst 33342 were 
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removed and cells were washed three times with complete medium. Antioxidant or DMSO 
vehicle was added for 30 minutes, and then 400 µM tBHP was added. One hour after tBHP 
addition, 13 mm coverslips were placed onto a 25 mm coverslip inside an Attofluor® Cell 
Chamber (Life Technologies, A-7816) holder and washed with Hank’s balanced salt solution 
(HBSS) with calcium and magnesium. Images were taken of phase contrast, CellROX® 
Deep Red and Hoechst 33342 fluorescence. Multiple areas (5-6) of each coverslip were 
imaged. Post-acquisition analysis was performed using Volocity. A small area around each 
apparent cell nuclei was selected in all images and the mean fluorescence in arbitrary units 
(au) in these areas was calculated. The mean and standard error of mean (SEM) were 
calculated from the fluorescence value of each image.  
2.2.7.5  Ratio of Oxidised and Reduced Glutathione 
The GSH/GSSG Ratio Assay Kit from Merck Millipore (371757) was used with 
metaphosphoric acid (Sigma, 04103). Cells were incubated as previously with AO-1-530 or 
DMSO vehicle control for 30 minutes before the addition of 400 µM tBHP for 2 hours. Cells 
were then washed in ice cold PBS, scraped from the cell culture plates and placed on ice. 
After centrifugation at 300g for 5 minutes pellets were resuspended in 5% metaphosphoric 
acid and lysed using a 25-gauge needle. Immediately a sample was moved to 1-methyl-2-
vinylpyridinium trifluoromethanesulphonate (M2VP) to scavenge the GSH leaving the 
GSSG. Samples were then centrifuged to remove debris and the supernatant was moved to a 
fresh 1.5-ml microfuge tube. Samples were then diluted 1:61 for GSH and 1:15 for GSSG in 
the appropriate assay buffer. 50 µl sample, blank or standard was loaded into a 96-well plate 
in duplicate. To this 50 µl chromagen and 50 µl enzyme was added. The plate was mixed 
gently and incubated at room temperature for 5 minutes. Then 50 µl NADPH was added and 
the change in absorbance 412 nm was measured every 15-30 seconds for 3 minutes using a 
FLUOstar OMEGA (BMG LabTech) plate reader. The slopes were calculated, the blank 
sample was subtracted and concentration was determined relative to the standard curve for 
GSH. From this the percentage GSH and GSSG were determined.  
2.2.7.6 Nrf2 Experiment  
SH-SY5Y cells were seeded at 1.25x105 cells/cm2 on coverslips and incubated for 24 hours 
when AO-1-530 or DMSO as a control was added for 30 minutes. Then 400 µM tBHP was 
added for 4.5 hours when cells were fixed in 4% PFA for Nrf2 immunocytochemistry 
(Section 2.4.6.1) or lifted for RNA extraction and subsequent qRT-PCR (Sections 2.4.2-
2.4.4). After immunocytochemistry Nrf2 images were quantified using ImageJ. The z-stack 
images were flattened and a mask was created using the DAPI channel. This mask was then 
	   39	  
used to calculate the nuclear red fluorescence intensity. The mean fluorescence from each 
image (2-4 images) and from each coverslip was calculated. 
2.2.7.7 8-Hydroxy-2-deoxyguanosine (8-OHdG) Experiment  
SH-SY5Y cells were seeded at 1.25x105 cells/cm2 on coverslips and incubated for 24 hours 
when AO-1-530 or vehicle control, DMSO, was added for 30 minutes. Then 400 µM tBHP 
was added for 4.5 hours when cells were fixed in 4% PFA for 8-OHdG 
immunocytochemistry (Section 2.4.6.1). The 8-OHdG images were quantified using ImageJ. 
The z-stack images were flattened and a mask was created using the DAPI channel, this 
mask included the nuclei and the area surrounding the nuclei by reducing the threshold. This 
mask was then used to calculate the nuclear green fluorescence intensity. The mean 
fluorescence from each image was calculated. 
2.2.7.8  Mitochondrial Fragmentation 
SH-SY5Y cells were seeded onto 25 mm coverslips at 2.5 x104 cells/cm2. The next day the 
appropriate volume of BacMam was added (as stated in Figure 4.13). Mitochondrial 
morphology was analysed 24, 48 and 72 hours after transduction. To analyse mitochondrial 
morphology coverslips were placed into the Attofluor® Cell Chamber with medium. This 
coverslip holder was loaded onto an inverted confocal Leica TCS SP2 microscope with an 
environmental chamber to keep the temperature at 37°C and CO2 at 5%. The GFP was 
excited using the 488 nm laser and z-stack images were acquired. Subsequently the images 
were randomised and analysed blind using ImageJ. The axis of the mitochondria in each cell 
was calculated by dividing the length of the mitochondria by the width. Cells which 
contained mitochondria with an axis of >10 µm were classified as tubular, those with an axis 
of <3 µm were classified as fragmented and cells which contained both types of 
mitochondria were classified as intermediate. Excel was used to calculate and plot the 
percentage of cells at each time-point with each type of mitochondrial morphology.   
2.2.7.9  Dihydroethidium (DHE) ROS Production Assay 
DHE (Life Technologies, D11347) was dissolved in DMSO to a concentration of 5 mM. 
This compound is oxidised to ethidium and 2-hydroxyethidium, and upon binding to DNA, it 
fluoresces strongly in the red channel (excitation/emission, 518 nm/ 605nm). To perform the 
DHE assay, 25 mm coverslips with BacMam-treated adherent SH-SY5Y cells (Section 
2.2.5.2) were placed into an Attofluor® Cell Chamber. This coverslip holder was placed 
onto the Zeiss Axio Observer microscope stage and an appropriate area containing cells was 
selected. DHE (5 µM) in HBSS was added to the cells and time-lapse images with the 
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appropriate filter to detect ethidium and 2-hydroxyethidium (605 nm emission) were taken 
every 8 seconds for 15 minutes. Subsequently, areas within the cell nuclei were selected 
using Volocity and the average red fluorescence intensity for each image was measured over 
time. The red fluorescence intensity was plotted against time using Excel and linear 
regression was performed to calculate the slope. The slope was a measure the rate of ROS 
production.  
2.3  Mouse Brain Stem Slice Cultures 
2.3.1  Mouse Brain Slice Culture Medium 
The basal medium for mouse brain slice cultures contained 50% MEM with Earle’s salts 
(Life Technologies, 32360-026) and 25% Earle’s balanced salt solution (Life Technologies, 
24010-043). This was supplemented with 25% heat-inactivated horse serum (Life 
Technologies, 26050-088), 10 U/ml Penicillin, 10 µg/ml Streptomycin (Life Technologies, 
15140-122), 2 mM Glutamax (Life Technologies, 35050-038), 6.5 mg/ml glucose (Sigma, 
G8769), 1.25 µg/ml Fungizone (Life Technologies, 15290-018). The complete medium was 
then sterile-filtered using 0.22 µm filter (EMD Millipore). 
2.3.2  Mouse Brain Stem Slices 
All animal procedures were performed according to the Animal Scientific Procedures Act, 
UK, 1986. Mouse brain stem slices were performed as in Zhang et al, 2011. Briefly, P0-P2 
mice pups were decapitated and the hindbrain was dissected into L15 medium (Sigma, 
L5520). Sagittal sections (300 µm) of the hindbrain were cut using a McIllwain Tissue 
Chopper. Sections were then separated in slice culture medium and placed onto Millicell CM 
organotypic culture inserts (EMD Millipore, PICM0RG50) in 6-well plates. They were 
cultured for 8 days with a medium change every 2 days and fixed in 4% PFA for 45 minutes 
when colourimetric immunohistochemistry (Section 2.4.6.2) or immunocytochemistry for 
α-synuclein, TuJ-1 and Synapsin I (Section 2.4.6.1) was performed. 
2.4  Molecular Biology 
2.4.1  DNA Cloning Techniques 
2.4.1.1  Plasmids 
Three DNA plasmids were used for the DNA cloning in this thesis. One was the GeneArt 
Construct, which was synthesised by Life Technologies from the DNA sequence of 
mtGFP-SNCA that we provided (Figure 4.1a). The second was pENTR2B2, which is a Life 
Technologies Gateway Entry Vector (Figure 4.1c) and was a kind gift from Dr. Keisuke Kaji 
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(MRC Centre for Regenerative Medicine, University of Edinburgh). This entry clone was 
required to insert mtGFP-SNCA so Life Technologies could synthesise the BacMam 
construct. The third plasmid was a destination vector for Gateway Cloning, PB-CAG (Figure 
4.2b), which was a kind gift from Dr. Keisuke Kaji (MRC Centre for Regenerative 
Medicine, University of Edinburgh). After mtGFP-SNCA insertion into PB-CAG by 
Gateway Cloning the mtGFP-SNCA would be under the control of the pCAG promoter. 
Lipofection of this into cells would allow the expression of mtGFP-SNCA to be tested. 
2.4.1.2  Restriction Enzyme Digestion 
Restriction enzymes were used to produce plasmid fragments for ligation and as a diagnostic 
test to confirm the plasmid produced contains the insert. To produce fragments for ligation 
the GeneArt construct and the Gateway Entry Clone pENTR2B2 were digested. 3 µg of the 
GeneArt construct containing mtGFP-SNCA was digested with BamHI (10 units, New 
England Biolabs (NEB), R0136) and EcoRI (10 units, NEB, R0101) in a 30 µl reaction, 
containing buffer number 3 and BSA (Figure 4.1a). 2 µg of the Gateway Entry Vector 
pENTR2B2 (Figure 4.1c) was digested using BamHI (10 units) and EcoRI (10 units) in a 20 
µl reaction, containing buffer number 3 and BSA. For diagnostic testing of the ligated 
plasmid pENTR2B2-mtGFP-SNCA (Figure 4.1e) the restriction enzymes EcoRV (NEB, 
R0195S) and BstxI (R0113S, NEB) were used with buffer number 3. For diagnostic testing 
of the PB-CAG-mtGFP-SNCA plasmid (Figure 4.2c) the restriction enzymes EcoRV and 
SalI-HF® (R3138S, NEB) were used with buffer number 3 in the presence of BSA. Reaction 
mixes were incubated at 37°C for 1-2 hours. The fragments were then loaded onto an 
agarose gel for analysis of fragments or for gel extraction (Section 2.4.1.4).  
2.4.1.3  Gateway Cloning  
Gateway Cloning was performed to move the insert from the Entry Clone 
pENTR2B2-mtGFP-SNCA (Figure 4.1e and 4.2a) into the destination vector PB-CAG 
(Figure 4.2b). 10 µl reactions were set up using 2 µl Gateway® LR Clonase® II (Life 
Technologies, 11791), 150 ng PB-CAG, 150 ng pENTR2B2-mtGFP-SNCA and Tris-EDTA 
buffer solution (4.8 µl). The reaction was allowed to proceed at room temperature for 60 
minutes. The reaction was stopped by addition of 2 µg Proteinase K and incubation at 37°C 
for 10 minutes. The DNA products were transformed into competent DH5α cells (Sections 
2.4.1.7). 
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2.4.1.4  DNA Electrophoresis  
DNA electrophoresis was performed after restriction digests (Section 2.4.1.2) for analysis of 
DNA fragments and for gel extraction. 0.8-1% (w/v) agarose gels containing 1x SyberSafe 
(Life Technologies, S33102) for DNA band visualisation was prepared in 1x TAE Buffer (40 
mM Tris (Sigma), 20 mM Acetic Acid (Fisher), 1 mM EDTA (Sigma)). Samples were 
loaded with Orange G (Sigma) alongside a 1kb marker (Life Technologies, 15615-016). Gels 
were run at 100 V for 30-60 minutes. Fragments sizes, from BamHI/EcoRI digestion of 
pENTR2B2 and the GeneArt construct, for gel extraction are stated in section 2.4.1.5. The 
EcoRV/BstxI digestion of pENTR2B2-mtGFP-SNCA gave fragments of around 2415 and 
1191 base pairs. Whereas the EcoRV/SalI-HF® digest of PB-CAG-mtGFP-SNCA gave 
fragments of around 4368, 1922 and 1350 base pairs. 
2.4.1.5  DNA Extraction from Agarose Gel 
The 1323 base pair fragment from the GeneArt Construct BamHI/EcoRI restriction digest 
(Figure 4.1b) and the 2283 base pair fragment of the pENTR2B2 BamHI/EcoRI restriction 
digest (Figure 4.1d) were extracted from agarose gel using the QIAquick Gel Extraction kit 
(QUIAGEN, 28704) according to the manufacturer’s instructions. 
2.4.1.6  DNA Fragment Ligation 
The DNA fragments extracted from the agarose gel (Section 2.4.1.5) were ligated using T4 
DNA ligase (Life Technologies, 15224). A molar ratio of 1:4, pENTR2B2 fragment to 
GeneArt Construct fragment, was added to T4 DNA ligase and T4 DNA ligase buffer. The 
reaction was incubated at room temperature for 20 minutes before placing on ice. Ligated 
fragments were transformed into DH5α cells for DNA isolation (Sections 2.4.1.7 and 
2.4.1.8). 
2.4.1.7  Bacterial Transformation 
The ligation products of pENTR2B2-mtGFP-SNCA and the Gateway Cloning products of 
PB-CAG-mtGFP-SNCA, were transformed into DH5α cells to analyse the products. 5 µl of 
the ligation mix or 11 µl of the Gateway Cloning mix was added to 100 µl of DH5α 
competent cells. They were mixed and incubated on ice for 30 minutes. DH5α competent 
cells were heat shocked at 42°C for 30-45 seconds and placed on ice for 2 minutes. 250 µl 
LB broth was added to the bacteria and cultures shaken at 37°C with 200 rpm for 1 hour. 
Cultures were then plated onto Kanamycin (50 µg/ml) selection agar plates for 
pENTR2B2-mtGFP-SNCA or carbenicillin (50 µg/ml) selection agar plates for 
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PB-CAG-mtGFP-SNCA and incubated at 37°C overnight. Then DNA isolation was 
performed on selected colonies (Section 2.4.1.8).  
2.4.1.8  DNA Isolation from Bacteria 
The colonies produced on the agar plates from the bacterial transformation of 
pENTR2B2-mtGFP-SNCA and PB-CAG-mtGFP-SNCA (Section 2.4.1.7) were used for 
DNA isolation from bacteria. A single bacterial colony was picked and used to inoculate 4 
ml LB broth containing appropriate antibiotic (As in section 2.4.1.7). Cultures were shaken 
overnight at 200 rpm at 37°C. The next day DNA was isolated from the cells using the 
QIAprep™ Spin Miniprep kit (QIAGEN, 27104) according to manufacturer’s instructions. 
The samples containing the correct plasmids were selected after restriction digest diagnostic 
testing (Section 2.4.1.2). 
2.4.2  RNA Extraction 
RNA extraction was performed by 2 methods. RNA was extracted from NS-1 cells using the 
QIAGEN RNeasy Micro Kit (QIAGEN, 74004). Undifferentiated and differentiated 
SH-SY5Y RNA was extracted using the Epicentre MasterPure™ Complete DNA and RNA 
Purification Kit (Epicentre, MC85200). Both kits were used according to manufacturer’s 
instructions. RNA concentration was quantified using a Nanodrop spectrophotometer 
according to manufacturer’s instructions.  
2.4.3  cDNA Synthesis 
Total RNA (1-2 µg) was used for cDNA synthesis. RNase free water was added to the RNA 
to give a 10 µl sample. The samples were incubated with 1 µl dNTP mix (10 mM, Life 
Technologies, 10297018) and 1 µl random primers (50 ng/µl, Thermo Fisher, PCR-545-
020T) at 65°C for 5 minutes and then chilled on ice. After brief centrifugation, 4µl 5x First 
strand buffer (Life Technologies, Y02321), 2 µl 0.1M DTT (Life Technologies, Y00147) 
and 1µl RNAse OUT (40 units/µl, Life Technologies, 10777019) were added. The contents 
was incubated at 37°C for 2 minutes. Then 1 µl M-MLV reverse transcriptase (200 units/µl, 
Life Technologies, 28025013) or 1 µl RNase free water for the negative reverse transcriptase 
sample was added. This was mixed and incubated at room temperature for 10 minutes when 
it was moved to 37°C for 60 minutes. The reaction was inactivated by incubation at 90°C for 
10 minutes. The cDNA mix was placed on ice and 80 µl RNase free water was added. The 
cDNA samples were then ready for qRT-PCR.  
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2.4.4  Quantitative Reverse Transcription PCR (qRT-PCR) 
qRT-PCR was performed using the Roche LightCycler® 480 System with the Universal 
Probe Library (UPL) (Roche). The Roche UPL Assay design centre was used to design 
intron-spanning primers with a specific UPL probe (Table 2.1). Reactions containing 
primers, UPL Probe, UPL Probe Master Mix (Roche) and PCR water were performed in 
386-well plates as described in the manufacturer’s instructions. The results were normalised 
to TATA-binding protein (TBP) and the mean of biological replicates with SEM were 
calculated.  
Gene Primer (5’ – 3’) UPL Probe Number 
hTBP F gaacatcatggatcagaacaaca 87 
 R atagggattccgggagtcat  
hENO2 F ttgtcagggactatcctgtgg 27 
 R ggatccctacattggctgtg  
hMAP2 F ctctcctgtgttaagcggaaa 62 
 R aatacactgggagccagagc  
hSYP F caaggagatgcctgtctgc 17 
 R aggttcaggaagccgaaca  
hDBH F tggctactgcacggacaa 16 
 R agctgagaggcgaagatgtg  
hTH F gtaagcagaacggggaggt 56 
 R tctcaggctcctcagacagg  
hVMAT2 F tggcaatcagcaggaagg 67 
 R cgggattctgcatcatgttt  
hSLC6A4 F tgtctgaggtggccaaaga 75 
 R atgttggctatcgcttctgc  
hSNCA F gagggagtggtgcatggt  68 
 R  tgctgtcacacccgtcac  
hCHAT F catcgtcctggtgcagtg 4 
 R gagctcgctgacggagtc  
hNFE2L2/hNrf2 F acacggtccacagctcatc 18 
 R tgcctccaaagtatgtcaatca  
hHMOX1 F cagtcaggcagagggtgatag 42 
 R agctcctgcaactcctcaaa  
hNQO1 F acgctgccatgtatgacaaa 9 
 R ggatcccttgcagagagtaca  
rTBP F ccctatcactcctgccaca 110 
 R ggtcaagtttacagccaagattc  
rBach1 F acagcgagtcctgttctgc 15 
 R ttgagcattgaaaggcagttt  
rCKB F gacctcaacccagacaacct 85 
 R gcgagctcagcacgtagtt  
rGAP43 F cggagactgcagaaagcag 63 
 R cgggcactttccttaggttt  
rVGF F agacgggtccggattttc 10 
 R ggtacccagtgcctcctg  
Table 2.1 – qRT-PCR primer sequences and UPL probe numbers  
F - Forward primer; R- Reverse primer. h -human primers; r -rat primers. 
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2.4.5  Western Blot 
All solutions for the western blot were from Fisher and all powders from Sigma, unless 
otherwise stated. Cells were lysed using RIPA Buffer (Santa Cruz, sc-24948) with Protease 
Inhibitor Cocktail (Roche, 05892791001), according to manufacturer’s instructions. These 
were kept on ice for 30 minutes. The samples were then sonicated to break up the DNA and 
centrifuged to remove debris. To determine sample protein concentration the BioRad DC 
Protein assay (500-0111) was used, according to manufacturer’s instructions using BSA for 
the standard curve. Samples were prepared for loading into the gel by incubating 10 µg 
protein with NuPAGE® LDS Sample Buffer (4x, Life Technologies), NuPAGE® Reducing 
Agent (10x, Life Technologies) and deionised water (to 10 µl) at 75°C for 10 minutes. The 
gel (4-12% Bis-Tris NuPAGE® gel, Life Technologies, NP0322BOX) was loaded into the 
tank with running buffer (20x NuPAGE® MOPS SDS Running Buffer in deionised water, 
Life Technologies, NP0001). Protein samples were loaded along with the SeeBlue Plus 2 
protein marker (LC5925, Life Technologies). The gel was run at 200 V for 70 minutes at 
room temperature.  
 Nitrocellulose membranes (Amersham Hybond ECL, GE Healthcare Life Science, 
RPN68D) were soaked in distilled water for 30 seconds and then incubated with transfer 
buffer (3.02 g Tris, 14.4 g glycine, 800 ml water and 200 ml methanol). The gel was 
removed and prepared for transfer to the nitrocellulose membrane. The transfer apparatus 
was assembled with the sponge, two pieces of Whatman paper, the gel, then the 
nitrocellulose membrane, two pieces of Whatman paper and another sponge, being careful to 
avoid bubbles. It was then loaded into the transfer tank, transfer buffer was added and the 
blot was run at 395 mA for 70 minutes at 4°C. 
 The membrane was removed and incubated in blocking solution (10% non-fat 
powdered milk in 0.05% TBS-N buffer (8.775 g NaCl, 1.22 g Tris base, 0.74 ml 
concentrated hydrochloric acid in 1 L distilled water) with 0.05% NP-40) overnight at 4°C. 
After removal of blocking solution the membrane was incubated with primary antibody 
(α-synuclein 1:1000, BD Biosciences, 610787 or GFP, 1:1000, Life Technologies, A11122) 
in blocking solution (5% non-fat powdered milk in 0.15% TBS-N (as 0.05% TBS-N but with 
0.15% NP-40)) at room temperature for 2 hours. The membrane was washed 3 times for 15 
minutes in wash buffer (TBS, 0.5M NaCl and 0.3% Triton X-100) and then incubated with 
secondary antibody (anti-mouse HRP; 1:7000, Promega, W402B or anti-rabbit; 1:7000; 
Promega, W401B) in blocking buffer for 1 hour at room temperature. Subsequently, the 
membrane was washed in wash buffer 3 times for 15 minutes before HRP was detected 
using the Pierce ECL Western Blot substrate kit (Thermo Scientific, 32109), according to 
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manufacturer’s instructions. Then the membrane was wrapped in cling film, exposed to 
autoradiographic film and the film was developed using an automated autoradiograph 
developer. Images were scanned and band intensities were analysed using ImageJ. 
2.4.6  Histochemical Techniques 
2.4.6.1  Immunocytochemistry  
Cells were fixed by the addition 4% PFA (Sigma) for 20 minutes, unless otherwise stated. 
They were then washed three times with PBS. Immunocytochemistry was performed by the 
addition of blocking buffer (0.1% Triton X-100 or 0.3% Triton-X100 for nuclear staining, 
2% goat serum, PBS) for 0.5 to 1 hour. Primary antibodies  (Table 2.2) in blocking buffer 
were added to cells for 16 hours at 4°C, when they were washed 3 times in PBS with 0.1% 
Triton X-100. Secondary antibodies (Table 2.3) in blocking buffer were incubated with cells 
for 2 to 2.5 hours at room temperature in foil, when they were washed 3 times in PBS with 
0.1% Triton X-100. DAPI (10-50 µg/ml, Life Technologies, D1306) in PBS was added for 5 
to 10 minutes. Cells were imaged using Olympus IX51 inverted fluorescence microscope 
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Antigen Isotype Conjugate Concentration Supplier 
Mouse IgG2a Goat IgG AlexaFluor 488 1:1000 Molecular 
Probes 
Rabbit IgG Goat IgG AlexaFluor 555 1:1000 Molecular 
Probes 




Rabbit IgG Goat IgG AlexaFluor 488 1:1000 Molecular 
Probes 
Mouse IgG1 Goat IgG AlexaFluor 488 1:1000 Molecular 
Probes 
Mouse IgG1 Goat IgG AlexaFluor 555 1:1000 Molecular 
Probes 
Rabbit IgG Goat IgG AlexaFluor 647 1:1000 Molecular 
Probes 
Mouse IgG2b Goat IgG Alexa Fluor 488 1:1000 Molecular 
Probes 
Table 2.3 – Secondary antibodies used for immunocytochemistry 
2.4.6.2  Colourimetric Immunohistochemistry  
Envision+ System-HRP DAB kit (DAKO, K4006) was used with the α-synuclein primary 
antibody, according to manufacturer’s instructions.  
2.4.7  FACS Analysis 
Cells were lifted using trypsin, washed in PBS with 2% FBS and resuspended in 100 µl PBS 
with 2% FBS. The cell solution was filtered and incubated with PI (1 µg/ml) at room 
temperature for 10 minutes or put directly on ice. 300 µl PBS with 2% FBS was added. Cells 
were kept on ice until fluorescence was analysed using the FACS Calibur. FlowJo X was 
used to perform post-acquisition analysis.  
2.5  Other Methods 
2.5.1  Antioxidant Fluorescence 
1 mM solutions of AO-1-530, myricetin and quercetin in DMSO were added to a 96-well 
plate in triplicate. The fluorescence was read using a FLUOstar OMEGA (BMG LabTech) 
plate reader with excitation 485 nm and emission 520 nm. DMSO background fluorescence 
was subtracted. 
2.5.2  Galvinoxyl Absorbance 
Gavinoxyl  (8 µM, Sigma, G307) in DMSO with the appropriate antioxidant concentrations 
were added to a 96-well plate. The absorbance change at 428 nm over time was measured 
using FLUOstar OMEGA (BMG LabTech) plate reader. DMSO absorbance was subtracted 
to give the galvinoxyl absorbance. The difference between galvinoxyl alone and galvinoxyl 
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with the antioxidants was calculated to give a change in absorbance. This was then plotted 
against antioxidant concentration. The slope of the change in absorbance was also calculated.   
2.5.3  Galvinoxyl Electron Paramagnetic Resonance (EPR) Spectroscopy 
Experiments 
The EPR experiments were performed with the help of Dr. Tilo Kunath, Dr. Janet Lovett 
(Centre of Magnetic Resonance, University of St. Andrews) and Dr. Mark Miller (BHF 
Centre for Cardiovascular Science, Queens Medical Research Institute (QMRI), University 
of Edinburgh). Galvinoxyl (182 µM) was mixed with 5 µM or 10 µM antioxidants in DMSO. 
These were then loaded into capillaries. The capillary was loaded into the Tech Miniscope 
MS200 ESR Machine at the QMRI and measurements were taken. Measurements were taken 
2, 4 and 6 minutes after addition of antioxidant to galvinoxyl. EPR Settings: BO= 3364.05 
G; Sweep= 69.59 G; Sweep Time= 20 s; Smooth= 0 s; Steps= 4096; Number of passes= 1 
pass; Modulation= 1500 G; Mw atten= 7dB; Gain= 1E2; Phase= 180. 
2.6  Statistical Analysis 
Statistical Analysis was performed in Minitab using the Analysis of Variance (ANOVA) 
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Chapter 3 – Neuronal Cell Models 
3.1 Introduction 
The symptoms experienced in α-synucleinopathies are caused by the loss of neurons in the 
brain. For example, the Parkinsonism motor symptoms, including tremor and slow 
movement, are caused by the loss of SNpc dopaminergic neurons (Parent & Parent, 2010). In 
addition, the loss of serotonergic and noradrenergic neurons in the brain stem result in sleep 
disturbances (Boeve et al, 2007). Therefore to model α-synucleinopathies a neuronal cell 
model was needed. 
3.2 Neuronal Cell Lines 
3.2.1 Clonal Variability of SH-SY5Y Cell Lines 
The SK-N-SH cell line was derived from a bone marrow aspiration of a female patient who 
had a neuroblastoma in the upper chest, which spread to the bone marrow. This cell line 
contained both epithelial and neuroblast-like cells (Biedler et al, 1973). Repeated subcloning 
of this cell line to remove the epithelial cells produced a number of cell lines, including the 
thrice-subcloned SH-SY5Y cell line (Biedler et al, 1978). Originally, the SH-SY5Y cell line 
appeared to be a homogeneous neuroblast-like population (Biedler et al, 1978). However, 
longer-term culture showed the presence of both epithelial and neuroblast-like cells (Ross et 
al, 1983). The neuroblast-like cells are thought to be of sympathetic nervous system origin, 
with fetal sympathetic neuron morphology (Ross et al, 1983). Further analysis of the 
SK-N-SH and SH-SY5Y cell lines suggests they have properties of catecholaminergic and 
cholinergic neurons (Biedler et al, 1978; Ciccarone et al, 1989).  
SH-SY5Y cells are used extensively in the literature, especially as a cell model of 
PD, and are referred to as a dopaminergic cell line. However, few groups assess whether the 
cell line has dopaminergic or even catecholaminergic characteristics. This is necessary since 
long-term culture of this cell line is known to cause loss of their neuronal character. 
Therefore, the presence of catecholaminergic and neuronal proteins was assessed in three 
SH-SY5Y cell lines from different sources – London, Greece and Edinburgh (Figure 3.1). 
Immunocytochemistry for the catecholaminergic marker TH and the neuronal marker TuJ-1 
in the undifferentiated state showed the three SH-SY5Y cell lines were all different (Figure 
3.1a). The cell line from London contained only a few TuJ-1 positive cells and no TH 
staining, suggesting it had lost its neuronal character. In contrast, the cell line from Greece 
stained positive for TuJ-1 and weakly positive for TH, suggesting it is capable of 
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catecholamine synthesis. Finally, the cell line from Edinburgh stained positive for TuJ-1 but 
was negative for TH.  
Figure 3.1 - SH-SY5Y cell lines from different sources express different markers and have 
varied differentiation potential. Immunocytochemistry for the neuronal marker TuJ-1 (green) and 
the catechloaminergic marker TH (red) was performed on fixed undifferentiated (a) and 6-day 
differentiated (b) SH-SY5Y cell lines from three different labs, London, Greece and Edinburgh. Cell 
lines were differentiated by the addition of 10% FBS medium with 10 µM retinoic acid. DAPI 
staining (blue) was used to mark cell nuclei; scale bar: 160 µm. 
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SH-SY5Y cells can be differentiated by the addition of retinoic acid to cell culture 
media. These three SH-SY5Y cell lines were differentiated in 10% FBS containing cell 
culture medium with the addition of 10 µM retinoic acid for 6 days (Figure 3.1b). The 
London cell line continued to proliferate and the cells did not elongate. These cells were 
negative for both TH and TuJ-1, confirming they had lost their neuronal properties. In 
contrast, the line from Greece showed most of the cells halted or reduced proliferation and 
the cells elongated. These cells stained positive for TH and TuJ-1. The cell line from 
Edinburgh showed elongation of the cells and extension of neurites but they also continued 
to proliferate. These cells were positive for TuJ-1 but were negative for TH, indicating they 
are neuronal but not catecholaminergic. This shows the clonal variability of SH-SY5Y cells, 
highlighting the importance of investigating the characteristics of different SH-SY5Y 
subclones. 
From this data the most appropriate cell line to choose, as a model for 
α-synucleinopathies would be the one from Greece. However, this cell line had been 
transduced with ectopic transgenes, therefore the cell line from Edinburgh was chosen due to 
its neuronal characteristics.  
3.2.2 Edinburgh SH-SY5Y Cell Line 
The SH-SY5Y cell line referred to from here onwards in this thesis is the Edinburgh 
SH-SY5Y cell line. This SH-SY5Y cell line was found to continue to proliferate after 
retinoic acid addition to serum containing medium; therefore a literature search was 
performed to find an alternative differentiation method. Forsby, 2011 used the neuronal 
medium N2 with the addition of retinoic acid (Forsby, 2011). This produced cells with a 
neuronal morphology, with small cell bodies and extended neurites. Therefore, the 
SH-SY5Y cell line was differentiated using this method (Figure 3.2).  
Replacing the basal FBS containing medium with N2 medium reduced the 
proliferation rate of the cells. Cells began to extend neurites as early as day 3 and the number 
of neurites increased over time. To confirm their neuronal character cells were fixed and 
immunocytochemistry was performed for TuJ-1, and the catecholaminergic marker TH 
(Figure 3.3). As the morphology suggested the cells were neuronal shown by TuJ-1 staining. 
The cells project neurites within 7 days and develop extensive neuronal networks by day 14. 
In addition, by day 14 clusters of cell bodies can be seen with neurites projecting out from 
them. As was found in the serum containing medium the cells did not express high levels of 
TH, suggesting they are not catecholaminergic.  
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Figure 3.2 - Morphological changes during the differentiation of SH-SY5Y cells in the presence 
of N2 medium with 10 µM retinoic acid. SH-SY5Y cells were cultured for 48 hours before 
differentiation was started, by the addition of N2 medium with 10 µM retinoic acid. Images of live 
cells were taken every 3 days; scale bar: 160 µm. 
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Figure 3.3 - Time-course of neuronal marker expression in the differentiated SH-SY5Y cells. 
SH-SY5Y cells were differentiated in the presence of N2 medium with 10 µM retinoic acid. Cells 
were fixed at day 0, 7, 14 and 21 of differentiation, when immunocytochemistry was performed for 
TuJ-1 (red) and TH (green). The negative control samples were incubated without primary antibodies 
but in the presence of secondary antibodies. Cells were then counterstained with DAPI (blue) to label 
cell nuclei; scale bar: 160 µm. 
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TuJ-1 is a marker for both mature and immature neurons. Therefore to assess the 
maturity of the neuronal cells produced more mature neuronal markers were used. SH-SY5Y 
cells differentiated for 28 days were fixed and immunocytochemistry for MAP2, Synapsin I 
and α-synuclein was performed (Figure 3.4).  
Originally, MAP2 was thought to be a specific marker for neurons but has since 
been found in some other tissues (Loveland et al, 1999). In neurons MAP2 is expressed in 
dendrites. During neuronal differentiation different MAP2 isoforms are expressed. The 
antibody used here recognises all isoforms. MAP2 can be seen in some neurites of the 
differentiated SH-SY5Y cells (Figure 3.4a). However, in the undifferentiated and some of 
the differentiated SH-SY5Y cells MAP2 was nuclear. Nuclear staining has been found in the 
testis, due to the nuclear localisation signal in exon 10 of MAP2 (Loveland et al, 1999). The 
MAP2 neurite staining suggests the cells are neuronal. 
Synapsin I is a neuronal specific protein, which is found in synaptic vesicles at the 
presynaptic terminal of synapses in most neurons (De Camilli et al, 1979; Huttner et al, 
1983). Synapsin I was present in both the undifferentiated and differentiated SH-SY5Y cells 
(Figure 3.4b). Undifferentiated SH-SY5Y cells had cytoplasmic staining, whereas 
differentiated cells showed the typical punctate staining along the neurites as seen in 
neurons. This suggests neuronal synapses have been formed.  
α-Synuclein protein is strongly expressed in neurons in the nucleus, cytoplasm and 
in the presynaptic terminal of synapses (Zhong et al, 2009). However, it is not neural 
specific as it has also been found in other tissues (Scherzer et al, 2008). The presynaptic 
α-synuclein expression is at a number of neuronal synapses, including catecholaminegic and 
glutamatergic neurons, but not in all (Totterdell & Meredith, 2005; Totterdell et al, 2004; Li 
et al, 2002). In the SH-SY5Y cells α-synuclein was found to increase in differentiated cells 
compared to undifferentiated cells and showed both nuclear and cytoplasmic staining. 
However, punctate presynaptic staining was not observed (Figure 3.4c). The expression of 
these three proteins confirms SH-SY5Y cells become more mature neurons and form 
synapses when exposed to N2 medium with retinoic acid.  
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Figure 3.4 - Neuronal maturation marker expression in the differentiated SH-SY5Y cells. 
SH-SY5Y cells were differentiated in the presence of N2 medium and retinoic acid for 28 days. Cells 
were fixed and immunocytochemistry was performed for (a) MAP2 (red), (b) Synapsin I  (red) and (c) 
α-synuclein (green). Immunocytochemistry was also performed on undifferentiated cells for 
comparison. Cells were counterstained with DAPI (blue) to mark cell nuclei; scale bar: 76 µm. 
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In order to further characterise SH-SY5Y neuronal differentiation, gene expression 
during differentiation was assessed. qRT-PCR was performed for genes related to neuronal 
maturation and neuronal subtype (Figure 3.5). The expression of genes that increase as 
neurons mature (ENO2 and MAP2) and synaptic markers (Synaptobrevin, SYP and 
α-synuclein, SNCA) was examined. These markers appear to reach a maximum at day 14 and 
either plateau or reduce in expression after this day (Figure 3.5). This suggests by day 14 the 
cells are as mature as they will become. Therefore experiments should be performed at day 
14. 
Figure 3.5 - Neuronal maturation and neuronal subtype gene expression during differentiation 
of SH-SY5Y cells. SH-SY5Y cells were differentiated in the presence of N2 medium and retinoic 
acid. RNA was extracted from the cells at the stated time points and qRT-PCR was performed. The 
results were normalised to TATA binding box protein (TBP) gene expression. Bars represent the 
average from 2-3 separate differentiation experiments that contained single or duplicate wells (ENO2, 
MAP2, SNCA, TH and CHAT show the average from 3 experiments; SYP, DBH, VMAT2 and SLC6A4 
show the average from 2 experiments). The error bars represent the SEM. ANOVA with a Tukey 
post-hoc test was performed to assess the significant difference between gene expression on day 7, 14 
or 21 relative to gene expression on day 0; * p<0.05; ns, not significant, p>0.05. 
 
The literature suggests that SH-SY5Y cells have the potential to become both 
catechloaminergic and cholinergic neurons (Biedler et al, 1978). TH and 
Dopamine-β- hydroxylase (DBH) are required for the synthesis of catechloamines. TH gene 
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expression is low until day 21 of differentiation, whereas DBH gene expression decreases 
after day 7 of differentiation (Figure 3.5). Therefore the neurons produced are unlikely to be 
catecholaminergic. Vesicular monoamine transporter 2 (VMAT2) is required for 
neurotransmitter loading into synaptic vesicles of serotonin, catecholamines and histamine. 
VMAT2 gene expression was found to increase by day 14 (Figure 3.5). SLC6A4 is a 
serotonin transporter required to recycle serotonin into presynaptic neurons. As with the 
neuronal maturation markers its RNA levels increase to day 14 and reduce thereafter (Figure 
3.5). Therefore the neurons may be serotonergic. Choline acetyltransferase (CHAT) is 
required for the synthesis of the cholinergic neuron neurotransmitter acetylcholine. Its gene 
expression increased during differentiation suggesting cholinergic neurons may be produced 
(Figure 3.5). 
Undifferentiated SH-SY5Y cells express a number of neuronal markers, highlighting 
their neuronal character. Differentiation of these cells in the presence of N2 medium and 
retinoic acid causes an increase in the expression of neuronal genes, suggesting neuronal 
differentiation and maturation occurs. However, the markers of all neuronal subtypes appear 
to increase. The qRT-PCR and immunocytochemistry data suggest catecholaminergic 
neurons are not produced from SH-SY5Y differentiation. The neurons may be serotonergic 
or cholinergic. However, further analysis of the presence of proteins rather than just RNA is 
needed. In addition, analysis of the neurotransmitters that are synthesised would allow the 
neuronal subtype to be confirmed. 
3.2.3 Neuroscreen™-1 Cell Line 
Another cell line used extensively as a model for PD is the rat noradrenergic cell line, PC-12. 
The PC-12 cell line was subclonally derived from a neuroendocrine tumour in the adrenal 
gland of a rat, known as rat adrenal pheochromocytoma. The cell line was found to contain 
both dopamine and noradrenaline synthesising enzymes and neurotransmitters (Greene & 
Tischler, 1976). In addition, the cell line showed termination of cell proliferation and 
extension of processes 7 days after NGFβ addition (Greene & Tischler, 1976). 
Neurotransmitter presence reduced after NGFβ treatment. The PC-12 line had a number of 
disadvantages for high throughput screening so the Ramer lab derived a subclonal line from 
the PC-12 cell line, NS-1. The NS-1 cell line is reported to proliferate more quickly, does not 
form aggregates and extends processes within 2 days of NGFβ addition (Radio et al, 2008; 
Dijkmans et al, 2008). Therefore this cell line was also assessed for its use as a neuronal cell 
model.  
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Figure 3.6 - Gene and protein expression in undifferentiated and NGFβ differentiated NS-1 
cells. NS-1 cells were differentiated for 3 days by the reduction of serum and the addition of NGFβ. 
After 3 days cells were fixed to perform immunocytochemistry (a) or RNA was extracted to perform 
qRT-PCR (b). (a) Immunocytochemistry was performed for α-synuclein (red), TuJ-1 (green) and TH 
(magenta) and cells were counterstained with the nuclear marker DAPI (blue); scale bar: 76 µm. (b) 
Bars represent the mean gene expression from 2 independent experiments each with duplicate or 
triplicate wells. Error bars represent the SEM. Expression was normalised to TBP expression. 
ANOVA with a Tukey post-hoc test was performed to assess the significant difference between gene 
expression on day 0 and on day 3; * p<0.05; ns, not significant, p>0.05. 
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The gene and protein expression in undifferentiated and NGFβ differentiated NS-1 cells was 
examined (Figure 3.6). Differentiation for 3 days was chosen for two reasons. Firstly studies 
suggest the extension of neurites plateau at this day (Dijkmans et al, 2008). Secondly, during 
NS-1 differentiation cells still appeared to proliferate and they detached around day 6. The 
phase images show that by day 3 the cells have extended processes. TuJ-1 is expressed in 
both undifferentiated and differentiated NS-1 cells, suggesting they are neuronal (Figure 
3.6a). In addition, α-synuclein and TH were both present in undifferentiated NS-1 cells. 
Their levels appear to decrease after differentiation, as was found in PC-12 cells (Greene & 
Tischler, 1976).  
The gene expression before and after NS-1 differentiation was assessed to confirm 
the differentiation was similar to that reported in the literature (Dijkmans et al, 2008). 
Dijkmans et al. reported an increase in GAP43, CKB, VGF and BACH1 gene expression 
within 3 days of differentiation. In agreement with this study GAP43, VGF and CKB all 
increased after 3 days (Figure 3.6b). However, BACH1 did not show an increase. This was 
the gene that showed the lowest fold change in their studies and had not been reported in 
other studies. The difference may be due to slight differences in the differentiation protocol 
or may be due to subclonal variability of the cell line. These results suggest NS-1 cells are 
neuronal and that the NGFβ differentiation is similar to that seen in the literature for PC-12 
and NS-1 cells.  
3.3 Discussion and Future Directions 
The SH-SY5Y and the NS-1 cell lines investigated here are both neuronal cell lines. It was 
found that SH-SY5Y cell lines from different sources had variable protein expression and 
differentiation potential. Nonetheless, the SH-SY5Y cell line chosen for further investigation 
had neuronal protein and gene expression in the undifferentiated state that increased after 
their differentiation in the presence of N2 medium with retinoic acid. The neuronal subtype 
produced by differentiation requires further investigation. The NS-1 cell line was found to 
have catecholaminergic neuronal protein expression in the undifferentiated state, which 
reduced after differentiation. However, their neuronal protein expression remained the same 
and their neuronal gene expression increased. Therefore both of these neuronal cell lines are 
suitable to use as a model for α-synucleinopathies and were used in chapter 4 and chapter 5 
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Chapter 4 - α-Synuclein-Induced Neuronal Cell Toxicity  
4.1 Introduction 
The α-synuclein protein, encoded by the SNCA gene, is expressed highly in the nervous 
system and has been found in presynaptic termini and nuclei of neurons (Maroteaux et al, 
1988). However, its expression level is not the same in all neurons; different neuronal 
subtypes show variable levels of nuclear and presynaptic expression (Li et al, 2002; Iwai et 
al, 1995). This presynaptic localisation and synuclein knockout mice suggest synucleins are 
involved in presynaptic function and neurotransmission (Greten-Harrison et al, 2010; Anwar 
et al, 2011). 
 α-Synuclein first became implicated in neural cell toxicity when it was found to be 
the main component of protein inclusions in some neurodegenerative diseases, including PD 
and DLB (Spillantini et al, 1997; Wakabayashi et al, 1998). These diseases are now known 
as α-synucleinopathies. α-Synuclein was further implicated in neurodegeneration when a 
mutation in the α-synuclein protein, A53T, was found in families displaying Parkinsonism 
symptoms (Polymeropoulos et al, 1997). Further missense mutations in the α-synuclein 
protein have since been linked to other familial Parkinsonism patients (Kiely et al, 2013; 
Lesage et al, 2013; Krüger et al, 1998). In addition, triplication or duplication of the SNCA 
gene has been identified to cause early onset Parkinson’s. α-Synuclein triplication patients 
have 4 copies of the SNCA gene and this results in twice as much α-synuclein protein than 
control patients (Singleton, AB et al, 2003; Farrer et al, 2004). Whereas, duplication patients 
have 3 copies of the SNCA gene and from this gene dosage they are likely to have 1.5 times 
more α-synuclein protein than controls (Chartier-Harlin et al, 2004). This difference in 
protein level affects the average age of onset of the disease and the severity of symptoms 
experienced, with triplication patients having an earlier age of onset and symptoms including 
hallucinations and dementia (Nishioka et al, 2006; Chartier-Harlin et al, 2004; Gwinn et al, 
2011; Ahn et al, 2008). This led to the theory that the levels of α-synuclein may be 
fundamental in the development of α-synucleinopathies. However, mutations and 
multiplications of the SNCA gene are not common. Variations in the SNCA gene sequence 
might affect its level of protein expression (Edwards et al, 2010; Farrer et al, 2001b; 
Chiba-Falek & Nussbaum, 2001). Alternatively, there may be a deficit in α-synuclein protein 
degradation, for example due to heterozygous β-glucosidase (GBA) mutations (Murphy et al, 
2014).  
A number of labs have performed wild-type α-synuclein overexpression studies with 
varying results. Some studies have shown slight toxicity in catecholaminergic neurons or 
neuroblastoma cells but others have shown no toxicity (Zhou et al, 2002; Bisaglia et al, 
	   61	  
2010; Zhou et al, 2000). However, these studies all suggest cells overexpressing α-synuclein 
are more susceptible to oxidative insults (Zhou et al, 2000; Bisaglia et al, 2010). Further 
evidence that α-synuclein is toxic comes from rat in vivo experiments that resulted in 
progressive neurodegeneration from 3 weeks after α-synuclein adeno-associated viral 
overexpression (Kirik et al, 2002). These results are conflicting and; therefore the aim was to 
determine whether an increase in wild-type α-synuclein protein could cause neuronal cell 
toxicity. This would further provide a model of α-synucleinopathies to allow investigation of 
the involvement of mitochondrial dysfunction and oxidative stress in neurodegeneration.  
4.2 BacMam – Construct Design 
There are a number of viral and non-viral methods that can be used to overexpress a protein. 
It was chosen to use the baculovirus method to overexpress α-synuclein for a number of 
reasons. Firstly, baculoviruses are capable of transducing neuroblastoma cells and primary 
neurons with high efficiency (Sarkis et al, 2000). Secondly, they can be used at high 
concentrations with limited toxicity and a dose-dependent increase in the level of protein 
expression can be achieved (Kost & Condreay, 2002; Boyce & Bucher, 1996). Thirdly, they 
are mostly non-integrating and therefore should not cause alterations to endogenous genes 
(Condreay et al, 1999). Fourthly, they have been found to be safe and non-replicating in 
mammalian cells (Tjia et al, 1983). Finally, using a baculovirus system to overexpress 
α-synuclein makes it easily amenable to use in different cell types by the simple addition of 
the virus to the culture media. A baculovirus that contains a gene whose expression is 
controlled by a mammalian promoter is known as BacMam.  
Life Technologies have a commercially available BacMam with a mitochondrial 
targeted GFP (mtGFP). In this virus they report the use of emerald GFP with the pyruvate 
dehydrogenase- E1α leader sequence to target it to the mitochondria (Dahl et al, 1987). 
Since this BacMam would be used as a control these DNA sequences were chosen for use in 
the α-synuclein overexpression construct. In addition, the presence of mtGFP would allow 
the transduction efficiency to be assessed easily in live cells. In order to include more than 
one gene in the same construct a 2A peptide was used. 2A peptides can produce separate 
proteins from the same mRNA construct by translational skipping (Szymczak et al, 2004). 
This is because the ribosome is not capable of forming a peptide bond, resulting in two 
separate proteins from one mRNA transcript (Donnelly et al, 2001b). 2A peptides have the 
advantage over internal ribosome entry sequences (IRES) because the two proteins are 
produced at similar levels, while the coding sequence downstream of the IRES is often 
poorly translated. However, a small part of the 2A peptide is left on the protein upstream of 
the 2A peptide, which may affect its function. There are a number of 2A peptides with 
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varying efficiency in different cell types. In human 293T cells P2A was reported to be the 
most efficient, followed by T2A and E2A (Kim et al, 2011). However, previous reports in 
vitro suggested T2A had the highest cleavage efficiency (Donnelly et al, 2001a). Therefore, 
the T2A sequence was used to separate mtGFP and SNCA. The SNCA gene encoding the 
full-length human wild-type α-synuclein protein was used since previous studies suggest the 
full-length protein had potential to cause toxicity, and the triplication and duplication SNCA 
patients do not have any coding mutations. 
The SNCA sequence was codon optimised for more efficient translation and the final 
sequence encoding mtGFP and the α-synuclein protein (mtGFP-SNCA) was sent to Life 
Technologies GeneArt Gene Synthesis service; the construct received is shown in Figure 
4.1a. To produce the BacMam Life Technologies required the sequence in a Gateway Entry 
Clone. Therefore, BamHI and EcoRI were used to isolate the mtGFP-SNCA sequence and 
the pENTR2B2 vector backbone (Figure 4.1a-d). The fragments were then isolated from 
agarose gels and ligated. The ligation products were transfected into competent DH5α cells 
and colonies were assessed for the correct fragment ligation. The plasmid produced is shown 
in Figure 4.1e. This is a Gateway Entry Clone containing the mtGFP-SNCA sequence, which 
can be used with Gateway LR Clonase II to easily move the mtGFP-SNCA sequence into a 
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Figure 4.1 – mtGFP-SNCA Gateway Entry Clone preparation for BacMam generation. (a) The 
plasmid received from Life Technologies GeneArt Gene Synthesis service. (b) Restriction enzyme 
digestion of (a) with BamHI and EcoRI isolates the mtGFP-SNCA sequence. (c) Life Technologies 
pENTR2B2 Gateway Entry Vector. (d) Restriction digestion of (c) with BamHI and EcoRI isolates 
the backbone of the Gateway Entry Vector. (e) Ligation of (b) and (d) produced the Gateway Entry 
Clone ready to send to Life Technologies for baculovirus generation. KanR: Kanamycin resistance; 
T2A: Translational skipping peptide; Col/E1/origin: Origin of replication; attL1/attL2: Phage 
attachment sites for site-specific recombination; ccdB: Cytotoxic protein CcdB.  
 
4.3 mtGFP-SNCA Construct Testing 
 
The Gateway Entry Clone in Figure 4.1e was ready to send to Life Technologies to produce 
the BacMam. However, it was first necessary to confirm the mtGFP-SNCA insert sequence 
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gave the appropriate protein expression in cells. To do this Gateway Cloning with Gateway 
LR Clonase II was used to clone the mtGFP-SNCA sequence insert into the PB-CAG 
Destination Vector (Figure 4.2b). PB-CAG has a constitutively active promoter, pCAG 
(Niwa et al, 1991). The Expression Clone produced is shown in Figure 4.2c. This construct 
also contains piggyBac (PB) Long Terminal Repeat (LTR) sequences. In the presence of 
piggyBac transposase the contents between these PB-LTRs is integrated into the target cell 
genome (Ding et al, 2005). 
 In order to assess the presence of α-synuclein, an antibody specific to α-synuclein 
was required. Therefore, the specificity of a commercially available α-synuclein antibody 
from BD Transduction Laboratories™ was determined (Figure 4.3). A strain of C57BL/6 
mice from Harlan has been reported in the literature to lose the α-synuclein gene through 
inbreeding (Specht & Schoepfer, 2001). This C57BL/6 strain can be used to assess the 
specificity of the α-synuclein antibody. Immunohistochemistry was performed on ex vivo 
mouse brain stem slices from the inbred C57BL/6 strain and an outbred mouse strain using 
the BD Transduction Laboratories™ α-synuclein antibody. The C57BL/6 mice showed no 
α-synuclein staining, whereas the positive control had widespread α-synuclein staining 
(Figure 4.3a). In addition, ex vivo mouse brain stem slices were used for 
immunocytochemistry to detect the localisation of α-synuclein. Co-staining of α-synuclein 
with the neural marker TuJ-1, the synaptic marker Synapsin I and the nuclear stain DAPI 
showed the typical α-synuclein localisation, in the nucleus and at synapses of neurons 
(Figure 4.3b). The co-localisation of α-synuclein with DAPI shows α-synuclein nuclear 
localisation, whereas the Synapsin I and α-synuclein co-localisation show α-synuclein 
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Figure 4.2 – Gateway Cloning to produce a mtGFP-SNCA Expression Clone for use in cells. (a) 
The pENTR2B2 Entry Clone containing the mtGFP-SNCA sequence between the attL sites. (b) 
PB-CAG is a Destination Vector with attR sites. It was a kind gift from Keisuke Kaji. (c) The 
Expression Clone produced using Gateway LR Clonase II and plasmids (a) and (b). This Expression 
Clone was used to test the protein expression in cells with mtGFP-SNCA under the control of the 
pCAG constitutive promoter. KanR: Kanamycin resistance; AmpR: Ampicillin resistance; CmR: 
Chloramphenicol resistance; T2A: Translational skipping peptide; ColE1 origin: Origin of replication; 
attL1/attL2 and attR1/attR2: Phage attachment sites for site-specific recombination; ccdB: Cytotoxic 
protein CcdB; Rabbit b-globulin pA: rabbit β-globulin polyadenylation signal; PB 3’ LTR and PB 5’ 
LTR: piggyBac Long Terminal Repeat 3’ and 5’ respectively.  
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Figure 4.3 - α-Synuclein antibody testing. Hindbrain slices from mice were cultured for 8 days. 
They were then fixed and immunohistochemistry was performed. (a) Immunohistochemistry was 
performed for α-synuclein using an HRP secondary antibody and DAB to assess the specificity of the 
α-synuclein antibody. The negative control is in the absence of primary antibody; scale bar: 68 µM. 
(b) Immunocytochemistry was performed to assess the localisation of α-synuclein (red) relative to 
TuJ-1, Synapsin I (green) and DAPI (blue). TuJ-1 positive neurons (green) contain α-synuclein (red). 
α-Synuclein (red) co-localisation with Synapsin (green) show α-synuclein is found synaptically and 
α-synuclein (red) co-localisation with DAPI (blue) indicates it localises to the nucleus; scale bar: 11 
µM.	  
The construct in Figure 4.2c, with mtGFP-SNCA under the control of a 
constitutively active promoter, was introduced into SH-SY5Y cells by lipofection. 24 hours 
later the cells were fixed and immunocytochemistry was performed for α-synuclein. Proteins 
encoded by the construct are expressed as expected (Figure 4.4). The GFP is present and 
localises to the mitochondria. In addition, the GFP is found in cells that also express a higher 
level of α-synuclein protein. In Figure 4.4 the white arrow highlights a cell with high GFP 
and α-synuclein expression, the white arrowhead indicates a cell with weak GFP and 
α-synuclein expression and the blue arrow highlights a cell with no GFP fluorescence and 
weak endogenous α-synuclein expression. Finally, the α-synuclein protein is not restricted to 
the mitochondria indicating that the T2A peptide is working. The construct in Figure 4.1e 
was therefore sent to Life Technologies to produce the BacMam.  
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Figure 4.4 – mtGFP-SNCA construct protein expression in SH-SY5Y cells. SH-SY5Y cells were 
transfected with the plasmid in Figure 4.2c using Lipofectamine. Cells were cultured for 24 hours 
when they were fixed and immunocytochemistry was performed for α-synuclein (red), GFP (green) 
was present and cells were counterstained with DAPI (blue). White arrow indicates a cell with high 
GFP and α-synuclein expression. The blue arrow highlights a cell with no GFP and weak endogenous 
α-synuclein expression and the white arrowhead indicates a cell with weak GFP expression and weak 
α-synuclein expression; scale bar: 17 µM.  
4.4  BacMam Testing and Optimisation 
BacMam generation requires cloning of the sequence of interest into a vector containing a 
pCMV promoter and the baculovirus viral genome. This construct is then transfected into 
Sf9 insect cells and cells are cultured until they show signs of viral infection. At this point 
media is collected and centrifuged to remove cells and debris, to produce a P1 stock. To 
amplify the virus, the P1 stock can be used to infect Sf9 insect cells again. These are then 
incubated until cells show signs of infection when the media is collected, centrifuged to 
remove debris to give a P2 BacMam virus stock (Fornwald et al, 2007). Life Technologies 
performed this as a service and we received 200 ml of P2 viral stock, which is stored at 4oC. 
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Figure 4.5 - mtGFP-SNCA BacMam protein expression in SH-SY5Y cells. SH-SY5Y cells were 
incubated with 20 µl or 40 µl mtGFP-SNCA BacMam per 1x105 cells. They were fixed after 24 hours 
(a) or 48 hours (b) and immunocytochemistry was performed for α-synuclein (red). Cells expressed 
GFP (green) and were counterstained for DAPI (blue) to mark nuclei; scale bar: 76 µM. Insets show 
magnified images of α-synuclein (red) and mitochondrial targeted GFP co-localisation. 
The mtGFP-SNCA BacMam’s ability to transduce undifferentiated SH-SY5Y cells 
was tested. Two volumes of BacMam virus, 20 µl and 40 µl and two time points, 24 hours 
and 48 hours were examined (Figure 4.5). In all conditions the proteins were expressed as 
expected: GFP was present and located to the mitochondria; cells that expressed GFP had a 
higher level of α-synuclein, shown by yellow in the overlay and the α-synuclein was 
dispersed in the cell cytoplasm. At both time-points the higher volume of BacMam showed 
greater transduction efficiency, with more cells expressing α-synuclein at a higher level than 
the lower volume. The GFP and α-synuclein proteins could be detected at 24 hours and were 
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still present at 48 hours, with similar expression levels at both time-points (Figure 4.5a and 
b).  
 To quantify the transduction efficiency of different volumes of mtGFP-SNCA 
BacMam virus, FACS analysis was performed 24 hours after viral addition (Figure 4.6a). As 
a comparison the transduction efficiency of the control mtGFP BacMam virus was also 
tested (Figure 4.6b). The percentage of cells positive for GFP increased with the volume of 
BacMam added for both viruses, indicating increased transduction (Figure 4.6a and b). In 
addition, there is a dose dependent increase in the mean GFP fluorescence (Figure 4.6a and 
b). This data was plotted to give the volume of virus added on the x-axis and the mean GFP 
fluorescence on the y-axis (Figure 4.6c and d). Linear regression was performed on the data 
for mtGFP-SNCA and mtGFP viruses, and the equation of these lines was calculated. It was 
then calculated that we would need 5-fold more mtGFP-SNCA BacMam to achieve the same 
level of GFP fluorescence from the mtGFP BacMam virus (Figure 4.6e). For example, 1 µl 
of mtGFP BacMam virus gives the same level of GFP fluorescence as 5 µl of mtGFP-SNCA 
BacMam virus. 	  
 The BacMam is capable of increasing the GFP protein level but this does not 
provide information about the α-synuclein protein levels or the T2A cleavage. To determine 
the cleaving efficiency of the T2A and the α-synuclein protein levels, Dr. Fella Hammachi 
performed a western blot, with protein samples from transduced SH-SY5Y cells (Figure 4.7a 
and c). This showed that the T2A was capable of cleaving the proteins with only a small 
percentage that was not cleaved around 42 kDa, approximately 5% when 20 µl of 
mtGFP-SNCA BacMam was used (Figure 4.7a). α-Synuclein in its monomeric form is 
around 14 kDa (Figure 4.7a). Quantification of the 14 kDa α-synuclein bands showed an 
increase in relative protein levels with increasing volume of virus added (Figure 4.7b). An 
upper band positive for α-synuclein was also present, around the 49 kDa marker. This band 
appeared specific for α-synuclein as it increased as more baculovirus was added and may be 
an oligomer. However, the specificity of the band for α-synuclein would need to be 
confirmed using an additional α-synuclein antibody, for example the C-20 antibody from 
Santa Cruz. If this band is specific for α-synuclein, then mass spectrometry could be 
performed on the isolated band to identify the protein composition. Previous studies have 
reported a 45 kDa band that is thought to be an azo bond between α-synuclein monomers, 
similar to a dityrosine bond (Leng et al, 2001). The GFP blot also shows a very small 
proportion of the proteins are not cleaved at the T2A site (Figure 4.7c). Emerald GFP has a 
molecular weight around 26.9 kDa, in this blot it can be seen at around the 28 kDa marker 
(Figure 4.7c). Quantification of this band using ImageJ showed the GFP protein increased 
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with increasing volumes of virus (Figure 4.7d). In addition, it appears that 5 µl mtGFP may 
be equivalent to 25 µl mtGFP-SNCA, as the FACS plot suggested. There is a faint band that 
is likely to be a weak, uncleaved dimer around 56 kDa. The lower band around 17 kDa is 
likely to be a degradation product (Figure 4.7c). There is no β-actin blot here but the protein 
levels were quantified using Bio-Rad DC Protein assay to load equal volumes of protein 
samples. 
Figure 4.6– mtGFP-SNCA and mtGFP BacMam transduction efficiencies. SH-SY5Y cells were 
incubated with mtGFP-SNCA (a) or mtGFP (b) BacMam. The volume stated is per 1x105 cells. After 
24 hours cells were lifted for FACS analysis to determine the number of GFP positive cells and the 
mean GFP fluorescence. At least 30,000 cells were counted for each condition. The mean GFP 
fluorescence was then plotted against the volume of (c) mtGFP-SNCA BacMam or (d) mtGFP 
BacMam added. Then the relative volume of mtGFP-SNCA and mtGFP BacMam needed to give the 
same GFP fluorescence was calculated (e).	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Figure 4.7 – α-Synuclein and GFP protein expression levels after BacMam transduction and 
T2A cleavage efficiency. SH-SY5Y cells were incubated with mtGFP or mtGFP-SNCA for 24 hours 
when cells were lifted and western blots were performed to assess the level of α-synuclein (a) and 
GFP (c) protein expression. The volumes stated are per 1x105 cells (data from Dr. Fella Hammachi). 
The 14 kDa α-synuclein band in (a) and the 28 kDa GFP band in (c) were quantified for each 
condition using ImageJ; n=1 (b and d, respectively).  
 
 GFP and α-synuclein proteins increase after viral transduction, but BacMam 
expression is known to be transient. To assess how long the protein expression is maintained, 
differentiated SH-SY5Y cells were used. Differentiated SH-SY5Y cells would undergo 
fewer divisions and therefore may maintain expression for longer than undifferentiated 
SH-SY5Y cells. mtGFP-SNCA BacMam (50 µl) was added at day 7 of differentiation. The 
GFP expression levels were analysed using FACS analysis after 24 hours and every 3 days 
thereafter (Figure 4.8). The percentage of GFP positive cells begins to decrease between day 
7 and day 10. In addition, the mean GFP fluorescence decreases over time but drops 
significantly between day 7 and day 10. Therefore, it was decided that to keep the protein 
expression levels high in differentiated cells the virus should be topped up every 7 days.  
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Figure 4.8 – Time-course of GFP expression after mtGFP-SNCA transduction in differentiated 
SH-SY5Y cells. SH-SY5Y cells were differentiated for 7 days in N2 medium with retinoic acid when 
50 µl mtGFP-SNCA BacMam was added per well of a 24-well plate. Cells were lifted after 24 hours 
and every 3 days thereafter to assess the percentage of GFP positive cells and the mean GFP 
fluorescence using FACS analysis (a and b). At least 10,000 cells were counted per time-point.   
4.5 BacMam Toxicity 
The optimisation experiments provided important information about the mtGFP-SNCA 
BacMam. Firstly, α-synuclein protein levels can be increased with increasing volume of 
BacMam. Secondly, in order to achieve the same level of GFP fluorescence 1 µl of the 
control mtGFP BacMam equals 5 µl of the α-synuclein overexpression mtGFP-SNCA 
BacMam. Thirdly, the T2A allows separation of most of the proteins. Finally, in 
differentiated SH-SY5Y cells the GFP protein starts to show a significant decrease in 
expression from day 7. From this knowledge experiments were designed to assess the 
toxicity of α-synuclein overexpression in undifferentiated SH-SY5Y cells. Preliminary 
experiments performed by Dr. Fella Hammachi indicated that the virus was not toxic over 5 
days at a volume of 50 µl mtGFP-SNCA per 1x105 cells. Therefore, the toxicity of an even 
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greater concentration of α-synuclein was assessed using the MTS assay. The MTS assay 
gives an absorbance reading, which is relative to the cellular metabolic activity (Figure 4.9a). 
The MTS assay involves the addition of membrane impermeable MTS and the electron 
carrier PMS to cells. PMS is taken up into cells and is reduced by the cells. It is thought 
NADH/NADPH, which are involved in metabolism, are the most abundant compounds that 
can reduce PMS. Hence, it is a measure of metabolic activity. The reduced PMS is 
membrane permeable and can then move out of the cell and donate the gained hydrogen to 
MTS. The reduction of MTS to formazan results in a colour change from yellow to brown, 
which can be quantified by measuring the absorbance at 490 nm. If the cells used are of the 
same type and cultured in the same medium they will have similar metabolic activity, 
therefore the absorbance will correlate with the number of cells. Cells were cultured in the 
presence of BacMam for 4 days when the MTS assay was performed to assess toxicity. 
Incubation was performed for 4 days because beyond that cells became over confluent. The 
volumes of mtGFP and mtGFP-SNCA used here were based on a previous calculation 
looking at the percentage of cells positive for GFP, therefore 1 µl mtGFP was used as an 
equivalent to 2 µl mtGFP-SNCA. Although this is an incorrect way of calculating the 
equivalent, these results still show that mtGFP-SNCA is not toxic at an equivalent volume of 
mtGFP. That is, the toxicity at 25 µl mtGFP is not statistically different from 100 µl or 200 
µl of mtGFP-SNCA even though it shows a difference to control (Figure 4.9b). Therefore, 
the toxicity detected is not due to the overexpression of α-synuclein but rather due to the 
baculovirus or the presence of mtGFP. In undifferentiated SH-SY5Y cells α-synuclein 
overexpression is not toxic to cells up to 4 days of culture. Beyond 4 days of culture was not 
assessed. 
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Figure 4.9 – MTS assay chemistry and α-synuclein toxicity in undifferentiated SH-SY5Y cells. 
(a) The MTS assay chemistry. MTS, which is yellow in colour, is added to cells in the presence of 
PMS, an electron coupler. MTS is membrane impermeable therefore the electron coupler is required 
to enter the cell and carry electrons to the MTS. The reduction of MTS by reduced PMS produces 
formazan that is brown in colour. The absorbance at 490 nm is a read-out of the relative formazan 
production. (b) SH-SY5Y cells were transduced with mtGFP or mtGFP-SNCA BacMam virus for 4 
days when the MTS assay was performed. The volumes stated are per 1x105 cells. The experiment 
was performed three times (n=3) with triplicate wells on each occasion. ANOVA with the post-hoc 
Tukey test was performed to assess statistical significance of the difference between samples and 
controls; * p<0.05; ns is not significant. 
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 Since the overexpression of α-synuclein did not cause toxicity in undifferentiated 
SH-SY5Y cells, the ability to cause toxicity with the addition of an inducer of oxidative 
stress was assessed (Figure 4.10). Rotenone is a mitochondrial complex I inhibitor, which 
also inhibits microtubule formation (Earley & Ragan, 1984; Srivastava & Panda, 2007). It 
was chosen as an inducer of oxidative stress because previous studies have suggested links 
between rotenone, α-synuclein aggregation and neuronal toxicity. Rotenone can cause 
oxidative modifications to α-synuclein that may enhance its aggregation (Mirzaei et al, 2006; 
Souza et al, 2000). In addition, chronic rotenone exposure increases the levels of insoluble 
α-synuclein with an increase in toxicity (Betarbet et al, 2000; Sherer et al, 2002). 
mtGFP-SNCA BacMam (50 µl) was added to SH-SY5Y cells for 24 hours before addition of 
rotenone. Cells were then cultured for a further 4 days when the MTS assay was performed. 
Rotenone caused a dose dependent decrease in SH-SY5Y cell number where no BacMam 
virus was added. However, the overexpression of α-synuclein did not increase this toxicity 
(Figure 4.10).  
 
Figure 4.10- Rotenone toxicity in the presence of α-synuclein overexpression. Undifferentiated 
SH-SY5Y cells were incubated with 50 µl mtGFP-SNCA per 1x105 cells or no virus for 24 hours. 
Then various rotenone concentrations were added for 4 days when the MTS assay was performed 
(n=1). 
	  
 One other study showed α-synuclein overexpression was not toxic to 
undifferentiated SH-SY5Y cells for up to 10 days. However, when SH-SY5Y cells were 
differentiated with retinoic acid the presence of α-synuclein was toxic after 6-8 days 
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(Vekrellis et al, 2009). Therefore α-synuclein toxicity in differentiated SH-SY5Y cells was 
assessed. The FACS experiment performed in Figure 4.8 indicated α-synuclein was not toxic 
in differentiated SH-SY5Y cells. However, GFP was lost between day 7 and 10. So the 
toxicity of α-synuclein overexpression for 2 and 4 weeks was assessed using the MTS assay, 
with the virus topped up every 7 days (Figure 4.11a and 4.12a). α-Synuclein overexpression 
showed no significant toxicity at 2 or 4 weeks (Figure 4.11a and 4.12a). However, 
immunocytochemistry performed for α-synuclein at 2 weeks and 4 weeks showed 
unexpectedly weak immunofluorescence for α-synuclein compared to the robust GFP 
expression. The merged images showed very little α-synuclein staining in GFP positive cells 
(Figure 4.11b and 4.12b). Since the differentiated cells formed clumps, these clumps may be 
inaccessible to the α-synuclein antibody preventing their staining. Therefore the α-synuclein 
protein level after differentiation should be quantified by western blot. If the α-synuclein 
protein level decreases quicker than the GFP this may be due to the degradation of 
α-synuclein being more efficient than GFP. α-Synuclein is degraded by the proteasome and 
autophagy, and its half-life in SH-SY5Y cells could be shorter than GFP (Webb et al, 2003). 
The half-life of GFP is reported to be approximately 26 hours in mammalian cells but amino 
acid modifications made to turn it into emerald GFP may enhance its stability (Corish & 
Tyler-Smith, 1999). In addition, the mitochondrial localisation may delay its degradation. 
The half-life reported for α-synuclein varies depending on the cell type it is expressed in; in 
HEK 293 cells the half-life is over 48 hours; in mouse primary cortical neurons it is 26-160 
hours depending on the maturity of neurons; in undifferentiated SH-SY5Y cells it is about 13 
hours and in differentiated SH-SY5Y it is about 50 hours (Paxinou et al, 2001; Li et al, 
2004). This suggests the half-lfe for α-synuclein is longer than GFP in some cell lines. 
However, the mitochondrial localisation of GFP may increase its half-life compared to the 
cytosolic α-synuclein protein. Therefore to determine if the half-life is influential in lack of 
α-synuclein-induced toxicity, the half-lives of both the α-synuclein protein and the 
mitochondrial targeted GFP protein should be determined. 
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Figure 4.11 – α-Synuclein toxicity in differentiated SH-SY5Y cells after 2 weeks. SH-SY5Y cells 
were differentiated in the presence of N2 medium and retinoic acid for 12 days. Then various volumes 
of mtGFP or mtGFP-SNCA were added to the 96-well plates. Note 50 µl added in Figure 4.8 is 
equivalent to 8 µl added to a 96-well plate here. Cells were then cultured for a further 2 weeks, with a 
virus top up every 7 days, when the MTS assay was performed (a) (n=1). At 2 weeks cells were fixed 
and immunocytochemistry for α-synuclein (red) was performed (b). Cells expressed GFP (green) and 
were counterstained with DAPI (blue); scale bar: 76 µM. 	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Figure 4.12 - α-Synuclein toxicity in differentiated SH-SY5Y cells after 4 weeks.	  SH-SY5Y cells 
were differentiated in the presence of N2 medium and retinoic acid for 12 days. Then various volumes 
of mtGFP or mtGFP-SNCA were added to the 96-well plates. Note 50 µl added in Figure 4.8 is 
equivalent to 8 µl added to a 96-well plate here. Cells were then cultured for a further 4 weeks, with a 
virus top up every 7 days, when the MTS assay was performed (a) (n=1). At 4 weeks cells were fixed 
and immunocytochemistry for α-synuclein (red) was performed (b). Cells expressed GFP (green) and 
were counterstained with DAPI (blue); scale bar: 76 µM.	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4.6 Effect of α-Synuclein Overexpression on Mitochondrial Morphology 
Both undifferentiated and differentiated SH-SY5Y cells did not show α-synuclein-induced 
toxicity, so more subtle differences were examined. In 2011 Nakamura et al. showed that 
transient overexpression of α-synuclein can result in mitochondrial fragmentation after 48 
hours (Nakamura et al, 2011). They found no change in mitochondrial function at 24 hours 
but by 48 hours there was a reduction in respiration and by 96 hours a very small increase in 
cell death was detected. Therefore, Xing Zheng, a Masters student, and Dr. Fella Hammachi 
assessed the effect of BacMam α-synuclein overexpression on mitochondrial morphology 
(Figure 4.13). Confocal images were taken 24, 48 and 72 hours after transduction of 
undifferentiated SH-SY5Y cells. The images were then randomised and mitochondrial 
morphology of each cell was classified blind using ImageJ. Each cell in the images was 
classified as having tubular, fragmented or intermediate mitochondrial morphologies, 
depending on the length divided by the width (axis) of their mitochondria. Cells that 
contained mitochondria with an axis of  >10 µm were classified as tubular. Those with an 
axis of <3 µm were classified as fragmented and cells that contained both types of 
mitochondria were classified as intermediate (Figure 4.13a). The percentage of cells with 
each type of mitochondrial morphology in each condition was calculated (Figure 4.13b). 
After 24 hours the majority of cells had tubular mitochondria. This changed by 48 hours 
when there was an increase in the number of cells containing fragmented mitochondria at the 
highest level of α-synuclein overexpression, 50 µl mtGFP-SNCA. The lower level of 
α-synuclein overexpression, 20 µl mtGFP-SNCA, and the control, mtGFP treated cells 
showed much fewer cells with fragmented mitochondria. The increase in mitochondrial 
fragmentation at the higher level of α-synuclein overexpression was maintained at 72 hours. 
However, the lower volume of mtGFP-SNCA and control mtGFP still showed no increase in 
mitochondrial fragmentation. In parallel, the same doses of virus used in the mitochondrial 
fragmentation assay were used to assess toxicity in undifferentiated SH-SY5Y cells using the 
MTS assay (Figure 4.13c). In this assay there was no toxicity detected up to 5 days after 
transduction, therefore the mitochondrial fragmentation does not appear to increase cellular 
toxicity. 
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Figure 4.13 – Effect of α-synuclein overexpression on mitochondrial morphology. 
Undifferentiated SH-SY5Y cells were incubated with mtGFP-SNCA or the control mtGFP for 24, 48 
or 72 hours, when live confocal images were taken (data from Dr. Fella Hammachi). The 
mitochondrial morphology was assessed and each cell was classified as tubular, fragmented or 
intermediate, if they contained both tubular and fragmented mitochondria (a); scale bar: 10 µM. The 
percentage of cells with each type of morphology for each condition was calculated (b) (n=1). In 
addition, the toxicity of mtGFP-SNCA and mtGFP was assessed using the MTS assay over 5 days (c). 
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Mitochondrial morphology is reliant on the balance between mitochondrial fission and 
fusion. If there is fragmentation this may be due to an increase in mitochondrial fission or a 
reduction in mitochondrial fusion. Dyanmin-related protein 1 (Drp1) is a major regulator of 
mitochondrial fission that moves from the cytosol to the mitochondria to induce fission 
(Smirnova et al, 1998). Therefore the protein levels of Drp1 and the subcellular localisation 
of Drp1 could determine whether there is an increase in mitochondrial fission. Mitofusin and 
OPA1 are involved in mitochondrial fusion (Chen et al, 2003;	  Olichon et al, 2002). The 
levels of these could determine whether there is a reduction in mitochondrial fusion. An 
increase in mitochdondrial fission could also be a sign of early apoptosis therefore whether 
cytochrome c has been released from the mitochondria or whether the proapoptotic protein 
BAX has increased should be assessed. Nakamura et al show that knock-out of Drp1 does 
not prevent α-synuclein induced fragmentation and instead α-synuclein directly interacts 
with cardiolipin in the mitochondrial membrane. Therefore this too should be assessed in the 
SH-SY5Y cell line.  	  	  
4.7 Effect of α-Synuclein Overexpression on Oxidative Stress 
High overexpression of α-synuclein increased the number of cells with fragmented 
mitochondria, possibly due to an increase in mitochondrial fission. Since the mitochondria 
may be a major source of ROS production in cells, this change in fragmentation may be 
associated with an increase in ROS production. Previous studies found aggregation of 
α-synuclein increases ROS production. In addition, oligomeric or sonicated α-synuclein 
fibrils are taken up into cells and increase ROS production, whereas fibrils or monomers do 
not (Cremades et al, 2012; Dryanovski et al, 2013).   
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Figure 4.14 – Effect of α-synuclein overexpression on ROS production. Undifferentiated 
SH-SY5Y cells on coverslips were cultured in the presence of 500 nM rotenone or vehicle, in 
duplicate, for 2 hours. Coverslips were loaded into coverslip holders and DHE was added. Images 
were taken every 8 seconds for 15 minutes. The nuclear red fluorescence intensity was measured 
using Volocity. This red fluorescence was plotted against time (a). The slope of the red fluorescence 
increase was calculated, as a measure of rate of ROS production, for both control and 500 nM 
rotenone (b). Undifferentiated SH-SY5Y cells were seeded on coverslips and mtGFP or mtGFP-
SNCA was added for 3 days (c) or 7 days (d) when DHE was added and the rate of red fluorescence 
increase was calculated. Coverslip samples for each condition were in duplicate or triplicate with n=1.  
  
 The rate of ROS production in cells was assessed with a DHE live-imaging assay. 
When DHE is oxidised to ethidium or 2-hydroxyethidium in cells it binds to genomic DNA 
resulting in an increase of nuclear red fluorescence over time. The rate of this increase is 
directly correlated to the rate of ROS production (Bindokas et al, 1996; Zhao et al, 2003). 
Initially the assay was optimised using rotenone as a positive control (Figure 4.14a and b). 
Cells were incubated with 500 nM rotenone or DMSO vehicle for 2 hours. They were then 
loaded into a coverslip holder and an area was selected for imaging. DHE (5 µM) in HBSS 
was added to cells on the microscope and images were taken every 8 seconds for 15 minutes. 
Subsequently, areas in the nuclei of each cell were selected using Volocity and the red 
fluorescence intensity was measured at each time point (Figure 4.14a). The slope of the red 
fluorescence increase was calculated as a measure of the rate of DHE oxidation, which is 
directly related to rate of ROS production. This showed that 500 nM rotenone had a greater 
increase of ROS production than the control treated cells; therefore the assay is capable of 
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detecting an increase in ROS production (Figure 4.14b). This DHE assay was used to assess 
the effect of α-synuclein overexpression on ROS production. In this assay, as previously, the 
volumes of the control mtGFP and mtGFP-SNCA used were based on a previous calculation 
where the percentage of GFP positive cells were compared, therefore 1 µl mtGFP was used 
as an equivalent to 2 µl mtGFP-SNCA. Even though this is an incorrect way of calculating 
the equivalent it resulted in a much higher volume of mtGFP being used than needed. The 
results show neither of the mtGFP treated cell samples had an increased ROS production.  
Therefore neither the baculovirus, nor the mtGFP have an effect on ROS production. 
α-Synuclein overexpression for 3 and 7 days at 20-25 µl per 100,000 cells also failed to 
show an increase in ROS production (Figure 4.14 c and d). However, 50 µl per 100,000 cells 
for 3 days appeared to show a decrease in ROS production but this was only from one 
experiment with duplicate coverslips. This experiment needs repeating to determine whether 
there is a significant reduction. Since 62.5 µl per 100,000 cells for 7 days did not show a 
decrease in ROS production it is possible that the reduction is not reproducible. If there is a 
reduction in ROS production then α-synuclein may be capable of preventing oxidative stress 
and therefore may be protective rather than toxic. However, this would require further 
investigation.  
4.8 Discussion and Future Directions 
α-Synuclein overexpression showed no toxicity in undifferentiated or differentiated 
SH-SY5Y cells, despite inducing mitochondrial fragmentation at high levels of 
overexpression.  
Overexpression was achieved using a BacMam construct that encoded α-synuclein 
and mtGFP. The transduction resulted in an increase in α-synuclein protein and GFP in a 
dose dependent manner after 24 hours. Increasing the α-synuclein levels for up to 5 days did 
not cause toxicity in undifferentiated SH-SY5Y cells. In addition, in the presence of 
rotenone, an initiator of oxidative stress, α-synuclein overexpression failed to show an 
increase in toxicity. In differentiated SH-SY5Y cells the increase in mtGFP was maintained 
at a high level for 7 days after which it was reduced. How this relates to α-synuclein protein 
expression is unknown but immunocytochemistry at 2 and 4 weeks suggested α-synuclein 
might be degraded more quickly than mitochondrially targeted GFP. However, this is in 
contrast to the published half-lives of α-synuclein, which is 50 hours in differentiated 
SH-SY5Y cells and cytosolic GFP, which is around 26 hours in mammalian cells (Corish & 
Tyler-Smith, 1999; Li et al, 2004). Therefore clarification of the α-synuclein protein level 
relative to the GFP protein level over time by western blot is needed to see how quickly the 
α-synuclein is degraded. If α-synuclein is degraded more quickly than mitochondrial GFP 
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then it could be why toxicity was not seen, and may mean the BacMam needs to be topped 
up more often than every 7 days. There are a number of possible reasons why no toxicity 
was found. The α-synuclein protein levels may not have been at a high enough level for long 
enough to cause toxicity. An inducible increase of longer-lasting and higher levels of 
α-synuclein could be achieved by creating cell lines with inducible α-synuclein gene 
expression. Alternatively toxic oligomeric α-synuclein may not have been produced. 
Another reason may be due to the cell type that was used. SH-SY5Y cells are a cancer cell 
line that is likely to be more robust than neurons. The use of a different cell line or primary 
neurons with catecholaminergic properties may be needed. In addition, cells or neurons with 
a greater level of endogenous α-synuclein expression and with presynaptic localisation could 
be required. 
No lethal toxicity was found in either undifferentiated or differentiated SH-SY5Y 
cells but there may be more subtle defects in cell function. α-Synuclein has been shown to be 
capable of preventing protein degradation therefore its ability to inhibit proteasomal function 
could be assessed. This could be assessed by analysis of the ubiquitination of proteins over 
time by western blotting in α-synuclein overexpressing cell lines and control cell lines. If 
there is a build up of ubiquitinated protein in the α-synuclein overexpressing cell lines 
compared to the control cell lines then it would suggest the proteasome function is inhibited. 
In addition, since there is an increase in mitochondrial fragmentation this could be 
investigated further to determine what causes the fragmentation. The levels of mitophagy 
could be assessed using a lysotracker dye. If the lysotracker dye co-locates with the 
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Chapter 5 – tert-Butyl hydroperoxide-Induced Oxidative Stress Cell Model 
5.1 Introduction 
Antoxis Limited have developed a number of novel compounds based on natural 
antioxidants. They showed AO-1-530 was one of their lead compounds at protecting against 
microsome lipid peroxidation (Bennett et al, 2004). This antioxidant property makes it an 
exciting compound to test in models of α-synucleinopathies, where oxidative stress has been 
implicated (Dryanovski et al, 2013; Cremades et al, 2012). However, since an α-synuclein-
induced toxicity model could not be produced, a toxin-based neuronal model was 
established. This model was used to assess the protective potential of AO-1-530 compared to 
other natural antioxidants and allowed investigation into its mechanism of protection.  
5.2 Antioxidants 
Antoxis’ lead compound AO-1-530 is a flavonol. Flavonols are a subgroup of flavonoid 
antoxidants the structures of which is shown in Figure 5.1a. They have a hydroxyl group 
attached to position 3 of the C ring, which is a pyran-4-one. These ring structures with 
hydroxyl groups attached make them good hydrogen donators to free radicals due to the 
delocalisation of electrons. There is significant literature comparing flavonoid antioxidants 
to determine the functional groups important for optimal antioxidant action. The best 
antioxidants have a catechol group (a benzene ring with 2 hydroxyl groups attached) at the B 
ring, a double bond in the C ring between carbon 2 and 3 and a 4-oxo group in the C ring 
surrounded by hydroxyl groups at carbon 3 and 5 (van Acker et al, 1996; Bors et al, 1990). 
Myricetin and quercetin have these groups (Figure 5.1b) and are some of the best flavonol 
antioxidants. Comparing flavonoids to ascorbic acid and Trolox, a water-soluble derivative 
of vitamin E, showed flavonols are more potent free radical scavengers (Oliveira et al, 2014; 
Rice-Evans et al, 1997). However, flavonoids do not have the same absorption through the 
diet as vitamin E (Duthie & Morrice, 2012). Therefore, combining the radical scavenging 
potential of flavonols, like myricetin, and the bioavailability of vitamin E may produce a 
more effective antioxidant. Antoxis Limited develop novel compounds, combining 
antioxidant properties of flavonoids with improved bioavailability. They synthesised a 
variety of compounds with a myricetin head groups and varying chain length, chain position 
and chain branching (Bennett et al, 2004). This showed the 8-carbon chain length with 
methyl groups attached like vitamin E and the straight 10-carbon chain were the best 
protectors against lipid peroxidation. The 10-carbon chain antioxidant is Antoxis’ lead 
compound AO-1-530. AO-1-530 was compared to the three other natural antioxidants in 
Figure 5.1b for their ability to protect against oxidative stress. 




Figure 5.1 - Antioxidant chemical structures. (a) This shows the structure of the subgroup of 
flavonoids known as flavonols. (b) The natural antioxidants myricetin and quercetin and the synthetic 
antioxidant AO-1-530 contain the flavonol scaffold. AO-1-530 has a similar head group to myricetin 
with a lipophilic tail that was based on that of vitamin E. These four antioxidants were compared for 
their ability to protect cells against oxidative stress.  
	  
Flavonols, which have a carbonyl group next to the hydroxyl group at position 3 on 
ring C naturally fluoresce (Mukai et al, 2011; McMorrow & Kasha, 1984). The fluorescence 
of the antioxidants in DMSO was confirmed using a fluorescence plate reader with 
excitation 485 nm and emission 520 nm (Figure 5.2). All three flavonoid antioxidants 
showed green fluorescence to varying degrees. AO-1-530 was highly fluorescent, whereas 
myricetin and quercetin showed a similar lower fluorescence. 
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Figure 5.2 - Flavonol antioxidants naturally fluoresce green. 1 mM antioxidant solutions in DMSO 
were loaded into a 96-well plate in triplicate. The fluorescence level was assessed in a plate reader 
with excitation 485 nm and emission 520 nm. Each bar represents the mean of four separate 
experiments and the error bars represent the SEM. ANOVA with a Tukey post-hoc test was performed 
to assess the significant difference between samples and the control; * p<0.05. 
 
The flavonoid antioxidants fluoresce green so their uptake and localisation within 
cells can be examined (Figures 5.3-5.5). A 10-fold lower concentration of AO-1-530 than 
myricetin or quercetin was used because AO-1-530 is toxic at 100 µM. This toxicity could 
be due to auto-oxidation of AO-1-530 producing H2O2, which has also been found for 
myricetin (Mukai et al, 2011; Kajiya et al, 2001). Confocal microscopy showed AO-1-530 
was taken up into cells, excluded from the nucleus and enriched in filamentous structures, 
which looked mitochondrial (Figure 5.3). Therefore, the co-localisation of AO-1-530 with 
Mitotracker Deep Red was assessed (Figure 5.4). The overlay shows AO-1-530 was enriched 
in the mitochondria and was found elsewhere in the cytoplasm. Quercetin was also taken up 
into cells, but in contrast to AO-1-530, quercetin showed strong nuclear localisation (Figure 
5.3). The cells incubated with myricetin showed no green fluorescence, indicating it was not 
taken up into cells. This may be due to myricetin’s lower lipophilicity (Kajiya et al, 2001) or 
due to its instability at neutral pH (Yao et al, 2014).  
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Figure 5.3 - Flavonol antioxidant localisation in SH-SY5Y cells. SH-SY5Y cells were incubated 
with antioxidants (myricetin, 100 µM; quercetin, 100 µM; AO-1-530, 10 µM) for 2 hours, fixed, 
counterstained with DAPI (blue) and mounted with Vectashield onto slides. They were then imaged 
using the 63x objective of the Leica TCS SPE confocal microscope; scale bar: 11 µm. 
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Figure 5.4 - AO-1-530 localisation in SH-SY5Y cells. SH-SY5Y cells were incubated with 
Mitotracker Deep Red (100 nM) for 20 minutes. Then AO-1-530 (10 µM) was added for 2 hours. 
Cells were fixed, counterstained with DAPI (blue), mounted with Vectashield onto slides and imaged 
using the 63x objective of the Leica TCS SPE confocal microscope; scale bar: 11 µm. 
 
 FACS analysis was performed to get a quantitative measure of the number of cells 
that had taken up the antioxidant (Figure 5.5). The FACS plot in Figure 5.5a shows that, as 
with confocal microscopy, AO-1-530 and quercetin were inside the cells but myricetin was 
not. All cells have taken up some AO-1-530 or quercetin. FACS analysis was performed 
twice with triplicate samples; the mean fluorescence and SEM are shown in Figure 5.5b. 
This confirms the antioxidants that were taken up into cells. However, it is important to note 
the fluorescence intensity varies with antioxidant (Figure 5.2), so just because AO-1-530 
incubated cells have a higher level of fluorescence it does not mean more AO-1-530 has 
been taken up into cells than quercetin. 
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Figure 5.5 - Flavonol antioxidant uptake into cells determined using FACS analysis. Antioxidants 
(myricetin 100 µM; quercetin 100 µM and AO-1-530 10 µM) were added to SH-SY5Y cells for 2 
hours. Cells were then lifted using trypsin, washed and incubated with PI, to exclude dead cells. The 
level of green fluorescence from each cell was analysed using the FACS Calibur (a). (b) Bars 
represent the mean green fluorescence from two separate FACS experiments each with triplicate 
samples and error bars represent the SEM. ANOVA with a Tukey post-hoc test was performed to 
assess the significant difference between samples and the control; * p<0.05; ns, not significant, 
p>0.05. 
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5.3 Protection against tBHP-Induced Toxicity 
In order to compare the antioxidant capabilities of AO-1-530 and the natural antioxidants an 
oxidative stress cell model was needed. Undifferentiated SH-SY5Y cells and NS-1 cells 
were used with the toxin tBHP. tBHP is an organic peroxide, easily taken up by cells. Once 
inside cells tBHP is a substrate for the enzyme GPx, which enzymatically reduces it to 
tert-butyl alcohol (Flohe, 1982). However, not all of the tBHP is removed in this way. When 
tBHP comes into contact with transition metal ions, free radicals are produced, initially 
alkoxyl (RO) and subsequently peroxyl  (ROO) radicals. These free radicals are capable of 
damaging cellular components (Van der Zee et al, 1996). tBHP was chosen as an inducer of 
oxidative stress for a number of reasons. Firstly, tBHP is known on reaction with iron (II) to 
produce the alkoxyl radical (RO) which can induce a lipid peroxidation chain reaction in 
cellular membranes (Van der Zee et al, 1996). The lipophilic tail attached to AO-1-530 may 
embed it in the membrane, like vitamin E, inhibiting lipid peroxidation. Secondly, tBHP 
rather than H2O2 was chosen as cells have a more effective antioxidant response to H2O2. 
Therefore the induction of oxidative stress is more consistent with tBHP (Alía et al, 2005). 
Thirdly, a number of studies have evaluated the effect of tBHP on isolated mitochondria. 
This has shown tBHP is capable of inducing lipid peroxidation of the mitochondrial 
membrane (Radi et al, 1993). Finally, addition of tBHP to hepatocytes has shown that the 
mitochondrial NADPH is reduced and the mitochondrial and cytosolic oxidative stress 
increases. Therefore, tBHP addition to intact cells damages the mitochondria (Nieminen et 
al, 1997). 
In order to quantify the toxicity of tBHP and the protection of antioxidants a number 
of cell viability assays were used. One of these was the MTS assay (Figure 4.9a). To 
optimise undifferentiated SH-SY5Y cells for use with the MTS assay, cells were seeded at 
different densities into 96-well plates and cultured for 24 hours when the MTS assay was 
performed (Figure 5.6). The cells show a linear correlation of cell number to absorbance up 
to 40,000 cells per well. In this case the assay was being optimised for use as a measure of 
toxicity therefore a point at the higher end of the linear slope was chosen, 40,000 cells per 
well for further experiments (Figure 5.6). 
Based on a time-course of tBHP addition, the toxin, should be added to cells for 5 
hours. It was then necessary to determine the appropriate concentration of tBHP to use 
(Figure 5.7a). 100 µM tBHP or below was not significantly toxic but concentrations above 
200 µM were toxic. The toxicity plateaued at 400 µM, therefore this concentration was 
chosen to induce a significant reduction in metabolic activity, allowing the antioxidant 
protective potential to be assessed.  
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Figure 5.6 - Optimisation of SH-SY5Y cell number. The MTS assay was performed on SH-SY5Y 
cells seeded at different densities. MTS and PMS were incubated with cells for 1 hour when the 
absorbance at 490 nm and reference wavelength 650 nm were recorded. Each point represents the 
average absorbance from three separate experiments each with triplicate samples and the error bars 
show the SEM. ANOVA with a Tukey post-hoc test was performed to assess the significant difference 
between samples and 10,000 cells absorbance * p<0.05. 
 
In addition, the antioxidant toxicity was assessed (Figure 5.7b and c). Discussion 
with Antoxis Limited and preliminary experiments were used to choose an appropriate 
concentration range for each antioxidant. AO-1-530 would be used at up to 10 µM. Since it 
was also shown to be significantly toxic at 40 µM and above (Figure 5.7c). Myricetin and 
quercetin would be used at up to 100 µM and vitamin E at up to 300 µM. Cells treated for 16 
hours with antioxidants showed most antioxidant concentrations were not significantly toxic, 
except for 100 µM quercetin (Figure 5.7b).  
 These optimisation experiments led to the following experimental design; SH-SY5Y 
cells were pre-incubated for 30 minutes with the vehicle or antioxidants before addition of 
400 µM tBHP. The cells were then incubated for 5 hours or 16 hours when the cell viability 
was assessed by examining cellular morphology (Figure 5.8) and using the MTS assay 
(Figure 5.9), LDH assay (Figure 5.11) and PI with FACS analysis (Figure 5.12). 
The cell morphology 5 hours after tBHP addition appeared rounded and the short 
processes were retracted (Figure 5.8). Pre-incubation with 10 µM AO-1-530 or 100 µM 
quercetin protected the cells from rounding up; cells were attached and spread out similar to 
control treated cells. In contrast, pre-incubation with 100 µM myricetin or 300 µM vitamin E 
failed to prevent the cells rounding up. Similar protection results can be seen in the videos on 
the enclosed CD, which were imaged every 30 minutes for 12 hours after tBHP addition.  
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Figure 5.7 - tBHP and antioxidant toxicity in SH-SY5Y cells. tBHP was added to SH-SY5Y cells 
for 5 hours (a), antioxidants were added for 16 hours (b) or AO-1-530 was added for 48 hours (c). The 
MTS assay was then performed in the last hour when the absorbance was read. Each bar represents 
the average absorbance relative to untreated control cells from three separate experiments; each with 
triplicate wells. Error bars represent the SEM. ANOVA with a Tukey post-hoc test was performed to 
assess the significant difference between samples and the control; * p<0.05; ns, not significant, 
p>0.05. 
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Figure 5.8 – Antioxidant protection against tBHP-induced toxicity assessed by cell morphology. 
SH-SY5Y cells were pre-incubated with the stated antioxidants or vehicle for 30 minutes, when 400 
µM tBHP was added. 5 hours later live images were taken; scale bar: 76 µm. 
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Figure 5.9 - Antioxidant protection against tBHP-induced toxicity assessed using the MTS assay. 
SH-SY5Y cells were pre-incubated with antioxidants or vehicle for 30 minutes, when tBHP was 
added for 5 hours (a) or 16 hours (b). In the last hour MTS was added and the absorbance was read. 
Each bar represents the average absorbance relative to untreated control cells (black bar) from three 
separate experiments each with triplicate wells, error bars represent the SEM. ANOVA with a Tukey 
post-hoc test was performed to assess the significant difference between samples and the tBHP treated 
cells; * p<0.05; ns, not significant. 
	  
Figure 5.9a shows the antioxidant protection against tBHP-induced toxicity assessed 
by the MTS assay. 400 µM tBHP caused a 50% reduction in metabolic activity 5 hours after 
its addition. If cells were pre-incubated with AO-1-530, there was a concentration dependent 
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protection against toxicity. 10 µM AO-1-530 was the only treatment that was not 
significantly different from the control, making it the most effective antioxidant treatment 
tested. A 10-fold higher concentration of quercetin was needed to show a similar level of 
protection. The flavonol which AO-1-530 is based, myricetin showed limited protection 
against tBHP-induced cell death. In addition, vitamin E, Idebenone and coenzyme Q10 
showed no protection against tBHP. Coenzyme Q10 is a natural antioxidant found in the 
mitochondria and Idebenone is a synthetic drug based on coenzyme Q10. tBHP treatment for 
16 hours (Figure 5.9b) produced an even greater reduction in metabolic activity to less than 
2%. Only pre-incubation with 10 µM AO-1-530 or 50-100 µM quercetin showed significant 
protection. Vitamin E and myricetin showed no protection. 
The antioxidant protection revealed using MTS was also assessed in 14 day 
differentiated SH-SY5Y cells. The neurons were pre-incubated with antioxidant for 30 
minutes before the addition of tBHP. They were incubated for a further 8 hours when the 
MTS assay was performed for 1 hour (Figure 5.10). 400 µM tBHP was found to reduce 
metabolic activity to 30%. As with undifferentiated SH-SY5Y cells, AO-1-530 and quercetin 
showed protection, whereas myricetin did not. In this assay 10 µM AO-1-530 and both 
concentrations of quercetin were not statistically different from control treated cells. 
 
Figure 5.10 - Antioxidant protection against tBHP-induced toxicity assessed using the MTS 
assay in differentiated SH-SY5Y cells. 14 day differentiated SH-SY5Y cells were pre-incubated 
with antioxidants or vehicle for 30 minutes, when 400 µM tBHP was added for 9 hours. In the last 
hour the MTS assay was performed. Each bar represents the average absorbance relative to untreated 
control cells (black bar) from four experiments (Three of which were performed at the same time) 
each with triplicate or quadruplicate wells, error bars represent the SEM. ANOVA with a Tukey 
post-hoc test was performed to assess the significant difference between samples and the tBHP treated 
cells; * p<0.05, ns not significant. 
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Antioxidant protection in undifferentiated SH-SY5Y cells was confirmed using 
another assay, the LDH assay at 5 hours and 16 hours after tBHP addition (Figure 5.11). 
LDH is an intracellular enzyme. When the cell membrane integrity is lost, LDH is released 
into the culture medium. This assay measures the levels of LDH in the medium and is 
therefore a measure of the number of cells that have lost their cell membrane integrity. 
Figure 5.11a shows 5 hours after tBHP addition, AO-1-530 and quercetin are the only 
antioxidants tested that show significant protection of the cell membrane. Myricetin does not 
protect the cell membrane but vitamin E does show a trend towards protection that was not 
significant. The negative quercetin cytotoxicity at 6 hours may be due to quercetin absorbing 
at the 650 nm reference wavelengths. 16 hours after tBHP addition AO-1-530 and quercetin 
still showed protection (Figure 5.11b). As with the MTS assay 10 µM AO-1-530 was the 
only antioxidant condition that showed no significant difference statistically from the 
control. Quercetin showed protection but a 10-fold higher concentration than AO-1-530 was 
needed.	  
PI is a nuclear stain, which is only taken up into cells that have lost their cell 
membrane integrity. Therefore, PI can be used to assess cell viability. 6 hours after tBHP 
addition there is not a significant increase in PI staining (Figure 5.12a), preventing 
AO-1-530 protection from being assessed. If the cells were left for a further 10 hours there 
was a significant increase in PI positive cells. This allowed the protective affect of 
pre-incubation with 1 µM and 10 µM AO-1-530 to be examined. 1 µM AO-1-530 showed 
significant but limited protection. 10 µM AO-1-530 significantly protected cells against 
tBHP-induced toxicity and was not significantly different from control treated cells. In 
addition, AO-1-530 was not toxic in this assay as there was no increase in the number of PI 
positive cells. These experiments clearly show that pre-incubation with AO-1-530 is capable 
of preventing or delaying tBHP-induced toxicity.  
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Figure 5.11 – Antioxidant protection against tBHP-induced toxicity assessed using the LDH 
assay. SH-SY5Y cells were pre-incubated with antioxidants or vehicle for 30 minutes, when tBHP 
was added for 5 hours (a) or 16 hours (b). Media was collected from each well and the LDH assay 
was performed to determine the amount of LDH released from cells. Each bar represents the average 
absorbance relative to untreated control cells and from fully lysed cells from three separate 
experiments each with triplicate wells. Error bars represent the SEM. ANOVA with a Tukey post-hoc 
test was performed to assess the significant difference between samples and the tBHP treated cells; * 
p<0.05; ns, not significant. 
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Figure 5.12 – Antioxidant protection against tBHP-induced toxicity assessed using PI staining 
with FACS analysis. SH-SY5Y cells were pre-incubated with AO-1-530 or vehicle for 30 minutes, 
when tBHP was added for 6 hours (a) or 16 hours (b). Cells were lifted, incubated with PI and 
analysed using the FACS Calibur. The bars represent the average number of cells positive or negative 
for PI from (a) one experiment with triplicate samples or (b) two experiments with triplicate samples; 
error bars represent the SEM. ANOVA with a Tukey post-hoc test was performed to assess the 
significant difference between samples and the tBHP treated cells; * p<0.05; ns, not significant. 
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5.3.1 Intracellular AO-1-530 Protection 
In all of the protection experiments mentioned so far the antioxidants were present in the 
media when tBHP was added so the antioxidant and tBHP may be interacting outside the 
cell. To try to assess the intracellular AO-1-530 protection SH-SY5Y cells were incubated 
with AO-1-530 for 30 minutes. It was then removed and tBHP was added to the cells. Cells 
were then cultured for a further 5 hours with the MTS assay being performed in the last hour 
(Figure 5.13). AO-1-530 was found to be significantly protective at all concentrations added 
but higher concentrations were needed to obtain the same level of protection as when it was 
present in the media. This proves a significant portion of the protection is due to the 
intracellular activity of AO-1-530. 
Figure 5.13 - Intracellular AO-1-530 protection. SH-SY5Y cells were pre-incubated with 
AO-1-530 for 30 minutes. Then AO-1-530 was removed and 400 µM tBHP was added. Cells were 
cultured for a further 5 hours when the MTS assay was performed. Each bar represents the average 
absorbance relative to untreated control cells from three separate experiments each with triplicate 
wells, error bars represent the SEM. ANOVA with a Tukey post-hoc test was performed to assess the 
significant difference between samples and the tBHP treated cells; * p<0.05; ns, not significant. 
 
5.3.2 Antioxidant Protection of Cells after tBHP Addition 
Another question is whether AO-1-530 and quercetin can protect cells that are already in a 
state of oxidative stress (Figure 5.14). Cells were either pre-incubated with antioxidant (-0.5 
hour), co-treated with antioxidant and tBHP (0 hour) or post-tBHP treated with antioxidant 
(1 hour and 1.5 hour). 10 µM AO-1-530 was significantly protective when added after tBHP, 
even at 1.5 hours after tBHP addition. Quercetin also showed protection post-tBHP addition 
at a 10-fold higher concentration but was only protective up to 1 hour after tBHP treatment 
addition.  
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Figure 5.14 – Antioxidant protection in cells already in a state of oxidative stress. SH-SY5Y cells 
were either: pre-incubated with antioxidant for 30 minutes before tBHP addition, co-incubated with 
antioxidant and tBHP or post-incubated with antioxidant after tBHP addition. Antioxidants AO-1-530 
(a) and quercetin (b) were used. Cells were cultured for 5.5 hours in total with the MTS assay 
performed in the last hour. Each bar represents the average absorbance relative to untreated control 
cells from three separate experiments each with triplicate wells, error bars represent the SEM. 
ANOVA with a Tukey post-hoc test was performed to assess the significant difference between 
samples and the tBHP treated cells; * p<0.05; ns, not significant. 
 
5.3.3 Antioxidant Protection against tBHP in Neuroscreen™-1 Cells 
To observe the antioxidant protection in another cell line, NS-1 was used. Initially, the cell 
density was optimised for the use of 3 day NGFβ differentiated NS-1 cells with the MTS 
assay. Seeding at 10,000 cells per well was chosen as this gave a strong absorbance to allow 
toxicity to be detected, and was in the linear range where absorbance is relative to cell 
number (Figure 5.15a). The tBHP concentration was also optimised for this number of cells 
at 16 hours after addition (Figure 5.15b). Significant toxicity was found at 100 µM tBHP and 
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above, therefore 200 µM tBHP was chosen to give an 80% reduction in metabolic activity. In 
addition, the toxicity of antioxidants was examined and showed AO-1-530 and myricetin 
were not toxic at the concentrations used but quercetin was significantly toxic (Figure 
5.15c). As mentioned previously toxicity may be due to auto-oxidation of the flavonols 
producing toxic H2O2. Alternativey it coud be due to the reduction of ROS levels that are 
required for cell signalling. These experiments led to the following experimental design to 
assess the protection of antioxidants against tBHP-induced toxicity: NS-1 cells were 
differentiated for 3 days, then pre-incubated with antioxidants or vehicle for 30 minutes 
before the addition of 200 µM tBHP. Cells were then cultured for 15 hours before the MTS 
assay was performed for 1 hour (Figure 5.16). As with the SH-SY5Y cell line, AO-1-530 
and quercetin showed significant protection, whereas myricetin showed no protection. This 
confirmed that the AO-1-530 protection could also be seen in differentiated NS-1 cells. 
 
 
AO-1-530 is significantly protective against tBHP-induced oxidative stress. 
Myricetin shows limited protection. A 10-fold higher concentration of quercetin compared to 
AO-1-530 is needed to provide a similar level of protection. These results may be due to 
their uptake into cells, their localisation in cells relative to the location of free radical 
production or their radical scavenging potency. Further experiments were performed to 
investigate the mechanism by which AO-1-530 protects cells.	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Figure 5.15 - tBHP-induced toxicity in differentiated NS-1 assay optimisation. (a) Differentiated 
NS-1 cell number optimisation. Cells were differentiated for 3 days when the MTS assay was 
performed. (b) Optimisation of tBHP concentration toxicity in 3 day differentiated NS-1 cells. tBHP 
was added for 15 hours when the MTS assay was performed for 1 hour. (c) Assessment of antioxidant 
toxicity in 3 day differentiated NS-1 cells after 16-hour exposure using the MTS assay. Each bar 
represents the average absorbance relative to untreated control cells from three separate experiments 
each with triplicate wells, error bars represent the SEM. ANOVA with a Tukey post-hoc test was 
performed to assess the significant difference between samples and the control treated cells; * p<0.05; 
ns, not significant. In (a) significant difference between NS-1 cell number and 1000 NS-1 cells 
absorbance, * p<0.05. 	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Figure 5.16 – Antioxidant protection against tBHP-induced toxicity in differentiated NS-1 cells. 
3 day differentiated NS-1 cells were pre-incubated with vehicle or antioxidant for 30 minutes, and 
then they were exposed to 200 µM tBHP. 15 hours later MTS was added for 1 hour, when the 
absorbance was read. Bars represent the mean from three independent experiments with triplicate 
wells. Error bars show the SEM. ANOVA with a Tukey post-hoc test was performed to assess the 
significant difference between samples and the tBHP treated cells; * p<0.05; ns not significant. 
	  
5.4 Radical Scavenging Potential of Antioxidants 
5.4.1 Galvinoxyl Radical Scavenging 
Galvinoxyl is a known stable free radical. It has one unpaired electron making it a free 
radical. There are two reasons why it shows slow reactivity with oxygen and is therefore 
stable (Coppinger, 1957). Firstly, the unpaired electron is delocalised across the molecule. 
Secondly, the presence of the tert-butyl groups provides steric hindrance, protecting the 
unpaired electron and preventing dimerization. The presence of this unpaired electron gives 
galvinoxyl a strong absorbance at 428 nm (Shi et al, 2001). The loss of this unpaired electron 
by donation of a hydrogen atom from another molecule results in a reduction in absorbance 
at 428 nm. Therefore, galvinoxyl can be used to examine the hydrogen donating ability or 
scavenging potential of antioxidants. Shi et al. used this method to assess the hydrogen 
donating ability of myricetin, quercetin and vitamin E. In these conditions myricetin donated 
the most hydrogen atoms and it was the most reactive with galvinoxyl. Quercetin was 
capable of donating more hydrogen atoms than vitamin E but the rate of the donation of each 
hydrogen atom was slower. To compare the hydrogen donating ability of AO-1-530 to 
myricetin and quercetin the change in absorbance at 428 nm at different antioxidant 
concentrations was assessed (Figure 5.17a). The slope of the change in absorbance of each of 
the antioxidants was calculated (Figure 5.17b). This slope is correlated with the hydrogen 
donating ability. AO-1-530 has a similar scavenging potential as myricetin, both of which 
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are better hydrogen donators than quercetin. In these experiments the rate of hydrogen 
donation was not determined.   
	  
Figure 5.17 - Radical scavenging ability of flavonol antioxidants assessed using galvinoxyl 
absorbance. Galvinoxyl and antioxidants were mixed at the appropriate concentrations, 6 minutes 
later the absorbance at 428 nm was measured. The change in absorbance was plotted against the 
antioxidant concentration (a). The slope was calculated, as this is a measure of scavenging potency 
(b). Points represent the average of four independent experiments with duplicate or triplicate wells. 
ANOVA with the post-hoc Tukey test was performed to assess statistical significance; * p<0.05, ns 
not significant.	  
	  
The unpaired electron in galvinoxyl also makes it possible to measure the relative 
concentration using EPR spectroscopy. The unpaired electron is like a magnet that can align 
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parallel or antiparallel to an external magnetic field, with two energy levels. This electron 
can move from the lower energy level to the upper energy level by absorbing energy, if a 
specific energy in the form of electromagnetic radiation is present. The absorbance is 
measured and presented as the rate of change in absorbance. An unpaired electron’s 
absorbance will be affected by the atoms, which surround it, as these too have charges. 
Galvinoxyl shows a signal using EPR. When mixed with antioxidants that can donate 
hydrogen to the unpaired electron, the unpaired electron is lost resulting in a reduction in the 
signal intensity (Figure 5.18). EPR has been used to study hydrogen donating ability and rate 
of reaction of galvinoxyl with antioxidants, including myricetin, quercetin and vitamin E 
(McPhail et al, 2003). When comparing these three antioxidants the order was the same for 
hydrogen donating ability and rate of reaction with myricetin the best followed by quercetin 
and then vitamin E. To compare the hydrogen donating ability of AO-1-530 with myricetin 
and quercetin EPR experiments were performed.  It was found the ability of antioxidants to 
donate hydrogen atoms to galvinoxyl was time dependent. The reaction reached the 
maximum by 6 minutes, similar to the time point used by McPhail et al. (Figure 5.18a). The 
scavenging potential of AO-1-530, myricetin and quercetin is concentration dependent with 
10 µM scavenging more radicals than 5 µM (Figure 5.18b). The overlay of 10 µM 
scavenging of each antioxidant shows AO-1-530 and myricetin have similar scavenging 
ability with quercetin showing a lower ability, as was found in the plate reader experiment 
(Figure 5.18b and 5.17). The kinetics of the reaction for AO-1-530 scavenging galvinoxyl 
was not measured here. However, the time-course radical scavenging experiments (Figure 
5.18a) indicate at 2 minutes and 4 minutes after antioxidant addition AO-1-530 was slightly 
slower in scavenging than myricetin. 
These galvinoxyl experiments show AO-1-530 is capable of donating the same 
number of hydrogen atoms as myricetin, which is more than quercetin. Therefore, AO-1-530 
and myricetin are more potent antioxidants in solution. However, this measure of scavenging 






	   107	  
Figure 5.18 - Radical scavenging ability of flavonol antioxidants assessed using galvinoxyl EPR 
spectroscopy. The EPR signal of galvinoxyl represents the presence of an unpaired electron. When 
antioxidants donate a hydrogen atom to the galvinoxyl radical the signal is lost. Galvinoxyl was mixed 
with the stated concentration of antioxidants and loaded into a capillary for EPR spectroscopy. The 
times stated are the times after initial mixing of galvinoxyl and antioxidants. The speed at which the 
radical is lost represents the antioxidant reactivity towards galvinoxyl (a). The scavenging potential at 
6 minutes is relative to the concentration that was added (b). These are results from one experiment, 
but are representative of a number of experiments.	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5.4.2 Intracellular Radical Scavenging - CellROX® Deep Red 
In order to investigate the intracellular antioxidant radical scavenging potency of these 
flavonol antioxidants, the commercially available dye from Life Technologies, CellROX® 
Deep Red was used. This dye is membrane permeable and in the reduced state is 
non-fluorescent. Once inside cells it can become oxidised by ROS to produce a fluorescent 
compound (emission, 665 nm). This can be quantified as a measure of cellular ROS 
production (Figure 5.19).  
Initially, it was necessary to optimise the CellROX® dye for use with the SH-SY5Y 
cell line and tBHP. In these optimisation experiments, the dye appeared to show uneven 
fluorescence after fixation, therefore it was chosen to image the cells live. In addition, there 
appeared to be no difference if the CellROX® was incubated in the presence of complete 
media or HBSS therefore complete media was chosen for future experiments. It was also 
necessary to pre-incubate the cells with 10 µM CellROX®. Addition of CellROX® after 
removal of tBHP showed no difference in fluorescence and addition in the presence of tBHP 
resulted in tBHP directly oxidising the dye.  
These optimisation experiments led to the following experimental plan. 10 µM 
CellROX® Deep Red and 2.8 µg/ml Hoechst 33342 were added to SH-SY5Y cells for 30 
minutes, the cells were then washed 3 times with cell culture medium. The antioxidants were 
added for 30 minutes before the addition of 400 µM tBHP for one hour. The cells were then 
washed once in HBSS and imaged live in HBSS. Images were taken with the appropriate 
filters for CellROX® (emission, 665 nm) and Hoechst 33342 (emission, 461 nm), as well as 
phase contrast images (Figure 5.19a). The far-red fluorescence intensity in a small area of 
each cell was quantified for each image using Volocity. The mean and SEM relative to the 
mean number of cells counted from a number of experiments was calculated (Figure 5.19b).  
The addition of tBHP in the presence of vehicle increased the levels of ROS in 
SH-SY5Y cells (Figure 5.19b). Myricetin pre-incubation significantly reduced the ROS 
production compared to tBHP treated cells but the reduction was not to control levels. 
AO-1-530 and quercetin were both capable of reducing ROS production to control levels, 
with quercetin being added at a 10-fold higher concentration than AO-1-530. Incubation 
with AO-1-530 alone was not significantly different from control treated cells so at 10 µM 
AO-1-530 is incapable of significantly reducing basal intracellular ROS.     
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Figure 5.19 - Intracellular flavonol antioxidant scavenging potential using CellROX® Deep Red. 
SH-SY5Y cells were incubated with CellROX® Deep Red and Hoechst 33342 for 30 minutes when 
they were washed. Antioxidants were then added for 30 minutes, when 400 µM tBHP was added for 
one hour. Cells were washed and phase, CellROX® and Hoechst 33342 images were taken (a). The 
mean CellROX® Deep Red fluorescence was quantified (b). Bars represent the mean from four 
independent experiments for AO-1-530, two for myricetin and one for quercetin with duplicate 
coverslips. Error bars represent the SEM. ANOVA with the post-hoc Tukey test was performed to 
assess statistically significant difference to control treated cells; * p<0.05; ns, not significant. 
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Unlike the galvinoxyl experiments the CellROX® assay takes into account the 
cellular uptake of antioxidants. For this reason myricetin, which is poorly taken up into cells, 
shows less scavenging potency than AO-1-530 and quercetin. This data suggests the ability 
of AO-1-530 and quercetin to prevent tBHP-induced toxicity may be through their ability to 
scavenge the radicals produced by tBHP. To further investigate the antioxidant scavenging 
effect of AO-1-530 on tBHP-induced oxidative stress, oxidative stress responses were 
examined. 
5.5 Cellular Oxidative Stress Responses 
5.5.1 Cellular Redox Status – Ratio of Oxidised to Reduced Glutathione 
GSH is an antioxidant synthesised in cells and is present at high concentrations. Its direct 
antioxidant function as a free radical scavenger comes from the presence of a thiol group, 
allowing it to act as an electron donor. In addition, GSH acts as a cofactor for GPx and GST 
that act to remove peroxides and xenobiotics, respectively. GSSG is then reduced by 
glutathione reductase. The presence of oxidative stress increases the levels of GSSG. 
Therefore the ratio of GSSG to GSH is a read-out of the redox status of the cells. 
As mentioned previously tBHP is taken up into cells and the main detoxification 
method the cells have is through GPx degradation. GPx uses GSH as a cofactor to convert 
tBHP to tert-butyl alcohol. This seems to be a separate pathway than the reaction of tBHP 
with metal ions to produce alkoxyl radicals (RO).  
tBHP significantly increased the levels of GSSG after 2 hours treatment (Figure 
5.20). This could be due to the actions of GPx and/or through GSH acting as a direct radical 
scavenger of tBHP radicals. AO-1-530 pre-incubation was incapable of preventing this tBHP 
oxidation of GSH. This can be explained if AO-1-530 is acting as a direct radical scavenger 
of the alkoxyl radicals produced, then it is unlikely to have any effect on the GPx oxidation 
of GSH. This has been found with other antioxidants (Masaki et al, 1989). Alternatively, if 
the increase in GSSG were due to GSH acting as a direct radical scavenger then AO-1-530 
would be expected to reduce the levels of GSSG. However, AO-1-530 does not reduce the 
GSSG and therefore could be acting in conjunction with the natural antioxidant defence, 
GSH with GPx, to improve cell survival. Another possible reason AO-1-530 protection 
against tBHP induced GSSG is not detected may be due to the low sensitivity of the assay as 
two wells of a 6-well plate were needed to detect the tBHP induced increase. It is not 
possible from this experiment to separate these two pathways but this data suggests 
AO-1-530 and GSH work independently to remove tBHP from the cell and prevent its 
toxicity. These two pathways could be separated by inhibiting GPx with mercaptosuccinic 
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acid at the same time as addition of tBHP. In the absence of GPx activity if there is still a 
tBHP induced increase in GSSG, then GSH is acting as a direct antioxidant rather than a 
GPx cofactor. If there is no GSSG increase in the presence of tBHP then GSH acts mainly as 
a GPx cofactor.    
Figure 5.20 – Measurement of oxidised and reduced glutathione. SH-SY5Y cells were 
pre-incubated with antioxidant or vehicle for 30 minutes, when 400 µM tBHP was added for 2 hours. 
Cells were then scraped to lift and lysed. The level of GSH and GSSG was measured using 
GSH/GSSG Ratio assay kit from Calbiochem. Bars represent the ratio of GSSG to GSH from three 
independent experiments. Error bars represent the SEM. ANOVA with the post-hoc Tukey test was 
performed to assess statistical significance relative to tBHP treated cells; * p<0.05; ns, not significant. 
5.5.2 Oxidative Stress Response - Nrf2 Nuclear Localisation 
Nrf2 is a transcription factor found in most cells. In cellular stress conditions Nrf2 activates 
transcription of detoxification and antioxidant genes, to combat the stress and prevent cell 
death (Figure 1.6). In the absence of stressors, the Nrf2 protein binds to the Keap1 protein, 
which targets Nrf2 for degradation by the ubiquitin-proteosome degradation system 
(Kobayashi et al, 2004). However, in the presence of oxidative stress cysteine residues in the 
Keap1 protein are altered preventing its degradation of Nrf2, allowing Nrf2 to locate to the 
nucleus (Yamamoto et al, 2008). Once inside the nucleus Nrf2 can heterodimerise with 
small Maf proteins and activate transcription of ARE containing genes, including HMOX1 
and NQO1 (Itoh et al, 1997). Therefore, the nuclear localisation of Nrf2 in cells and the 
activation of ARE containing genes can be a measure of cellular oxidative stress.  
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Figure 5.21 - AO-1-530 protection against tBHP-induced Nrf2 nuclear localisation and ARE 
gene activation. AO-1-530 or vehicle was added to cells for 30 minutes before the addition of 400 
µM tBHP. Cells were incubated for 4.5 hours when they were fixed and immunocytochemistry was 
performed for Nrf2 (red) and nuclei were stained by DAPI (blue) (a), scale bar 54 µm. The intensity 
of nuclear fluorescence was quantified using ImageJ. The p-values for control to tBHP was 0.155 and 
tBHP to AO-1-530 and tBHP was 0.09. (b). Bars represent the mean from three individual coverslips 
with 2-4 images per coverslip. Error bars represent the SEM. ANOVA with the post-hoc Tukey test 
was performed to assess statistical significance relative to tBHP treated cells; ns, not significant 
p>0.05. Alternatively, 4.5 hours after tBHP addition cells were lifted and RNA was extracted for 
qRT-PCR of Nrf2 also known as NFE2L2, HMOX1 and NQO1 (c). Bars represent the mean from one 
experiment with duplicate or triplicate wells. Error bars represent the standard deviation.   
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Immunocytochemistry was performed to assess the localisation of Nrf2 4.5 hours 
after tBHP treatment with AO-1-530 or vehicle pre-incubation (Figure 5.21a). The nuclear 
Nrf2 levels were quantified using ImageJ (Figure 5.21b). SH-SY5Y cells treated with tBHP 
showed a trend towards an increase in Nrf2 nuclear localisation compared to control treated 
cells (Figure 5.21a and b). AO-1-530 pre-incubation reduced the nuclear levels of Nrf2 to 
control levels. In all experiments tBHP had a higher Nrf2 nuclear staining intensity than 
control treated cells and 2 of the 3 experiments the difference was significant. However, 
when the results from 3 experiments were merged the differences were not statistically 
significant due to variability in Nrf2 staining intensity between coverslips. This may be due 
to underrepresentation and therefore if the number of experiments were increased there may 
be a significant difference.  
To confirm the ability of AO-1-530 to reduce Nrf2 nuclear localisation and ARE 
gene transcription, the gene expression of two ARE containing genes was assessed, NQO1 
and HMOX1 (Figure 5.21c). The presence of tBHP for 4.5 hours increased the transcription 
of HMOX1 and NQO1 compared to control treated cells. AO-1-530 pre-incubation reduced 
the gene expression compared to tBHP with vehicle but did not reduce it to control levels. 
As found in other studies the presence of oxidative stress has no effect on the transcriptional 
level of Nrf2 itself (Figure 5.21c) (Purdom-Dickinson et al, 2007).  
 These experiments suggest that AO-1-530 can reduce Nrf2 nuclear translocation. 
Since Nrf2 nuclear localisation occurs due to the presence of oxidative stress, this suggests 
that AO-1-530 can reduce the levels of oxidative stress. AO-1-530 is not capable of 
completely preventing Nrf2 activated ARE gene expression but it does reduce it. This 
reduction may be enough to allow the cell to cope with the tBHP-induced stress. Therefore, 
AO-1-530 may act in conjunction with ARE response genes to reduce oxidative stress and 
protect the cell from death.  
5.6 Oxidative DNA Damage 
Another method to assess oxidative stress in cells is to quantify the damage produced by 
ROS. These are known as biomarkers or fingerprints of oxidative stress. Oxidative damage 
is usually an end product of oxidative stress and is therefore present in the cell for longer 
than ROS. However, it is important to take into account that there are also repair 
mechanisms for oxidative damage. If these repair mechanisms are overwhelmed with 
damage, they are incapable of repairing it all and this can be detected. 
A major product of DNA oxidative damage is 8-OHdG (Figure 1.4) (Gajewski et al, 
1990; Kasai et al, 1986; Dizdaroglu et al, 1991). It is formed from oxidation of the nucleic 
acid guanosine and can therefore be found in damaged RNA and DNA. Cells have been 
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found to have a natural repair mechanism to 8-OHdG damage, indicating it is normally 
produced in cells at sufficient levels to require repair. Other bases are also damaged by 
oxidation but 8-OHdG is the most studied.  
To characterise the potency of AO-1-530 to protect against RNA and DNA oxidative 
damage anti- 8-OHdG immunocytochemistry was performed (Figure 5.22a). The majority of 
the staining did not appear to be nuclear; instead it was around the edges of the nuclei and in 
the cytoplasm. The intensity of fluorescence in and around the nuclei was quantified using 
ImageJ (Figure 5.22b). tBHP significantly increased the level of 8-OHdG oxidative damage 
compared to control treated cells. Whereas AO-1-530 pre-incubation before tBHP addition 
significantly reduced the intensity of 8-OHdG immunocytochemistry to control levels.  
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Figure 5.22 - AO-1-530 protection against 8-OHdG oxidative DNA damage. SH-SY5Y cells were 
pre-incubated with AO-1-530 or vehicle for 30 minutes before the addition of 400 µM tBHP. Cells 
were incubated for 4.5 hours when they were fixed and immunocytochemistry was performed for 
8-OHdG (green) and nuclei were stained with DAPI (blue) (a), scale bar 54 µm. The intensity of 
fluorescence in and around the nuclei was quantified using ImageJ (b). Bars represent the mean from 
three coverslips from three independent experiments with 2-4 images per coverslip. Error bars 
represent the SEM. ANOVA with the post-hoc Tukey test was performed to assess statistical 
significance relative to tBHP treated cells; * p<0.05. 
5.7 Discussion and Future Directions 
AO-1-530 is a potent mitochondrial-targeted antioxidant. Cell viability assays showed 
AO-1-530 was protective against tBHP-induced oxidative stress at a 10-fold lower 
concentration than quercetin, whereas myricetin had limited protection. However, from the 
galvinoxyl assay AO-1-530 and myricetin are both potent radical scavengers. Since 
myricetin is unstable and poorly taken up into cells it cannot scavenge intracellular radicals. 
This was confirmed using the CellROX® assay to assess intracellular scavenging capability. 
The lipophilic tail of AO-1-530 enhanced its uptake, mitochondrial location in cells and may 
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improve its stability. Quercetin is a less potent antioxidant scavenger and locates to the 
nucleus. These two characteristics could be why a 10-fold higher concentration of quercetin 
is needed than AO-1-530 to protect against tBHP-induced toxicity. However, the 
intracellular concentration of antioxidants was not determined so this too may be influential.  
 AO-1-530 was found to scavenge intracellular ROS using the CellROX® assay. 
This antioxidant capability was further assessed for downstream effects of oxidative stress. 
These results show AO-1-530 works with the cells natural antioxidant defences, GSH and 
Nrf2 mediated transcription to prevent DNA oxidative damage caused by tBHP. To confirm 
this AO-1-530’s ability to prevent other biomarkers of oxidative stress could be assessed, for 
example protein carbonyls and lipid peroxidation. The Nrf2 results are slightly inconsistent 
with the CellROX® data, which suggested AO-1-530 is capable of scavenging all ROS 
produced. However, it is not clear which tBHP-induced ROS are capable of reacting with 
CellROX® to increase fluorescence and the sensitivity of the fluorescent dye is not known. 
Therefore, AO-1-530 appears to act in conjunction with other cellular responses to 
tBHP-induced oxidative stress to promote cell survival.  
 It is important to note, flavonoid antioxidants are capable of scavenging metal ions 
as well as radicals. Since iron is required for tBHP radical production, AO-1-530 could 
prevent radical production or scavenge the radicals produced or both. To distinguish between 
these two antioxidant mechanisms, free radical producing toxins that do not require iron 
could be used. 
 The potency of AO-1-530 may be due to the AO-1-530 radicals produced being 
recycled by other antioxidants in the cell, back to AO-1-530, as happens with vitamin E. 
This could be assessed in solution using EPR. 
 MitoQ is another mitochondrial-targeted antioxidant but its uptake into the 
mitochondria appears to be reliant on mitochondrial membrane potential. The data here 
suggests AO-1-530 does not rely on the membrane potential at least for maintenance of its 
localisation, since it is still present after fixation. In addition, AO-1-530 can protect in cells 
already exposed to oxidative stress. However, the direct assessment could be done using the 
uncoupler trifluorocarbonylcyanide phenylhydrazone (FCCP) to depolarise the mitochondria 
and then assess if AO-1-530 can still be found in the mitochondria. 
 Antoxis Limited have now synthesised AO-1-530 without one of the hydroxyl 
groups on the B-ring, so with a quercetin head group. Preliminary experiments suggest it 
does not locate to the nucleus and may locate to the mitochondria. However, this needs 
further assessment. If this derivative does locate to the mitochondria, then the lipophilic tail 
is responsible for the mitochondrial localisation. The ability of this antioxidant to scavenge 
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radicals is expected to be similar to quercetin and this could be confirmed using the 
galvinoxyl assay. If this is the case, then comparing the ability of AO-1-530 and this new 
compound to protect against tBHP-induced oxidative stress could distinguish between the 
importance of radical scavenging potential and mitochondrial localisation. In addition, 
mitochondiral ROS probes, for example MitoSOX or MitoHR, could be used to assess 
whether there is an increase in mitochondrial ROS and whether AO-1-530 could prevent 
this.  
This mitochondrial-targeted antioxidant, AO-1-530, can be used as a tool to assess 
the involvement of mitochondrial oxidative stress in disease models, like α-synucleinopathy 
models. This would improve understanding of the disease processes and help with 
development of treatments. In addition, AO-1-530 could be used during cell transplantation, 
for example during dopaminergic neuron transplantations in PD patients where oxidative 
stress has been implicated in the poor cell survival. This would involve incubation of 
midbrain cells with AO-1-530 after isolation from aborted fetuses. These cells would then be 
transplanted into PD patients. AO-1-530 may prove protective due to its radical scavenging 
ability. However, AO-1-530 was found to be toxic at high concentrations and it is not 
capable of preventing all of the Nrf2 ARE gene activation. Therefore, further experiments 
are needed to determine the appropriate concentration and timing to incubate cells with 
AO-1-530 to prevent toxicity but to allow a reduction in oxidative stress. In addition, 
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Chapter 6 – Discussion and Summary 
The aim of this project was to examine whether reducing oxidative stress could prevent 
neuronal cell toxicity in a α-synucleinopathy model. To do this a neuronal model of 
α-synucleinopathy needed to be developed. However, the attempts to create this model by 
overexpression of α-synuclein failed to show any toxicity in the cell types used. Therefore a 
toxin-induced oxidative stress cell model was established. Using this system the protective 
ability of the synthetic flavonoid, AO-1-530, was shown to be very potent. The localisation 
of AO-1-530 to the mitochondria may be responsible for some of its potent activity. Other 
possible properties responsible for AO-1-530’s potent protective activity can be speculated 
upon by its comparison with natural flavonoid antioxidants.  
6.1 SH-SY5Y Subclonal Variation 
Since neurons die in α-synucleinopathies, neuronal cell lines were needed to model the 
disease. SH-SY5Y and NS-1 cell lines are commonly used in the literature as PD models and 
are reported to be neuronal and catecholaminergic (Biedler et al, 1978; Greene & Tischler, 
1976; Radio et al, 2008). However, when a number of SH-SY5Y cell lines from different 
sources were examined differences were found in their neuronal and catecholaminegic 
properties. In addition, they had varied differentiation capabilities (Figure 3.1). The parental 
SH-SY5Y cell line was thrice subcloned from the original neuroblastoma cell line SK-N-SH 
(Biedler et al, 1978; Cohen et al, 2003). Therefore the differences between cell lines from 
different sources may be due to further subcloning of the parental SH-SY5Y cell line. This 
subcloning may be the result of genetic modifications caused when the cells are stressed, for 
example by cell passaging or cell freezing. These cells are not known to be modified and 
therefore retain the name of the parental cell line, SH-SY5Y. This highlights the importance 
of confirming the cell lines characteristics before their use. The genetic alterations that occur 
in different subclones could be distinguished using whole genome sequencing or whole 
genome SNP analysis. Whole genome SNP analysis has been used to compare the SH-SY5Y 
cell line and its parental cell line SK-N-SH, which showed genetic changes in the SH-SY5Y 
subclone that were not present in the parental cell line (Kryh et al, 2011). The NS-1 cell line 
expressed neuronal and catecholaminergic markers as expected. In addition, they were 
capable of differentiation by the addition of NGFβ (Figure 3.6). Therefore the neuronal SH-
SY5Y and NS-1 cell lines were used to try to produce a model of α-synucleinopathies.  
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6.2 Inability of BacMam Transient α-Synuclein Overexpression to Induce 
Toxicity 
The neuronal SH-SY5Y cell line from Edinburgh was used to determine the toxicity of 
α-synuclein overexpression. This overexpression was achieved using a BacMam construct 
encoding the SNCA gene and the GFP gene with a mitochondrial-targeting sequence 
separated by a translational skipping site. This GFP expression allowed confirmation of 
transduced cells and the relative levels of expression to be determined. The control BacMam 
construct only contained the mitochondrial-targeted GFP construct. Using this system 
α-synuclein overexpression for up to 5 days showed no toxicity in undifferentiated 
SH-SY5Y cells (Figure 4.9 and 4.13). This is similar to a previous study that found no 
α-synuclein toxicity up to 10 days in undifferentiated SH-SY5Y cells, using a doxycycline 
controlled α-synuclein overexpression system (Vekrellis et al, 2009). In addition another 
study using a different dopaminergic neuroblastoma cell line, BE(2)-M17, that had stable 
α-synuclein overexpression found no toxicity using the LDH assay (Ostrerova-Golts et al, 
2000). However, these cells were shown to have a greater susceptibility to oxidative insults, 
including addition of dopamine, L-DOPA and the Fenton reaction substrates, iron chloride 
(FeCl2) and H2O2 (Ostrerova-Golts et al, 2000; Bisaglia et al, 2010). Therefore the ability of 
rotenone, an inducer of superoxide production, in combination with α-synuclein 
overexpression to induce toxicity was examined. However, this too failed to show an 
increase in toxicity in the presence of α-synuclein overexpression (Figure 4.10). This could 
be due to the type of ROS that is induced and the location of the ROS production. Since 
rotenone will increase superoxide production in the mitochondria but dopamine would 
induce H2O2 production at various sites in the cell. Alternatively, the lack of toxicity may be 
due to the lack of dopaminergic cell line characteristics, since dopamine itself is known to 
produce oxidative stress (Klegeris et al, 1995; Rosenberg, 1988). Finally, since the models 
are cancer cell lines, they may possess highly robust characteristics making them less 
amenable to toxicity due to α-synuclein overproduction.  
 The Vekrellis et al, 2009 study showed even though there was no toxicity in the 
undifferentiated state there was toxicity after 6 days when α-synuclein was overexpressed 
during SH-SY5Y differentiation. This is in contrast to the results presented in this thesis, as 
there was no toxicity in differentiated SH-SY5Y cells after up to 4 weeks of overexpression 
(Figure 4.11 and 4.12). There are several possible reasons why there are differences in 
toxicity. The systems used to achieve α-synuclein overexpression were different. The 
BacMam system for overexpression used in this thesis is transient and from the 
immunocytochemistry of differentiated SH-SY5Y cells it suggests the α-synuclein may be 
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degraded more quickly than the GFP (Figure 4.11 and 4.12). However, this requires further 
analysis, as the published half-life for the α-synuclein is relatively long.  If, α-synuclein is 
degraded more quickly than mitochondrial GFP then overexpression may require top-up of 
the virus more often than every 7 days to maintain high protein levels. In addition, the 
SH-SY5Y subclones and the differentiation method used were different. The Vekrellis et al, 
2009 study used an SH-SY5Y cell line that expressed both neuronal and catecholaminergic 
proteins, which were differentiated by the addition of retinoic acid to FBS containing cell 
culture medium; whereas in this thesis the SH-SY5Y cell line was neuronal but not 
catecholaminergic and the cells were differentiated in N2 medium with retinoic acid. Other 
studies have shown α-synuclein overexpression for 5 days in human primary neurons may 
induce toxicity in dopaminergic neurons but not other neuronal subtypes (Zhou et al, 2002). 
In addition, this overexpression in primary catecholaminergic neurons results in increased 
susceptibility to oxidative insult induced cell death (Zhou et al, 2000). This importance of 
neuronal cell type is also highlighted in α-synucleinopathy disease patients where some 
neuronal subtypes, especially the SNpc neurons, are more susceptible to toxicity than others. 
Therefore the differentiated SH-SY5Y cells used here may not show toxicity, as they are not 
catecholaminergic. Whether the differentiated SH-SY5Y cells overexpressing α-synuclein 
are more susceptible to oxidative insults than control treated cells was not assessed in this 
thesis. Another possible reason for the lack of toxicity may be because the toxic α-synuclein 
oligomers have not formed. Native western blots could be performed to assess whether 
α-synuclein oligomers have formed and determine if this is the reason for the lack of 
toxicity. 
 One other study has used a BacMam system to overexpress α-synuclein. They used 
the LUHMES cell line, which is a human embryonic mesencephalic cell line containing 
v-myc expression, which is tetracycline controlled (Zhang et al, 2014). Therefore these cells 
differentiate by the addition of tetracycline. In this study BacMam α-synuclein 
overexpression during differentiation induces significant toxicity shown by a reduction in 
ATP and an increase in caspase 3/7 after just one day. However, there are a number of 
experiments missing from this paper. There is no indication as to the efficiency of BacMam 
transduction for α-synuclein and the GFP control. In addition, there are no images of the 
cells before use in the assays to show cellular morphology and no quantification of the 
number of live cells after one day to give a better indication of the percentage of cells that 
died. These pieces of data should be used to confirm the toxicity. The toxicity found in this 
paper was not found in this thesis for a number of possible reasons. Firstly, the cell line used 
was different. Secondly, the BacMam construct was different, as it does not contain a 
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mitochondrial-targeted GFP with the α-synuclein protein, whereas the control construct only 
contains GFP. Thirdly, the assays used to assess toxicity are different from those used in this 
thesis.     
 Even though high levels of α-synuclein overexpression used in this thesis failed to 
induce toxicity these levels did appear to induce mitochondrial fragmentation (Figure 4.13). 
This fragmentation of the mitochondria has been reported previously where α-synuclein was 
overexpressed in HeLa cells, COS cells and primary rat hippocampal neurons. The increase 
in fragmentation was detected within 48 hours in HeLa cells similar to that found in this 
thesis. However, in the Nakamura et al, 2011 study these HeLa cells had more intermediate 
mitochondria whereas in this thesis most of the cells had tubular mitochondria. This may be 
due to a difference in cell types. The fragmentation of the mitochondria in the Nakamura et 
al, 2011 study preceded a small increase in the number of dead cells and a reduction in 
mitochondrial respiration in COS cells and rat hippocampal neurons. However, no toxicity 
was found in this thesis. This may be due to the cell type that was used, as undifferentiated 
SH-SY5Y cells are a cancer cell line that produces most of their ATP through glycolysis 
rather than mitochondrial oxidative phosphorylation (Schneider et al, 2011; Xun et al, 2012). 
Alternatively it may be due to the MTS assay used for detection, as it may not be able to 
detect a small decrease in cell number. The Nakamura et al, 2011 study showed selective 
fragmentation of mitochondria rather than other subcellular compartments was due to the 
high cardiolipin content found in the mitochondria. Whether other subcellular compartments 
show fragmentation in the SH-SY5Y cells was not tested but could be assessed at the same 
time as the mitochondrial fragmentation.   
 The BacMam α-synuclein overexpression failed to show an increase in ROS 
production after up to 7 days (Figure 4.14). This is consistent with the Nakamura paper that 
showed no increase in superoxide production even though the mitochondria fragment. In 
addition, a previous study showed oligomeric forms of α-synuclein were capable of 
increasing ROS production using the DHE assay but the monomeric form had no effect on 
ROS levels (Cremades et al, 2012). Therefore the overexpression of α-synuclein using the 
BacMam system may increase monomeric α-synuclein and not induce the formation of 
oligomers, thus showing no increase in ROS production. Western blotting could be used to 
assess the absence of α-synuclein oligomers.    
 This thesis shows the transient overexpression of α-synuclein using the BacMam 
system does not cause SH-SY5Y neuronal cell toxicity in the undifferentiated or 
differentiated state. The reason for this lack of toxicity may be due to the length of time 
α-synuclein expression is maintained for, the level and consistency of α-synuclein 
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overexpression that is achieved or the robustness of the SH-SY5Y cancer cell line that is 
used. 
6.3 AO-1-530 Protection against Acute Oxidative Stress 
The inability of α-synuclein overexpression to induce toxicity meant the antioxidant ability 
of the novel flavonoid AO-1-530 needed to be assessed in a toxin-induced oxidative stress 
neuronal cell model. The toxin tBHP was used as an oxidative stress inducer as it is known 
to increase the production of ROS that can induce lipid peroxidation, resulting in cell death 
(Van der Zee et al, 1996).  
 AO-1-530 was shown to fluoresce like other flavonoids myricetin and quercetin but 
its emission was greater (Figure 5.2). This difference in levels of fluorescence emission by 
AO-1-530, quercetin and myricetin prevent the relative intracellular levels of antioxidants 
from being determined. However, this fluorescence did allow assessment of the localisation 
of flavonoid antioxidants. AO-1-530 was enriched in the mitochondria and was found 
elsewhere in the cytoplasm but was excluded from the nucleus (Figure 5.4). Quercetin was 
enriched in the nucleus and myricetin was not readily taken up into cells (Figure 5.3). This is 
consistent with reports in the literature that show quercetin is nuclear, although this was 
dependent on the cell line (Mukai et al, 2011). In addition, myricetin has a lower 
lipophilicity than quercetin and is unstable at neutral pH likely preventing its uptake into 
cells (Kajiya et al, 2001; Yao et al, 2014; Yokomizo & Moriwaki, 2006). This difference in 
intracellular antioxidant levels and subcellular localisation may be influential in their ability 
to protect against tBHP. 
 The poor cellular uptake of myricetin likely explains its limited protection against 
tBHP-induced oxidative stress, whereas AO-1-530 and quercetin, which are taken up into 
cells easily, were both highly protective (Figure 5.9 and 5.11). AO-1-530 was more potent 
than quercetin as it showed similar or more significant protection at a 10-fold lower 
concentration than quercetin. These results agree with published reports where quercetin is 
more protective than myricetin against H2O2 induced oxidative stress (Yokomizo & 
Moriwaki, 2006; Aherne & O'Brien, 1999). Other antioxidants, vitamin E, Idebenone and 
coenzyme Q10, which were tested, showed limited protection against tBHP induced 
oxidative stress. Vitamin E’s limited protection could be due to its inefficient uptake into 
cells in the presence of FBS, its poor solubility in media or its inability to scavenge radicals 
produced by such an acute high dose of tBHP (Anwar et al, 2006; Nowak et al, 2012). 
Coenzyme Q10 and its analogue Idebenone have been shown to protect against lipid 
peroxidation but the direct radical scavenging ability of coenzyme Q10 is lower than Trolox, 
the water-soluble form of vitamin E (McDaniel et al, 2005; Choi et al, 2009).  
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 AO-1-530 treatment alone was toxic at high concentrations (Figure 5.7c). This may 
be due to its auto-oxidation, since auto-oxidation of myricetin produces H2O2, which is toxic 
to cells (Mukai et al, 2011; Kajiya et al, 2001). Therefore the protective concentration range 
may be limited by its toxicity and this requires further investigation.  
 The AO-1-530 protection was shown to be at least partly due to its intracellular 
mechanism of action (Figure 5.13). In addition, AO-1-530 and a 10-fold higher 
concentration of quercetin were found to be protective when added after tBHP, indicating 
their potent scavenging ability (Figure 5.14).  
 To further assess the mechanism behind the differences between AO-1-530, 
myricetin and quercetin protection, their scavenging potencies were examined using the 
stable free radical galvinoxyl. In addition, their intracellular scavenging potential was 
examined using CellROX® Deep Red. As found in previous studies using galvinoxyl, 
myricetin was a more potent radical scavenger than quercetin since it has more hydrogen 
atoms to donate (Figure 5.17 and 5.18) (Shi et al, 2001; McPhail et al, 2003). AO-1-530 was 
shown to have similar scavenging potency to myricetin, although the kinetics of the 
hydrogen donation was not determined. The CellROX® Deep Red assay, which examined 
intracellular scavenging potency, showed both AO-1-530 and a 10-fold higher concentration 
of quercetin were capable of scavenging the tBHP radicals produced to control levels (Figure 
5.19). However, myricetin, which has a similar scavenging potency to AO-1-530, was 
incapable of reducing the intracellular ROS levels to control levels likely due to its lack of 
uptake into cells. AO-1-530 was shown to be more protective than quercetin against tBHP 
toxicity. This difference in toxicity at 5 hours after tBHP addition may still be due to 
different ROS levels but the CellROX® assay was performed 1 hour after tBHP addition, 
therefore a longer incubation with tBHP could result in an increase in ROS. Alternatively, 
the CellROX® dye may not be sensitive enough to detect small differences in ROS levels. In 
addition to scavenging the ROS produced, flavonoids can also scavenge metal ions 
preventing tBHP radical production (Fernandez et al, 2002). The CellROX® assay should 
also detect these differences, as it would result in overall lower levels of ROS.  
 Further investigation into the protective mechanism of AO-1-530 showed it is not 
capable of preventing the oxidation of GSH caused by tBHP (Figure 5.20). This 
tBHP-induced oxidation of GSH could be the result of direct radical scavenging of the tBHP 
radicals or the result of its action as a cofactor for the enzyme GPx, which breaks down the 
tBHP into tert-butyl alcohol. The inability of AO-1-530 to prevent GSH oxidation may be 
because GSH is acting as a cofactor for the GPx removal of tBHP rather than directly 
scavenging the tBHP radicals. This is consistent with other reports that suggest GSH acts 
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more as a cofactor for enzymes rather than a direct radical scavenger (Masaki et al, 1989; 
Jones et al, 2003). However, this requires further investigation using an inhibitor of the GPx 
enzyme to see wheter tBHP can still increase the GSSG levels. This would allow separation 
of the direct radical scavenging ability of GSH and its GPx cofactor function.  
 AO-1-530 was capable of preventing tBHP-induced nuclear localisation of Nrf2 
(Figure 5.21). This was not due to an increase in Nrf2 gene expression, which agrees with 
previously published data (Purdom-Dickinson et al, 2007). The tBHP-induced increase in 
nuclear Nrf2 resulted in an increase in the gene expression of two known ARE genes, 
HMOX1 and NQO1 (Alam et al, 2000; Nioi et al, 2003). The ability of AO-1-530 
pre-incubation to reduce nuclear Nrf2 also resulted in a reduction in the gene expression of 
HMOX1 and NQO1 (Alam et al, 2000; Nioi et al, 2003). However, the reduction was not to 
control levels. This is slightly contradictory to the Nrf2 immunocytochemistry, which 
suggests Nrf2 nuclear levels are the same as control levels when pre-incubated with 
AO-1-530. This may be because imunocytochemistry is not sensitive enough to detect small 
changes in protein levels, whereas qRT-PCR can detect small changes in gene expression. 
These results suggest that AO-1-530, the Nrf2 response and GSH act together to prevent 
tBHP-induced toxicity in cells.   
 AO-1-530 is also capable of preventing tBHP-induced 8-OHdG DNA oxidative 
damage (Figure 5.22). Immunocytochemistry performed 4.5 hours after tBHP addition using 
an 8-OHdG antibody showed pre-incubation with AO-1-530 reduced 8-OHdG levels to 
control levels. This is consistent with other studies that show flavonoids, including quercetin, 
are capable of reducing ROS induced DNA oxidative damage (Kanupriya et al, 2006; 
Aherne & O'Brien, 1999). 
 AO-1-530 is a potent flavonoid antioxidant that can protect against oxidative stress 
induced death at a 10-fold lower concentration than the natural flavonoid quercetin. This 
greater ability to protect against tBHP-induced cell death may be due to the higher 
intracellular level of antioxidant, the mitochondrial rather than nuclear subcellular 
localisation or the greater scavenging potency.    
 MitoQ and SS-31 are two published mitochondrial-targeted compounds. MitoQ is 
based on coenzyme Q10, but the isoprenoid side chain has been changed to a carbon side 
chain and the TPP lipophilic cation is attached to attract it to the mitochondria (Figure 1.8). 
SS-31 contains 4 amino acids, D-arginine, Dmt, lysine and phenylalanine (Figure 1.8). It is 
difficult to know how AO-1-530 compares to SS-31 and MitoQ in its antioxidant potential as 
they have each been used in different models. From stable free radical experiments 
coenzyme Q10 is a weaker scavenger than Trolox and the flavonols, myricetin and 
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quercetin, are stronger scavengers than vitamin E (Choi et al, 2009; McPhail et al, 2003). 
This would suggest AO-1-530 would be a more potent radical scavenger than MitoQ. 
However, MitoQ is also recycled back to its antioxidant state after it has scavenged a radical. 
This would increase its scavenging potential. The quercetin oxidation product can be 
recycled back to the antioxidant form by ascorbate (Boots et al, 2003; Skaper et al, 1997). 
Since AO-1-530 has a similar head group to quercetin it is likely it too can be recycled back 
to its antioxidant state by ascorbate. MitoQ protection against tBHP has not been assessed. 
SS-31 has been used in tBHP-induced oxidative stress cell models and was shown to protect 
at nanomolar concentrations. However, the concentrations of tBHP used were much lower. 
In addition SS-31 reduced ROS but was incapable of removing all ROS produced by 50 µM 
tBHP when assessed using the 2',7'-dichlorofluorescein (DCF) fluorescence, an indicator of 
ROS levels (Zhao et al, 2005). The scavenging potency of SS-31 with a stable free radical 
has not been reported. Therefore the differences in scavenging potency are unknown. The 
other influential characteristic in their protective potential is their mitochondrial localisation. 
MitoQ shows a 50% uptake into the mitochondria, whereas SS-31 shows 30% (Kelso et al, 
2001; Zhao et al, 2005). The percentage of AO-1-530 located to the mitochondria is 
unknown. The localisation of each of these antioxidants within the mitochondria may be 
different for example in the inner or outer membrane or the matrix. In addition, the reliability 
on the mitochondrial membrane potential differs. MitoQ requires the mitochondrial 
membrane potential to be protective, whereas SS-31 does not. Whether AO-1-530 requires 
an intact mitochondrial membrane potential is unknown. In order to objectively compare 
these antioxidants they would need to be assessed in the same assay and in the same cell 
type.  
6.4 Future Work 
Future work would include determining the properties of AO-1-530 that locate it to the 
mitochondria and assessing the most important properties of AO-1-530 that allow protection 
against tBHP. In addition, comparison of AO-1-530 to MitoQ and SS-31 in the same assay 
would allow the most potent antioxidant to be determined. Further modifications can also be 
made to try to produce a α-synuclein overexpression model of toxicity to assess oxidative 
stress involvement in α-synucleinopathies. In addition, another use of AO-1-530 is in cell 
transplantation to improve cell survival.     
 Other mitochondrial-targeted antioxidants rely on their charge and lipophilicity to 
locate them to the mitochondria; therefore the importance of these in AO-1-530’s 
mitochondrial localisation should be determined. To assess the importance of mitochondrial 
membrane potential the localisation of AO-1-530 in FCCP treated cells should be assessed. 
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FCCP causes the depolarisation of the mitochondria. In order to determine whether the 
lipophilic tail is important for mitochondrial localisation, another compound synthesised by 
Antoxis Limited can be used that has a head group like quercetin and a lipophilic tail like 
AO-1-530. If this new compound also locates to the mitochondria, it will show the lipophilic 
tail is required for mitochondrial localisation. In addition, if the scavenging potential of this 
new compound is the same as quercetin but less than AO-1-530, then the importance of the 
mitochondrial localisation and scavenging potential can be compared. It would also be useful 
to get an idea of the relative intracellular levels of AO-1-530 and quercetin from the 
fluorescence levels. By examining the fluorescence intensity at a number of different 
concentrations of AO-1-530 and quercetin, it would be possible to determine the 
fluorescence relative to the concentration. This would allow the relative concentration to be 
determined from the intracellular FACS fluorescence. Whether there is a difference in the 
intracellular concentration of AO-1-530 and quercetin can be determined and the relevance 
of this in the differences in their protective ability against tBHP can be assessed. Since tBHP 
is known to induce lipid peroxidation it is necessary to determine AO-1-530’s ability to 
prevent lipid peroxidation. There are a number of methods available, to assess lipid 
peroxidation, including the Click-iT® Lipid Peroxidation imaging kit from Life 
Technologies. In addition, if it is possible to get MitoQ and SS-31, which are not 
commercially available it would be interesting to directly compare them to AO-1-530 in 
their ability to protect in this tBHP-induced oxidative stress toxicity model.  
 Flavonoids are known to have anti-inflammatory, anti-allergic, anti-viral and 
anti-carcinogenic properties (Reviewed by Nijveldt et al, 2001). Therefore, whether 
AO-1-530 has other protective properties as well as its antioxidant action remain to be 
determined. If it does, these may complicate its use as a tool to determine the involvement of 
oxidative stress in a α-synucleinopathy disease model.  
 In order to develop an α-synucleinopathy model by α-synuclein overexpression it 
would be interesting to use a different cell line, for example primary catecholaminergic 
neurons or human embryonic stem cell derived catecholaminergic neurons. These cells are 
likely to have endogenous α-synuclein expression that is cytoplasmic, nuclear and 
presynaptic and they are likely to be less robust than SH-SY5Y cells. In addition, it is 
important to determine the length of time α-synuclein is overexpressed for using the 
BacMam system. This can be done using western blots to determine how the α-synuclein 
levels change over time to see how quickly the overexpression is lost. If the expression is too 
transient it may be necessary to create stable α-synuclein overexpressing cell lines. In 
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addition, it is necessary to perform native western blots to determine whether oligomeric 
α-synuclein has been produced, since this is thought to be the toxic form.  
 AO-1-530 could also be used to increase cell survival after transplantation. It is 
known after cell transplantation there is significant death of transplanted cells, which can 
prevent an improvement in symptoms. A possible reason for this death is oxidative stress 
that may occur during the transplantation procedure. Further evidence of the importance of 
oxidative stress was shown when lazaroids, which prevent lipid peroxidation and reduce 
brain trauma injury, were shown to improve catecholaminergic cell survival after 
transplantation into rats (Nakao et al, 1994; Othberg et al, 1997). Lazaroids have also been 
used in a PD patient cell transplantation study, but in this study all patients received lazaroid 
treated mesencephalic tissue therefore there was no lazaroid untreated control. Instead results 
are compared to a previous study, which is inadequate as the number of cells transplanted 
was different. The authors suggest that even though less tissue was transplanted into the 
patients they showed the same graft survival and improved symptoms therefore lazaroids 
increase cell survival after transplantation (Brundin et al, 2000). The other mitochondrial 
targeted compound SS-31 has been shown to improve islet cell survival after isolation from 
the donor. In addition, transplantation of these islet cells into diabetic mice caused a 
reduction in blood glucose levels in half of the mice, whereas islet cells isolated and cultured 
in the absence of SS-31 could not reduce blood glucose levels (Thomas et al, 2006). 
Therefore, AO-1-530 may also be capable of improving cell survival after transplantation. 
However, further experiments are required to determine the best dose of AO-1-530 to use, as 
it is toxic at high concentrations and how long cells should be exposed to AO-1-530 for.  
6.5 Conclusion 
AO-1-530 is a potent mitochondrial-targeted antioxidant that is capable of protecting against 
acute oxidative stress. Further research will determine how important the mitochondrial 
localisation and scavenging potency are in its protective ability. The use of this antioxidant 
in combination with other tools available to measure oxidative stress will allow the 
involvement of oxidative stress in cell based disease models, including α-synucleinopathies, 
to be assessed. This would help in understanding the disease process and could help in the 
development of treatments. In addition, AO-1-530 could be used as a tool to increase cell 
survival in situations where cells are exposed to higher levels of oxidative stress than 
normal, for example in cell culture or during cell transplantation. This would require further 
experiments to determine the appropriate concentrations of AO-1-530 to use and how long 
AO-1-530 incubation should be, as there is a balance between protection and toxicity. In 
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addition, the metabolism and distribution of AO-1-530 in tissue should be determined before 
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